(12) STANDARD PATENT　　　　　　(11) Application No. **AU 2006236649 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
Methods and compositions for modulating and detecting WISP activity

(51) International Patent Classification(s)
C07K 14/475 (2006.01)　　　　　*A61P 35/00* (2006.01)
A61K 39/395 (2006.01)　　　　　*C07K 16/22* (2006.01)

(21) Application No: **2006236649**　　　(22) Date of Filing: **2006.04.13**

(87) WIPO No: **WO06/113402**

(30) Priority Data

(31) Number　　　　　　　　(32) Date　　　　　　(33) Country
11/105,876　　　　　　　　　　**2005.04.14**　　　　　　　**US**

(43) Publication Date:　　　　　**2006.10.26**
(44) Accepted Journal Date:　　　**2012.03.29**

(71) Applicant(s)
Genentech, Inc.

(72) Inventor(s)
Filvaroff, Ellen;Desnoyers, Luc

(74) Agent / Attorney
Griffith Hack, GPO Box 1285, Melbourne, VIC, 3001

(56) Related Art
WO 1999/021998 A1 (GENENTECH, INC.) 6 May 1999
WO 2004/003158 A2 (GENENTECH, INC.) 8 January 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(71) Applicant (for all designated States except US): GENEN-
TECH, INC. [US/US]; 1 Dna Way, Ms 49, South San Fran-
cisco, California 94080 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): DESNOYERS, Luc
[CA/US]; 2050 Stockton Street, San Francisco, California
94133 (US). FILVAROFF, Ellen [US/US]; 538 18th Av-
enue, San Francisco, California 94121 (US).

(74) Agent: HASAK, Janet, E. à; c/o GENENTECH, INC., 1
DNA Way, MS 49, South San Francisco, California 94080
(US).

(54) Title: METHODS AND COMPOSITIONS FOR MODULATING AND DETECTING WISP ACTIVITY

(57) Abstract: Methods and compositions for use in modulating the activity(s) of WISP-1 polypeptide are provided. WISP-1 an-
tagonists include anti-WISP-1 antibodies, WISP-1 immunoadhesins and WISP-1 variants (and fusion proteins thereof) which inhibit
or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of
mammalian cell. The invention also provides methods for in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian
cells or pathological conditions associated with native WISP-1 polypeptides.

METHODS AND COMPOSITIONS FOR MODULATING AND DETECTING WISP ACTIVITY

Field of the Invention

The present invention relates generally to methods and compositions for use in modulating the activity(s) of WISP polypeptides, particularly, WISP-1 polypeptides. The invention also relates to methods and compositions for *in vitro, in situ,* and/or *in vivo* diagnosis and/or treatment of mammalian cells or pathological conditions associated with WISP polypeptides.

Background of the Invention

Connective tissue growth factor (CTGF) is a growth factor induced in fibroblasts by many factors, including TGF-ß, and is essential for the ability of TGF-ß to induce anchorage-independent growth (AIG), a property of transformed cells. CTGF also is mitogenic and chemotactic for cells, and hence growth factors in this family are believed to play a role in the normal development, growth, and repair of human tissue. Five proteins related to CTGF, including Cyr61, Nov, WISP-1, WISP2, and WISP-3 have been isolated, cloned, sequenced, and characterized as belonging to the CCN gene family. Oemar and Luescher, Arterioscler. Thromb. Vasc. Biol., 17: 1483-1489 (1997); Brigstock, Endocrine Rev., 20:189-206 (1999). The gene encoding Cyr61 has been found to promote angiogenesis, tumor growth, and vascularization. Babic et al., Proc. Natl. Acad. Sci. USA, 95: 6355-6360 (1998). The *nov* gene is expressed in the kidney essentially at the embryonic stage, and alterations of *nov* expression, relative to the normal kidney, have been detected in both avian nephroblastomas and human Wilms' tumors. Martinerie et al., Oncogene, 9: 2729-2732 (1994). Wt1 downregulates human *nov* expression, which downregulation might represent a key element in normal and tumoral nephrogenesis. Martinerie et al., Oncogene, 12: 1479-1492 (1996).

The different members of the CCN family interact with various soluble or matrix associated macromolecules in particular sulfated glycoconjugates (Bork, FEBS Letters, 327:125-130). This interaction was used to purify Cyr61 and CTGF by affinity chromatography on heparin-agarose (Frazier et al., J. Invest. Dermatol., 107:404-411 (1996); Kireeva et al., Mol. Cell. Biol., 16:1326-1334 (1996)). Cyr61 is secreted and associated with both the extracellular matrix and the cell surface due to its affinity for heparan sulfate (Yang et al., Cell. Growth Diff., 2:351-357 (1991)). Recently, WISP-1 was

shown to interact with decorin and biglycan, two secreted dermatan sulfate proteoglycans. (Desnoyers, et al., J. Biol. Chem., 276:47599-47607 (2001)).

5   The murine protein ELM1 was recently identified in low metastatic cells. Hashimoto et al., J. Exp. Med., 187:289-296 (1998). The elm1 gene, a mouse orthologue of WISP-1 disclosed below, is another member of the CNN gene family. It suppresses in vivo tumor growth and metastasis of K-1735 murine melanoma cells. Another recent article on rCop-1, the rat orthologue of WISP-2 described

10   below, describes the loss of expression of this gene after cell transformation. Zhang et al., Mol. Cell. Biol., 18:6131-6141 (1998).

       Wnts are encoded by a large gene family whose members have been found in round worms, insects, cartilaginous fish, and vertebrates.

15   Holland et al., Dev. Suppl., 125-133 (1994). Wnts are thought to function in a variety of developmental and physiological processes since many diverse species have multiple conserved Wnt genes. McMahon, Trends Genet., 8: 236-242 (1992); Nusse and Varmus, Cell, 69: 1073-1087 (1992). Wnt genes encode secreted glycoproteins that

20   are thought to function as paracrine or autocrine signals active in several primitive cell types. McMahon, supra (1992); Nusse and Varmus, supra (1992). The Wnt growth factor family includes more than ten genes identified in the mouse (Wnt-1, -2, -3A, -3B, -4, -5A, -5B, -6, -7A, -7B, -8A, -8B, -10B, -11, -12, and -13) (see, e.g.,

25   Gavin et al., Genes Dev., 4: 2319-2332 (1990); Lee et al., Proc. Natl. Acad. Sci. USA, 92: 2268-2272 (1995); Christiansen et al., Mech. Dev., 51: 341-350 (1995)) and at least nine genes identified in the human (Wnt-1, -2, -3, -5A, -7A, -7B, -8B, -10B, and -11) by cDNA cloning. See, e.g., Vant Veer et al., Mol.Cell.Biol., 4: 2532-2534

30   (1984).

       The Wnt-1 proto-oncogene (int-1) was originally identified from mammary tumors induced by mouse mammary tumor virus (MMTV) due to an insertion of viral DNA sequence. Nusse and Varmus, Cell, 31: 99-109 (1982). In adult mice, the expression level of Wnt-1 mRNA is

35   detected only in the testis during later stages of sperm development. Wnt-1 protein is about 42 KDa and contains an amino- terminal hydrophobic region, which may function as a signal sequence for secretion (Nusse and Varmus, supra, 1992). The expression of Wnt-2 is detected in mouse fetal and adult tissues and its distribution

40   does not overlap with the expression pattern for Wnt-1. Wnt-3 is associated with mouse mammary tumorigenesis. The expression of Wnt-3

in mouse embryos is detected in the neural tubes and in the limb

buds. Wnt-5a transcripts are detected in the developing fore- and

hind limbs at 9.5 through 14.5 days and highest levels are

concentrated in apical ectoderm at the distal tip of limbs. Nusse

5   and Varmus, *supra* (1992). Recently, a Wnt growth factor, termed Wnt-

x, was described (WO95/17416) along with the detection of Wnt-x

expression in bone tissues and in bone-derived cells. Also described

was the role of Wnt-x in the maintenance of mature osteoblasts and

the use of the Wnt-x growth factor as a therapeutic agent or in the

10   development of other therapeutic agents to treat bone-related

diseases.

        Wnts may play a role in local cell signaling. Peifer and

Polakis, Science, 287:1606-1609 (2000). Biochemical studies have

shown that much of the secreted Wnt protein can be found associated

15   with the cell surface or extracellular matrix rather than freely

diffusible in the medium. Papkoff and Schryver, Mol. Cell. Biol.,

10: 2723-2730 (1990); Bradley and Brown, EMBO J., 9: 1569-1575

(1990).

        Studies of mutations in Wnt genes have indicated a role for

20   Wnts in growth control and tissue patterning. In *Drosophila, wingless*

(*wg*) encodes a Wnt-related gene (Rijsewik *et al.*, Cell, 50: 649-657

(1987)) and *wg* mutations alter the pattern of embryonic ectoderm,

neurogenesis, and imaginal disc outgrowth. Morata and Lawerence,

Dev. Biol., 56: 227-240 (1977); Baker, Dev. Biol., 125: 96-108

25   (1988); Klingensmith and Nusse, Dev. Biol., 166: 396-414 (1994). In

Caenorhabditis elegans, lin-44 encodes a Wnt homolog which is

required for asymmetric cell divisions. Herman and Horvitz,

Development, 120: 1035-1047 (1994). Knock-out mutations in mice have

shown Wnts to be essential for brain development (McMahon and

30   Bradley, Cell, 62: 1073-1085 (1990); Thomas and Cappechi, Nature,

346: 847-850 (1990)), and the outgrowth of embryonic primordia for

kidney (Stark *et al.*, Nature, 372: 679-683 (1994)), tail bud (Takada

et al., Genes Dev., 8: 174-189 (1994)), and limb bud. Parr and

McMahon, Nature, 374: 350-353 (1995). Overexpression of Wnt-1 in the

35   mammary gland can result in mammary hyperplasia (McMahon, *supra*

(1992); Nusse and Varmus, *supra* (1992)), precocious alveolar

development (Bradbury *et al.*, Dev. Biol., 170: 553-563 (1995)), and

mammary adenocarcinomas (Li et al., Oncogene, 19:1002-1009 (2000)).

        Wnt-5a and Wnt-5b are expressed in the posterior and lateral

40   mesoderm and the extraembryonic mesoderm of the day 7-8 murine

embryo. Gavin *et al.*, *supra* (1990). These embryonic domains

contribute to the AGM region and yolk sac tissues from which
multipotent hematopoietic precursors and HSCs are derived.   Dzierzak
and Medvinsky, Trends Genet., 11: 359-366 (1995); Zon et al., in
Gluckman and Coulombel, ed., Colloque, INSERM, 235: 17-22 (1995),
5   presented at the Joint International Workshop on Foetal and Neonatal
Hematopoiesis and Mechanism of Bone Marrow Failure, Paris France,
April 3-6, 1995; Kanatsu and Nishikawa, Development, 122: 823-830
(1996). Wnt-5a, Wnt-10b, and other Wnts have been detected in limb
buds, indicating possible roles in the development and patterning of
10   the early bone microenvironment as shown for Wnt-7b. Gavin et al.,
supra (1990); Christiansen et al., Mech. Devel., 51: 341-350 (1995);
Parr and McMahon, supra (1995).

       For a review on Wnt, see Cadigan and Nusse, Genes & Dev., 11:
3286-3305 (1997).

15   Pennica et al., Proc. Natl. Acad. Sci., 95:14717-14722 (1998)
describe the cloning and characterization of two genes, WISP-1 and
WISP-2, that are up-regulated in the mouse mammary epithelial cell
line C57MG transformed by Wnt-1, and a third related gene, WISP-3.
(See also, WO 99/21998 published May 6, 1999; WO 99/21999 published
20   May 6, 1999). Pennica et al. report that these WISP genes may be
downstream of Wnt-1 signaling and that aberrant levels of WISP
expression in colon cancer may play a role in colon tumorigenesis.
WISP-1 has recently been identified as a ß-catenin-regulated gene and
the characterization of its oncogenic activity demonstrated that
25   WISP-1 might contribute to ß-catenin-mediated tumorigenesis (Xu et
al., Gene & Develop., 14:585-595 (2000)). WISP-1 overexpression in
normal   rat   kidney   cells   (NRK-49F)   induced   morphological
transformation, accelerated cell growth and enhanced saturation
density.   In addition, these cells readily form tumors when injected
30   into nude mice suggesting that WISP-1 may play some role in
tumorigenesis (Xu et al., supra 2000).   WISP-1 is also overexpressed
in transformed human breast cancer cell lines and in about 47% of
primary human breast cancer associated with certain advanced
features.   Xie et al., Cancer Res., 61:8917-8923 (2001); Saxena et
35   al., Mol. Cell Biochem., 228:99-104 (2001); Michaelson et al.,
Oncogene, 20:5093-5099 (2001). A particular WISP-1 variant has also
been reported to be overexpressed in about 86% of human scirrhous
gastric carcinoma cells.   Tanaka et al., Oncogene, 20:5525-5532
(2001).

40   Hurvitz et al., Nature Genetics, 23:94-97 (1999) describe a
study involving WISP3 in which nine different mutations of WISP3 in

unrelated individuals were found to be associated with the autosomal recessive skeletal disorder, progressive pseudorheumatoid dysplasia (PPD). *WISP3* expression by RT-PCR was observed by Hurvitz et al. in human synoviocytes, articular cartilage chondrocytes, and bone-marrow-derived mesenchymal progenitor cells.

PCT application WO98/21236 published May 22, 1998 discloses a human connective tissue growth factor gene-3 (CTGF-3) encoding a 26 kD member of the growth factor superfamily. WO98/21236 discloses that the CTGF-3 amino acid sequence was deduced from a human osteoblast cDNA clone, and that CTGF-3 was expressed in multiple tissues like ovary, testis, heart, lung, skeletal muscle, adrenal medulla, adrenal cortex, thymus, prostate, small intestine and colon.

Hyaluronic acid (also referred to as HA, hyaluronate, or hyaluronan) is recognized in the literature as being an important component of the extracellular matrix (See, e.g., Hardingham et al., FASEB J., 6:861-870 (1992); Laurent et al., FASEB J., 6:2397-2404 (1992)). HA is a component of skin and mesenchymal tissues where it facilitates cell migration during wound healing, inflamation, and embryonic morphogenesis. (Knudson et al., FASEB J., 7:1233-1241 (1993); Knudson et al., CIBA Found. Symp., 143:150-169 (1989)). HA has also been reported to play a role in certain types of metastases. (Naor et al., CD44: Structure, Function and Association with the Malignant Process, Advances in Cancer Research, Academic Press (1997), pages 241-319). The largest concentrations of HA are found in the skin and musculo-skeletal system which account for over 50% of total body HA. (Banerji et al., J. Cell Biol., 144:789-801 (1999)).

Various investigators have reported on receptors which bind HA. One of the receptors identified for HA is the CD44 protein. (See, e.g., Culty et al., J. Cell Biology, 111:2765-2774 (1990); Aruffo et al., Cell, 61:1303-1313 (1990); Naor et al., CD44: Structure, Function and Association with the Malignant Process, Advances in Cancer Research, Academic Press (1997), pages 241-319); Ropponen et al., Cancer Res., 58:342-347 (1998); Masaki et al., Cancer, 92:2539-2546 (2001). CD44 is a family of cell-surface glycoproteins generated from a single gene by alternative splicing and differential glycosylation. (Wielenga et al., Am. J. Pathology, 154:515-523 (1999)). CD44 is believed to function as a cell adhesion receptor, linking extracellular molecules, specifically hyaluronate, to the cell and the cytoskeleton (Wielenga et al., supra). CD44 is expressed on epithelial, mesenchymal and lymphoid cells. (Lesley et al., Adv. Immunol., 54:271-335 (1994)). Wielenga et al. report that

CD44 expression may be regulated by the WNT pathway, based on certain experiments analyzing CD44 expression in the intestinal mucosa of mice and humans with genetic defects in either *APC* or *Tcf-4*. (Wielenga et al., supra).

Other HA receptors characterized to date include RHAMM (also referred to as receptor for hyaluronic acid mediated motility), a 58 kD intracellular protein expressed transiently on the surface of transformed lymphocytes (Hardwick et al., J. Cell Biol., 117:1343-1350 (1992); Turley et al., Exp. Cell Res., 207:277-282 (1993)). RHAMM expression in fibroblasts was reported to promote metastasis and play an important role in H-Ras transformation (Hall et al., infra).

Another receptor which binds HA was described by Banerji et al. (Banerji et al., supra). Banerji et al. report a receptor on lymph vessel walls, referred to as "LYVE-1", which is a 322-residue type I integral membrane polypeptide which has a 41% similarity to the CD44 receptor. Unlike the CD44 receptor for HA, the LYVE-1 protein is absent in blood vessels. In addition, layilin (Bono et al., Mol. Biol. Cell, 12:891-900 (2001)) and HARE (Zhou et al., J. Biol. Chem., 275:37733-37741 (2000)) were also described as HA receptors.

It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.

Summary of the Invention

A first aspect provides a method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

a) a WISP-1-domain 1 polypeptide consisting of amino acids 24 – 117 of SEQ ID NO:1; and

b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 – 117 of SEQ ID NO:1.

A second aspect provides a method of treating cancer in a mammal, comprising administering to said mammal an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

a) a WISP-1-domain 1 polypeptide consisting of amino acids 24 – 117 of SEQ ID NO:1; and

6

b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

A third aspect provides a method of inhibiting cancer cell motility, comprising exposing a cancer cell to an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

a) a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1; and

b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

A fourth aspect provides a method of inhibiting cancer cell motility in a mammal comprising administering to said mammal an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

a) a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1; and

b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

A fifth aspect provides use of a WISP-1-domain 1 polypeptide in the manufacture of a medicament for inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

a) a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1; and

b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

A sixth aspect provides use of a WISP-1-domain 1 polypeptide in the manufacture of a medicament for inhibiting cancer cell motility, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

a) a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1; and

b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

A seventh aspect provides use of a WISP-1-domain 1 polypeptide in the manufacture of a medicament for treating cancer, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

7

a)   a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1;   and

b)   a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

5   Applicant has surprisingly found that WISP-1 can induce HAS2 (hyaluronan synthase 2), CD44, and RHAMM mRNA expression, CD44 protein synthesis, and HA secretion. The induction or secretion of such molecules may promote or increase cancer cell growth, motility and/or metastatic potential. Disclosed herein are WISP-1 antagonists and methods of using 10   such antagonists. The antagonists described herein find utility for, among other things, *in vitro*, *in situ*, or *in vivo* diagnosis or treatment of mammalian cancer cells or other pathological conditions associated with the induction or secretion of HAS2, HA, CD44 or RHAMM.

Disclosed herein are isolated WISP-1 antagonists. Such antagonists 15   may comprise antibodies, such as WISP-1 antibodies.   In preferred embodiments, the antagonists may block or neutralize WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM.   Such antagonistic antibodies may, for example, be monoclonal antibodies, chimeric antibodies, humanized antibodies, or human antibodies. The WISP-1 antagonists contemplated for 20   use according to the disclosure include WISP-1 immunoadhesins, WISP-1 variants, covalently modified forms thereof, or fusion proteins thereof. By way of example, such antagonists may include pegylated WISP-1 or WISP-1 fused to heterologous sequences such as epitope tags or leucine zippers. The methods contemplate the use of a single type of antagonist molecule or 25   a combination of two or more types of antagonists.

The methods of the disclosure include methods to treat pathological conditions or diseases in mammals associated with or resulting from WISP-1, including, induction or secretion of HAS2, HA, CD44 or RHAMM by WISP-1. In the methods of treatment, WISP-1 antagonists may be administered to the 30   mammal suffering from such pathological condition or disease. For example, also disclosed is a method comprising exposing a mammalian cell(s), such as a cancer cell(s), to one or more WISP-1 antagonists in an amount effective to decrease, neutralize or block WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM. The cell may be in cell culture or in a mammal, *e.g.* a 35   mammal suffering from, for instance, cancer.

Also disclosed are compositions which comprise one or more WISP-1 antagonists. Optionally, the compositions of the invention will include pharmaceutically acceptable carriers or diluents. Preferably, the compositions will include one or more WISP-1 antagonists in an amount which 40   is therapeutically effective to treat a pathological condition or disease.

8

Also disclosed are articles of manufacture and kits which include one or more WISP-1 antagonists.

Also disclosed are methods of conducting screening assays to identify candidate molecules, such as small molecule compounds, polypeptides or antibodies, which act as antagonists with respect to blocking or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM.

Also disclosed are isolated WISP-1 antagonists which inhibit or neutralize the induction or secretion of HAS2, HA, CD44 or RHAMM by native WISP-1 polypeptide in at least one type of mammalian cell, said antagonist being selected from the group consisting of an anti-WISP-1 antibody, a WISP-1 immunoadhesin, a WISP-1 variant, and fusion proteins thereof. The antagonist may comprise an anti-WISP-1 antibody which binds native human WISP-1 polypeptide comprising amino acids 23-367 of Figures 9A-9C or one or more domains of WISP-1 comprising amino acids encoded by the sequences of SEQ ID NO:3; 4; 5; 6; 7; 8; 9; 10; or 11 herein. The anti-WISP-1 antibody may be a chimeric, humanized or human antibody.

Also disclosed are compositions comprising the antagonists described herein and a carrier, optionally the carrier is a pharmaceutically-acceptable carrier.

Also disclosed are methods of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of WISP-1 antagonist, wherein said WISP-1 antagonist is selected from the group consisting of:

a) a WISP-1 immunoadhesin;

b) a WISP-1 polypeptide linked to a nonproteinaceous polymer selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene;

c) a WISP-1 antibody; and

d) a WISP-1 variant.

The WISP-1 immunoadhesins employed in the methods may comprise a WISP-1 sequence fused to a Fc region of an immunoglobulin. The anti-WISP-1 antibodies employed in the methods may bind native human WISP-1 comprising amino acids 23-367 of Figures 9A-9C, or one or more of the domains of WISP-1 described in the Examples below. In the methods, the mammalian cells may comprise cancer cells, and optionally the cells comprise colon or colorectal cancer cells, breast cancer cells, lung cancer cells, or brain cancer cells (such as glioma or glioblastoma).

Also disclosed are methods of treating cancer in a mammal, comprising administering to said mammal an effective amount of WISP-1 antagonist.

9

Optionally, in said methods, the antagonist may inhibit or neutralize induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of mammalian cell and said antagonist is selected from the group consisting of an anti-WISP-1 antibody, a WISP-1 immunoadhesin and a WISP-1 variant. Optionally, the antagonist may act to inhibit cancer cell growth or cancer cell metastasis. The cancer in the mammal may comprise colon or colorectal cancer cells, breast cancer cells, lung cancer cells, or brain cancer cells (such as glioma or glioblastoma). Optionally, the antagonist(s) employed in the methods inhibits or reduces cancer cell growth or metastasis. Also, in the methods, chemotherapy, radiation, proodrug, cytotoxic agent, growth inhibitory agent, or cytokine may also be administered to the mammal.

Also disclosed are antibodies which specifically bind to one or more domains of WISP-1 polypeptide (described further in the Examples below) comprising amino acids encoded by the sequences of SEQ ID NO:3; 4; 5; 6; 7; 8; 9; 10; or 11 herein. Optionally, the antibody is a monoclonal antibody. Optionally, the monoclonal antibody comprises the 3D11, 11C2, 9C10, 5D4, or 9C11 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively.

Also disclosed are antibodies which bind to the same epitope as the epitope to which the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively, binds.

Also disclosed is the hybridoma cell line which produces monoclonal antibody 3D11, 11C2, 9C10, 5D4, or 9C11 and deposited with ATCC as accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively, and the monoclonal antibody 3D11, 11C2, 9C10, 5D4, or 9C11 secreted by the hybridoma deposited with ATCC as accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively.

Also disclosed are isolated anti-WISP-1 monoclonal antibodies, comprising antibodies which bind to WISP-1 polypeptide and competitively inhibit binding of the monoclonal antibody produced by the hybridoma deposited as ATCC accession no. PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627 to said WISP-1 polypeptide.

Also disclosed are chimeric or humanized anti-WISP-1 antibodies which specifically bind to WISP-1 polypeptide and comprise (a) a sequence derived from the 3D11, 11C2, 9C10, 5D4, or 9C11 antibody secreted by the hybridoma deposited with ATCC as accession number PTA-4624, PTA-4628, PTA-4625, or PTA-4627, respectively. Optionally, such antibodies may comprise

9a

a heavy chain, light chain or variable regions derived from the 3D11, 11C2, 9C10, 5D4, or 9C11 antibody.

5   The anti-WISP-1 antibodies may be linked to one or more non-proteinaceous polymers selected from the group consisting of polyethylene glycol, polypropylene glycol, and polyoxyalkylene, or to a cytotoxic agent or enzyme, or to a radioisotope, fluorescent compound or chemiluminescent compound.

<u>Brief Description of the Drawings</u>

Figures 1A-1F show WISP-1 promotion of hyaluronan production.
5   Particle exclusion assay demonstrating a hyaluronan coat at the
surface of NRK/WISP-1H (A) and NRK/WISP-1L (B) but absent from
NRK/control (C). NRK/WISP-1H (D) and NRK/control (E) were stained for
hyaluronan with bHABP. F, Time course of HA accumulation in
NRK/WISP-1H and NRK/control media.

10   Figures 2A-2C show WISP-1 increases HAS2, CD44 and RHAMM mRNA
expression and CD44 protein expression. A, Real time RT-PCR analysis
of HAS1, HAS2, HAS3, CD44, RHAMM and hyaluronidase (Hyal) mRNA
expression in NRK/WISP-1H, NRK/WISP-1L and NRK/control cells.
Results are given as fold induction over the expression in
15   NRK/control cells. B, Flow cytometry analysis of CD44 expression in
NRK/WISP-1H and NRK/control cells. The shaded area represents the
fluorescence intensity of the secondary antibody alone. C, Western
blot analysis of CD44 protein in NRK/WISP-1H and NRK/control cells.
Actin staining was used as a loading control.

20   Figures 3A-3G show WISP-1 expression increases cell motility
and modifies cellular morphology. NRK/control cells (A) formed
defined colonies when plated at low density whereas NRK/WISP-1L (B)
and NRK/WISP-1H cells (C) scattered. NRK/WISP-1H (E) showed a de-
differentiated spindloid morphology with lamelipodia compared to
25   NRK/control cells (D). F, The random migration of NRK/WISP-1H and
NRK/control cells was measured over 15 hours using time lapse
microscopy. Results represent the typical average migration distance
of cells in one field. G, Motility of NRK/WISP-1H and NRK/control
cells was evaluated by a cell wound healing assay and measured after
30   15 hours using time lapse microscopy. Data represent the results of
a typical experiment.

Figures 4A-4C show WISP-1 addition induces HAS2 mRNA expression
and haptotactic migration of NRK cells. A, Real time RT-PCR analysis
of HAS2 and CD44 expression in NRK cells seeded on coated surface.
35   In certain cases the coated substrates were further incubated with
WISP-1 (treatment). Results are given in fold induction over
expression in NRK cells plated on non-coated, non-treated surface.
The underside of modified Boyden chamber filters were coated and NRK
cells (B) or SW480 cells (C) were added to the upper chamber. In
40   certain cases, additions were made directly to the lower chamber.

Cell motility was evaluated by counting the cells that migrated to
the lower side of the insert.

Figures 5A-5E show WISP-1, HAS2 and CD44 over-expression and
increased cell motility in C57MG/Wnt-1 cells and MMTV-Wnt-1
5   transgenic mice mammary tumors. A, Real time RT-PCR analysis of
WISP-1, HAS2 and CD44 expression in C57MG/Wnt-1 and C57MG/control
cells. Results are given as fold induction over expression in
C57MG/control cells. B, Western blot analysis of CD44 content in
C57MG/Wnt-1 and C57MG/control cells. Actin staining was used as a
10   loading control. C, C57MG/control cells formed distinct colonies
when plated at low density whereas C57MG/Wnt-1 cells scattered.
Semi-quantitative RT-PCR analysis of HAS2 (D) and CD44 (E) in mammary
tumors of MMTV-Wnt-1 transgenic mice. Results are expressed as
relative fold induction over the expression in normal mammary gland
15   tissue.

Figures 6A-6H show WISP-1, HAS2 and CD44 expression and HA
accumulation in MMTV-Wnt-1 transgenic mammary tumors. In situ
hybridization of WISP-1 (A, B) HAS2 (C, D) and CD44 (E, F),
immunohistochemistry of CD44 (G) and bHABP fluorescent staining of
20   hyaluronan (H) in MMTV-Wnt-1 transgenic mouse mammary tumors. t,
tumor; s, stroma.

Figures 7A-7L show WISP-1 expression promotes metastatic lung
colonization and tumor growth. The effect of WISP-1 was analyzed by
injecting NRK/control, NRK/WISP-1L or NRK/WISP-1H cells in the tail
25   vein of nude mice. At various times after injection, lungs were
imaged by MRI (A, D, G, J), excised and their gross appearance (B, E,
H, K) and histological features (C, F, I, L) were recorded. The
severity of lung invasion by tumors was graded as normal (A, B, C);
grade I (D, E, F); grade 11 (G, H, I) or grade III (J, K, L).

30   Figures 8A-B show CD44 antibody prevents NRK/WISP-1H cell
metastasis. NRK/WISP-1H cells (2.5 X 10^5 cells) were injected in the
tail vein of nude mice. Mice were treated twice a week with 10 mg/kg
of a CD44 antibody, an isotype control antibody or with buffer only
(PBS). The lungs were excised after four weeks for gross anatomical
35   analysis. Picture of a normal lung is shown for comparison.

Figures 9A-9C show the nucleotide (SEQ ID NO:2) and putative
amino acid sequence (SEQ ID NO:1) of native human WISP-1.

Figure 10 shows the effects of WISP-1 expression on NRK
metastatic potential.

40   Figures 11A-B show the binding properties of WISP-1 antibodies
to various WISP-1 constructs and preparations.

Figures 12A-G show diagrams of various domains of WISP-1 polypeptide and the results of assays conducted to identify the epitopes recognized by the WISP-1 antibodies 11C2, 5D4, 9C11, and 3D11, respectively. Figure 12C illustrates the amino acid sequence provided in SEQ ID NO: 20.

Figure 13 shows the results on an assay conducted to identify the epitope recognized by the WISP-1 antibody 9C10.

Figure 14 shows the results of an ELISA demonstrating detection of WISP-1 by WISP-1 antibodies.

Figure 15 shows the results of an ELISA binding assay demonstrating that WISP-1 antibodies recognizing the variable region of WISP-1 can inhibit WISP-1 binding to heparin.

Figures 16A-B show the results of an assay detecting inhibition of haptotaxis of NRK cells by WISP-1 antibodies (16A) and a chart summarizing the properties and characteristics of WISP-1 antibodies (16B).

Figures 17A-E show the results of an in vivo study of the effects of WISP-1 antibodies. After 3 weeks, the severity of the lesions found in WISP-1 antibody treated animals was greatly attenuated compared to control (Fig. 17 a, b). The number of nodules and the average area of the metastatic foci found in mice treated with WISP-1 antibodies (n=5) were reduced compared to animals treated with a control antibody (Fig. 17 c,d). The total pulmonary area covered by the lesions was reduced by 82-97% compared to animal treated with an isotype control antibody (Fig. 17e).

Figure 18 is a bar diagram showing expression of WISP-1 in 4T1/control, 4T1/WISP-1L, 4T1/WISP-1H, NRK/control, NRK/WISP-1L, and WISP-1H cell lines as measured by semi-quantitative RT-PCR (Taqman).

Figure 19 shows the results of an in vitro assay on colony formation of 4T1/control, 4T1/WISP-1L, and 4T1/WISP-1H cell lines.

Figure 20 shows the results of an in vitro assay measuring invasion index using a Matrigel modified Boyden chamber system and 4T1/control, 4T1/WISP-1L, and 4T1/WISP-1H cell lines.

Figures 21A-B show effects of WISP-1 expression on mammary epithelial cell tumorigenesis. The effect of WISP-1 was analyzed by injecting 4T1/control 1, 4T1/control 2, 4T1/WISP-1L or 4T1/WISP-1H cells in Balb/C mice. Tumor volume (21A) and tumor weight (21 B) are reported.

Figure 22 is a bar diagram illustrating the relative expression of HAS2 and CD44 in tumors formed by the inoculated 4T1/control, 4T1/WISP-1L and 4T1/WISP-1H cells.

Figures 23A-F illustrate the WISP-1 effects on mammary epithelial cells metastasis evaluated in vivo by inoculating 4T1 cells in mice mammary fat pads and examining the extent of the metastatic propagation by micro computer tomography and histology.

5   After 31 days, the mice inoculated with 4T1/WISP-1L or 4T1/WISP-1H cells had extensive lung metastasis (Fig. 23b and 23d) compared to the 4T1/control injected mice (Fig. 23a and 23c). Using immunohistochemistry, it was also observed that the 4T1/WISP-1 pulmonary metastatic foci expressed high levels of CD44 (Fig. 23e).

10   In these tumors, CD44 was localized at the plasma membrane of the 4T1/WISP-1 cells (Fig. 23f).

Figure 24A shows WISP-1 expression in NRK/control, NRK/WISP-1_1234, NRK/WISP-1_134, NRK/WISP-1_234, NRK/WISP-1_123 and NRK/WISP-1_124 cells lines, as measured by semi-quantitative RT-PCR (Taqman);

15   the results are expressed as fold relative to WISP-1 expression in NRK/WISP-1_1234. Figure 24B illustrates the effects of these constructs on tumorigenesis in vivo; the results are shown by the effects on tumor volume.

Figure 25 shows the histological analysis of the excised tumors

20   referred to in Figure 24 and revealed that the neoplastic cells from NRK/WISP-1_234 tumors were phenotypically similar to the neoplastic cells from NRK/WISP-1_1234 tumors. In these tumors, cells appeared fibroblastic, differentiated and spindloid. The neoplastic cells from NRK/WISP-1_134 tumors were phenotypically different and appeared

25   less differentiated, frequently multinucleated and had a brisk mitotic rate as demonstrated by the presence of multiple mitotic figures (arrows).

Figure 26 shows the histological analysis of the excised tumors in the NRK/WISP-1_134 xenograft referred to in Figure 24, and reveals

30   the neoplastic cells invaded several blood vessels adjacent to the tumor.

Figure 27 shows expression as fold invasion compared to a control in which HEK 293 cells transfected with an empty vector were plated in the modified Boyden chamber system. 4T1 cells demonstrated

35   a 4 fold increase invasion when HEK 293 cells expressing constructs WISP-1_1234, WISP-1_134 or WISP-123 were seeded in the lower chamber.

Figures 28A-28B illustrate the effects of soluble WISP-1-domain-1 on WISP-1 promoted 4T1 cell invasion, as evaluated using a Matrigel coated modified Boyden chamber system. The results are

40   expressed as relative fold invasion compared to 4T1/ control cells.

WISP-1-domain-1-His and WISP-1-domain-1-Fc demonstrated a dose dependent
antagonistic activity toward WISP-1 promoted 4T1 invasion.

 Figure 29 illustrates an in situ hybridization analysis of tissues
from the HPAC xenograft model of human pancreatic adenocarcinomas to
evaluate WISP-1 expression.

 Figure 30 shows a graph illustrating the effects of WISP-1 constructs
on tumor volume in a nude mouse model.

 Figure 31 shows *in situ* hybridization analyses evaluating WISP-1
expression in primary human pancreatic adenocarcinomas.

 Figure 32 shows immunohistochemical staining evaluating WISP-1
expression in primary colon adenocarcinomas.

Detailed Description of the Invention

I. Definitions

 In the claims which follow and in the description of the invention,
except where the context requires otherwise due to express language or
necessary implication, the word "comprise" or variations such as
"comprises" or "comprising" is used in an inclusive sense, i.e. to specify
the presence of the stated features but not to preclude the presence or
addition of further features in various embodiments of the invention.

 The term "WISP polypeptide" refers to the family of native-sequence
human and mouse WISP proteins and variants described herein whose genes are
induced at least by Wnt-1. This term includes WISP-1 and variants thereof.
Such WISP-1 proteins are described further below and in PCT application
WO99/21998 published May 6, 1999, US 6,387,657 B1 issued May 14, 2002, and
in Pennica et al., Proc. Natl. Acad. Sci., 95:14717-14722 (1998).

 The terms "WISP-1 polypeptide", "WISP-1 homologue" and grammatical
variants thereof, as used herein, encompass native- sequence WISP-1 protein
and variants (which are further defined herein). The WISP-1 polypeptide
may be isolated from a variety of sources, such as from human tissue types
or from another source, or prepared by recombinant or synthetic methods, or
by any combination of these and similar techniques.

 The term "native-sequence WISP-1 polypeptide" comprises a polypeptide
having the same amino acid sequence as a WISP-1 polypeptide derived from
nature. Such native-sequence WISP-1 polypeptides can be isolated from
nature or can be produced by recombinant or synthetic means. The term
"native-sequence WISP-1 polypeptide" specifically encompasses naturally
occurring truncated or secreted forms of a WISP-1 polypeptide disclosed
herein, naturally occurring variant forms (*e.g.*, alternatively spliced

forms or splice variants), and naturally occurring allelic variants of a WISP-1 polypeptide. In one embodiment of the invention, the native-sequence WISP-1 polypeptide is a mature or full-length native-sequence human WISP-1 polypeptide comprising amino acids 23 to 367 of Figure 9 or

amino acids 1 to 367 of Figure 9, respectively, with or without N-terminal methionine.

In another embodiment of the invention, the native-sequence WISP-1 polypeptide is the full-length or mature native-sequence human WISP-1 polypeptide comprising amino acids 23 to 367 or 1 to 367 of Figure 9 wherein the valine residue at position 184 or the alanine residue at position 202 has/have been changed to an isoleucine or serine residue, respectively, with or without N-terminal methionine.

In another embodiment of the invention, the native-sequence WISP-1 polypeptide is the full-length or mature native-sequence human WISP-1 polypeptide comprising amino acids 23 to 367 or 1 to 367 of the Figure 9 wherein the valine residue at position 184 and the alanine residue at position 202 has/have been changed to an isoleucine or serine residue, respectively, with or without N-terminal methionine.

In another embodiment of the invention, the native-sequence WISP-1 polypeptide is one which is encoded by a nucleotide sequence comprising one of the human WISP-1 splice or other native-sequence variants, including SEQ ID NOS:23, 24, 25, 26, 27, 28, or 29 shown in WO99/21998, with or without an N-terminal methionine.

The term "WISP-1 variant" means an active WISP-1 polypeptide as defined below having at least about 80%, preferably at least about 85%, 86%, 87%, 88%, 89%, more preferably at least about 90%, 91%, 92%, 93%, 94%, most preferably at least about 95%, 96%, 97%, 98%, or 99% amino acid sequence identity with human mature WISP-1 having the deduced amino acid sequence shown in Fig. 9, or a soluble fragment thereof. Such variants include, for instance, WISP-1 polypeptides wherein one or more amino acid residues are added to, or deleted from, the N- or C-terminus of the full-length or mature sequences of Figure 9, or WISP-1 polypeptides wherein one or more amino acid residues are inserted or deleted from the internal sequence or domains of the polypeptide, including variants from other species, but excludes a native-sequence WISP-1 polypeptide. Preferably such a variant acts as an antagonist, as defined below.

An "extracellular domain", "ECD" or "secreted" protein refers to a form of a polypeptide which is essentially free of any transmembrane and cytoplasmic domains. A "secreted" form of a protein or polypeptide may or may not include a signal sequence.

"Stringent conditions" are those that (1) employ low ionic strength and high temperature for washing, for example, 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate

at 50°C; (2) employ during hybridization a denaturing agent, such as
formamide, for example, 50% (vol/vol) formamide with 0.1% bovine
serum albumin/0.1% Ficoll/0.1% polyvinylpyrrolidone/50 mM sodium
phosphate buffer at pH 6.5 with 750 mM sodium chloride, 75 mM sodium

5   citrate at 42°C; (3) employ 50% formamide, 5 x SSC (0.75 M NaCl,
0.075 M sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium
pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA
(50 μg/ml), 0.1% SDS, and 10% dextran sulfate at 42°C, with washes at
42°C in 0.2 x SSC and 0.1% SDS; or (4) employ a buffer of 10% dextran

10   sulfate, 2 x SSC (sodium chloride/sodium citrate), and 50% formamide
at 55°C, followed by a high-stringency wash consisting of 0.1 x SSC
containing EDTA at 55°C.

"Moderately stringent conditions" are described in Sambrook et
al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring

15   Harbor Laboratory Press, 1989), and include the use of a washing
solution and hybridization conditions (e.g., temperature, ionic
strength, and percent SDS) less stringent than described above. An
example of moderately stringent conditions is a condition such as
overnight incubation at 37°C in a solution comprising: 20% formamide,

20   5 x SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium
phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate, and
20 mg/mL denatured sheared salmon sperm DNA, followed by washing the
filters in 1 x SSC at about 37-50°C. The skilled artisan will
recognize how to adjust the temperature, ionic strength, etc., as

25   necessary to accommodate factors such as probe length and the like.

"Isolated," when used to describe the various polypeptides
disclosed herein, means polypeptide that has been identified and
separated and/or recovered from a component of its natural
environment. Contaminant components of its natural environment are

30   materials that would typically interfere with diagnostic or
therapeutic uses for the polypeptide, and may include enzymes,
hormones, and other proteinaceous or non-proteinaceous solutes. In
preferred embodiments, the polypeptide will be purified (1) to a
degree sufficient to obtain at least 15 residues of N-terminal or

35   internal amino acid sequence by use of a spinning cup sequenator, or
(2) to homogeneity by SDS-PAGE under non-reducing or reducing
conditions using Coomassie blue or, preferably, silver stain.
Isolated polypeptide includes polypeptide in situ within recombinant
cells, since at least one component of the WISP natural environment

40   will not be present. Ordinarily, however, isolated polypeptide will
be prepared by at least one purification step.

The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

A "liposome" is a small vesicle composed of various types of lipids, phospholipids and/or surfactant which is useful for delivery of a drug (such as the insulin and insulin variants disclosed herein) to a mammal. The components of the liposome are commonly arranged in a bilayer formation, similar to the lipid arrangement of biological membranes.

The terms "amino acid" and "amino acids" refer to all naturally occurring L-alpha-amino acids. This definition is meant to include norleucine, ornithine, and homocysteine. The amino acids are identified by either the single-letter or three-letter designations:

Asp	D	aspartic acid	Ile	I	isoleucine
Thr	T	threonine	Leu	L	leucine
Ser	S	serine	Tyr	Y	tyrosine
Glu	E	glutamic acid	Phe	F	phenylalanine
Pro	P	proline	His	H	histidine
Gly	G	glycine	Lys	K	lysine
Ala	A	alanine	Arg	R	arginine
Cys	C	cysteine	Trp	W	tryptophan
Val	V	valine	Gln	Q	glutamine
Met	M	methionine	Asn	N	asparagine

In the Sequence Listing and Figures, certain other single-
letter or three-letter designations may be employed to refer to and
identify two or more amino acids or nucleotides at a given position
5   in the sequence.

"Percent (%) amino acid sequence identity" with respect to the
polypeptide sequences identified herein is defined as the percentage
of amino acid residues in a candidate sequence that are identical
with the amino acid residues in such a polypeptide sequence
10   identified herein, after aligning the sequences and introducing gaps,
if necessary, to achieve the maximum percent sequence identity, and
not considering any conservative substitutions as part of the
sequence identity. Alignment for purposes of determining percent
amino acid sequence identity can be achieved in various ways that are
15   within the skill in the art, for instance, using publicly available
computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign
(DNASTAR) software. Those skilled in the art can determine
appropriate parameters for measuring alignment, including any
algorithms needed to achieve maximal alignment over the full-length
20   of the sequences being compared. For purposes herein, however, %
amino acid sequence identity values are obtained as described below
by using the sequence comparison computer program ALIGN-2, wherein
the complete source code for the ALIGN-2 program is provided in the
table below. The ALIGN-2 sequence comparison computer program was
25   authored by Genentech, Inc. and the source code shown in the table
below has been filed with user documentation in the U.S. Copyright
Office, Washington D.C., 20559, where it is registered under U.S.
Copyright Registration No. TXU510087. The ALIGN-2 program is
publicly available through Genentech, Inc., South San Francisco,
30   California or may be compiled from the source code provided in the
table below. The ALIGN-2 program should be compiled for use on a
UNIX operating system, preferably digital UNIX V4.0D. All sequence
comparison parameters are set by the ALIGN-2 program and do not vary.

The term "epitope tagged" when used herein refers to a chimeric
35   polypeptide comprising a polypeptide fused to a "tag polypeptide".
The tag polypeptide has enough residues to provide an epitope against
which an antibody can be made. The tag polypeptide preferably also
is fairly unique so that the antibody does not substantially cross-
react with other epitopes. Suitable tag polypeptides generally have
40   at least six amino acid residues and usually between about 8 and 50

amino acid residues (preferably, between about 10 and 20 amino acid residues).

As used herein, the term "immunoadhesin" designates antibody-like molecules which combine the binding specificity of a heterologous protein (an "adhesin") with the effector functions of immunoglobulin constant domains. Structurally, the immunoadhesins comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is "heterologous"), and an immunoglobulin constant domain sequence. The adhesin part of an immunoadhesin molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand. The immunoglobulin constant domain sequence in the immunoadhesin may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3, or IgG-4 subtypes, IgA (including IgA-1 and IgA-2), IgE, IgD or IgM.

The term "antagonist" is used in the broadest sense, and includes any molecule that partially or fully blocks, inhibits, or neutralizes one or more biological activities of WISP-1 polypeptide, *in vitro*, *in situ*, or *in vivo*. Examples of such biological activities of WISP-1 polypeptides include induction or secretion of HAS2, HA, CD44 or RHAMM in at least one type of mammalian cell. An antagonist may function in a direct or indirect manner. For instance, the antagonist may function to partially or fully block, inhibit or neutralize one or more biological activities of WISP-1 polypeptide, *in vitro*, *in situ*, or *in vivo*, e.g., as a result of its direct binding to WISP-1 polypeptide. The antagonist may also function indirectly to partially or fully block, inhibit or neutralize one or more biological activities of WISP-1 polypeptide, *in vitro*, *in situ*, or *in vivo* as a result of, e.g., blocking or inhibiting another effector molecule.

The term "WISP-1 antagonist" refers to any molecule that partially or fully blocks, inhibits, or neutralizes a biological activity of WISP-1 and include but are not limited to, antibodies, immunoadhesins, WISP-1 immunoadhesins, WISP-1 fusion proteins, covalently modified forms of WISP-1, WISP-1 variants and fusion proteins thereof, WISP-1 antibodies, and higher oligomer forms of WISP-1 (dimers, aggregates) or homo- or heteropolymer forms of WISP-1.

To determine whether a WISP-1 antagonist molecule partially or fully blocks, inhibits or neutralizes a biological activity of WISP-1, assays may be conducted to assess the effect(s) of the antagonist molecule on, for example, various cells (as described in the Examples)

19

or in an in vivo murine model of lung cancer metastasis. The various assays may be conducted in known *in vitro* or *in vivo* assay formats. Preferably, the WISP-1 antagonists employed in the methods described herein will be capable of blocking or neutralizing at least one type

5 of WISP-1 activity, which may optionally be determined in assays such as described herein.

The term "antibody" is used in the broadest sense and specifically covers, for example, single monoclonal antibodies, antibody compositions with polyepitopic specificity, single chain

10 antibodies, and fragments of antibodies. "Antibody" as used herein includes intact immunoglobulin or antibody molecules, polyclonal antibodies, multispecific antibodies (i.e., bispecific antibodies formed from at least two intact antibodies) and immunoglobulin fragments (such as Fab, F(ab')$_2$, or Fv), so long as they exhibit any of

15 the desired antagonistic properties described herein.

Antibodies are typically proteins or polypeptides which exhibit binding specificity to a specific antigen. Native antibodies are usually heterotetrameric glycoproteins, composed of two identical light (L) chains and two identical heavy (H) chains. Typically, each

20 light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies between the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V_H) followed by a number of constant

25 domains. Each light chain has a variable domain at one end (V_L) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain. Particular amino acid residues are

30 believed to form an interface between the light and heavy chain variable domains [Chothia et al., J. Mol. Biol., 186:651-663 (1985); Novotny and Haber, Proc. Natl. Acad. Sci. USA, 82:4592-4596 (1985)]. The light chains of antibodies from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and

35 lambda, based on the amino acid sequences of their constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG and IgM, and several of these may be further divided into subclasses

40 (isotypes), e.g., IgG-1, IgG-2, IgG-3, and IgG-4; IgA-1 and IgA-2. The heavy chain constant domains that correspond to the different classes

of immunoglobulins are called alpha, delta, epsilon, gamma, and mu, respectively.

"Antibody fragments" comprise a portion of an intact antibody, generally the antigen binding or variable region of the intact

5   antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments, diabodies, single chain antibody molecules, and multispecific antibodies formed from antibody fragments.

The term "variable" is used herein to describe certain portions of the variable domains which differ in sequence among antibodies and

10 are used in the binding and specificity of each particular antibody for its particular antigen. However, the variability is not usually evenly distributed through the variable domains of antibodies. It is typically concentrated in three segments called complementarity determining regions (CDRs) or hypervariable regions both in the light

15 chain and the heavy chain variable domains. The more highly conserved portions of the variable domains are called the framework (FR). The variable domains of native heavy and light chains each comprise four

FR regions, largely adopting a β-sheet configuration, connected by

three CDRs, which form loops connecting, and in some cases forming

20 part of, the β-sheet structure. The CDRs in each chain are held together in close proximity by the FR regions and, with the CDRs from the other chain, contribute to the formation of the antigen binding site of antibodies [see Kabat, E.A. et al., Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, MD

25 (1987)]. The constant domains are not involved directly in binding an antibody to an antigen, but exhibit various effector functions, such as participation of the antibody in antibody-dependent cellular toxicity.

The term "monoclonal antibody" as used herein refers to an

30 antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site.

35 Furthermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen.

The monoclonal antibodies herein include chimeric, hybrid and

40 recombinant antibodies produced by splicing a variable (including

21

hypervariable) domain of the antibody of interest with a constant
domain (e.g. "humanized" antibodies), or a light chain with a heavy
chain, or a chain from one species with a chain from another species,
or fusions with heterologous proteins, regardless of species of origin
5   or immunoglobulin class or subclass designation, as well as antibody
fragments (e.g., Fab, F(ab')$_2$, and Fv), so long as they exhibit the
desired biological activity or properties. See, e.g. U.S. Pat. No.
4,816,567 and Mage et al., in Monoclonal Antibody Production
Techniques and Applications, pp.79-97 (Marcel Dekker, Inc.: New York,
10   1987).

        Thus, the modifier "monoclonal" indicates the character of the
antibody as being obtained from a substantially homogeneous population
of antibodies, and is not to be construed as requiring production of
the antibody by any particular method. For example, the monoclonal
15   antibodies to be used in accordance with the present invention may be
made by the hybridoma method first described by Kohler and Milstein,
Nature, 256:495 (1975), or may be made by recombinant DNA methods such
as described in U.S. Pat. No. 4,816,567. The "monoclonal antibodies"
may also be isolated from phage libraries generated using the
20   techniques described in McCafferty et al., Nature, 348:552-554 (1990),
for example.

        "Humanized" forms of non-human (e.g. murine) antibodies are
specific chimeric immunoglobulins, immunoglobulin chains, or fragments
thereof (such as Fv, Fab, Fab', F(ab')$_2$ or other antigen-binding
25   subsequences of antibodies) which contain minimal sequence derived
from non-human immunoglobulin. For the most part, humanized
antibodies are human immunoglobulins (recipient antibody) in which
residues from a complementary determining region (CDR) of the
recipient are replaced by residues from a CDR of a non-human species
30   (donor antibody) such as mouse, rat, or rabbit having the desired
specificity, affinity, and capacity. In some instances, Fv framework
region (FR) residues of the human immunoglobulin are replaced by
corresponding non-human residues. Furthermore, the humanized antibody
may comprise residues which are found neither in the recipient
35   antibody nor in the imported CDR or framework sequences. These
modifications are made to further refine and optimize antibody
performance. In general, the humanized antibody will comprise
substantially all of at least one, and typically two, variable
domains, in which all or substantially all of the CDR regions
40   correspond to those of a non-human immunoglobulin and all or
substantially all of the FR regions are those of a human

immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin.

A "human antibody" is one which possesses an amino acid
5   sequence which corresponds to that of an antibody produced by a human and/or has been made using any of the techniques for making human antibodies known in the art or as disclosed herein. This definition of a human antibody includes antibodies comprising at least one human heavy chain polypeptide or at least one human light chain
10   polypeptide, for example an antibody comprising murine light chain and human heavy chain polypeptides. Human antibodies can be produced using various techniques known in the art. In one embodiment, the human antibody is selected from a phage library, where that phage library expresses human antibodies (Vaughan et al. Nature
15   Biotechnology, 14:309-314 (1996): Sheets et al. PNAS, (USA) 95:6157-6162 (1998)); Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Human antibodies can also be made by introducing human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have
20   been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126;
25   5,633,425; 5,661,016, and in the following scientific publications: Marks et al., Bio/Technology, 10: 779-783 (1992); Lonberg et al., Nature, 368: 856-859 (1994); Morrison, Nature, 368:812-13 (1994); Fishwild et al., Nature Biotechnology, 14: 845-51 (1996); Neuberger, Nature Biotechnology, 14: 826 (1996); Lonberg and Huszar, Intern.
30   Rev. Immunol., 13:65-93 (1995). Alternatively, the human antibody may be prepared via immortalization of human B lymphocytes producing an antibody directed against a target antigen (such B lymphocytes may be recovered from an individual or may have been immunized in vitro). See, e.g., Cole et al., Monoclonal Antibodies and Cancer Therapy,
35   Alan R. Liss, p. 77 (1985); Boerner et al., J. Immunol., 147 (1):86-95 (1991); and US Pat No. 5,750,373.

The term "Fc region" is used to define the C-terminal region of an immunoglobulin heavy chain which may be generated by papain digestion of an intact antibody. The Fc region may be a native
40   sequence Fc region or a variant Fc region. Although the boundaries of the Fc region of an immunoglobulin heavy chain might vary, the

human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at about position Cys226, or from about position Pro230, to the carboxyl-terminus of the Fc region (using herein the numbering system according to Kabat et al., supra). The Fc region of
5   an immunoglobulin generally comprises two constant domains, a CH2 domain and a CH3 domain, and optionally comprises a CH4 domain.

By "Fc region chain" herein is meant one of the two polypeptide chains of an Fc region.

The "CH2 domain" of a human IgG Fc region (also referred to as
10   "Cγ2" domain) usually extends from an amino acid residue at about position 231 to an amino acid residue at about position 340. The CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG
15   molecule. It has been speculated that the carbohydrate may provide a substitute for the domain-domain pairing and help stabilize the CH2 domain. Burton, Molec. Immunol.22:161-206 (1985). The CH2 domain herein may be a native sequence CH2 domain or variant CH2 domain.

The "CH3 domain" comprises the stretch of residues C-terminal
20   to a CH2 domain in an Fc region (i.e. from an amino acid residue at about position 341 to an amino acid residue at about position 447 of an IgG). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g. a CH3 domain with an introduced "protroberance" in one chain thereof and a corresponding introduced
25   "cavity" in the other chain thereof; see US Patent No. 5,821,333). Such variant CH3 domains may be used to make multispecific (e.g. bispecific) antibodies as herein described.

"Hinge region" is generally defined as stretching from about Glu216, or about Cys226, to about Pro230 of human IgG1 (Burton,
30   Molec. Immunol.22:161-206 (1985)). Hinge regions of other IgG isotypes may be aligned with the IgG1 sequence by placing the first and last cysteine residues forming inter-heavy chain S-S bonds in the same positions. The hinge region herein may be a native sequence hinge region or a variant hinge region. The two polypeptide chains
35   of a variant hinge region generally retain at least one cysteine residue per polypeptide chain, so that the two polypeptide chains of the variant hinge region can form a disulfide bond between the two chains. The preferred hinge region herein is a native sequence human hinge region, e.g. a native sequence human IgG1 hinge region.

A "functional Fc region" possesses at least one "effector function" of a native sequence Fc region. Exemplary "effector functions" include C1q binding; complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated
5 cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor; BCR), etc. Such effector functions generally require the Fc region to be combined with a binding domain (e.g. an antibody variable domain) and can be assessed using various assays known in the art for evaluating such antibody effector
10 functions.

A "native sequence Fc region" comprises an amino acid sequence identical to the amino acid sequence of a Fc region found in nature.

A "variant Fc region" comprises an amino acid sequence which differs from that of a native sequence Fc region by virtue of at least one
15 amino acid modification. Preferably, the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region or to the Fc region of a parent polypeptide, e.g. from about one to about ten amino acid substitutions, and preferably from about one to about five amino acid substitutions in a native sequence Fc
20 region or in the Fc region of the parent polypeptide. The variant Fc region herein will preferably possess at least about 80% sequence identity with a native sequence Fc region and/or with an Fc region of a parent polypeptide, and most preferably at least about 90% sequence identity therewith, more preferably at least about 95% sequence
25 identity therewith.

"Antibody-dependent cell-mediated cytotoxicity" and "ADCC" refer to a cell-mediated reaction in which nonspecific cytotoxic cells that express Fc receptors (FcRs) (e.g. Natural Killer (NK) cells, neutrophils, and macrophages) recognize bound antibody on a
30 target cell and subsequently cause lysis of the target cell. The primary cells for mediating ADCC, NK cells, express FcγRIII only, whereas monocytes express FcγRI, FcγRII and FcγRIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol., 9:457-92 (1991). To assess
35 ADCC activity of a molecule of interest, an in vitro ADCC assay, such as that described in US Patent No. 5,500,362 or 5,821,337 may be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of

interest may be assessed *in vivo*, *e.g.*, in a animal model such as
that disclosed in Clynes *et al.* PNAS (USA), 95:652-656 (1998).

"Human effector cells" are leukocytes which express one or more
FcRs and perform effector functions. Preferably, the cells express
5   at least FcγRIII and perform ADCC effector function. Examples of
human leukocytes which mediate ADCC include peripheral blood
mononuclear cells (PBMC), natural killer (NK) cells, monocytes,
cytotoxic T cells and neutrophils; with PBMCs and NK cells being
preferred. The effector cells may be isolated from a native source
10 thereof, *e.g.* from blood or PBMCs as described herein.

The terms "Fc receptor" and "FcR" are used to describe a
receptor that binds to the Fc region of an antibody. The preferred
FcR is a native sequence human FcR. Moreover, a preferred FcR is one
which binds an IgG antibody (a gamma receptor) and includes receptors
15 of the FcγRI, FcγRII, and FcγRIII subclasses, including allelic
variants and alternatively spliced forms of these receptors. FcγRII
receptors include FcγRIIA (an "activating receptor") and FcγRIIB (an
"inhibiting receptor"), which have similar amino acid sequences that
differ primarily in the cytoplasmic domains thereof. Activating
20 receptor FcγRIIA contains an immunoreceptor tyrosine-based activation
motif (ITAM) in its cytoplasmic domain. Inhibiting receptor FcγRIIB
contains an immunoreceptor tyrosine-based inhibition motif (ITIM) in
its cytoplasmic domain (reviewed in Daëron, Annu. Rev. Immunol.,
15:203-234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu.
25 Rev. Immunol., 9:457-92 (1991); Capel *et al.*, Immunomethods, 4:25-34
(1994); and de Haas *et al.*, J. Lab. Clin. Med., 126:330-41 (1995).
Other FcRs, including those to be identified in the future, are
encompassed by the term "FcR" herein. The term also includes the
neonatal receptor, FcRn, which is responsible for the transfer of
30 maternal IgGs to the fetus (Guyer *et al.*, J. Immunol., 117:587
(1976); and Kim *et al.*, J. Immunol., 24:249 (1994)).

"Complement dependent cytotoxicity" and "CDC" refer to the
lysing of a target in the presence of complement. The complement
activation pathway is initiated by the binding of the first component
35 of the complement system (C1q) to a molecule (*e.g.* an antibody)
complexed with a cognate antigen. To assess complement activation, a
CDC assay, *e.g.* as described in Gazzano-Santoro *et al.*, J. Immunol.
Methods, 202:163 (1996), may be performed.

An "affinity matured" antibody is one with one or more
40 alterations in one or more CDRs thereof which result an improvement

in the affinity of the antibody for antigen, compared to a parent
antibody which does not possess those alteration(s).   Preferred
affinity matured antibodies will have nanomolar or even picomolar
affinities for the target antigen.   Affinity matured antibodies are
5   produced by procedures known in the art.   Marks et al.
Bio/Technology, 10:779-783 (1992) describes affinity maturation by VH
and VL domain shuffling.   Random mutagenesis of CDR and/or framework
residues is described by: Barbas et al. Proc Nat. Acad. Sci, USA
91:3809-3813 (1994); Schier et al. Gene, 169:147-155 (1995); Yelton
10   et al. J. Immunol., 155:1994-2004 (1995); Jackson et al., J.
Immunol., 154(7):3310-9 (1995); and Hawkins et al, J. Mol. Biol.,
226:889-896 (1992).

The term "immunospecific" as used in "immunospecific binding of
antibodies" for example, refers to the antigen specific binding
15   interaction that occurs between the antigen-combining site of an
antibody and the specific antigen recognized by that antibody.

The terms "cancer", "cancerous", "metastasis" and "malignant"
refer to or describe the physiological condition in mammals that is
typically characterized by unregulated cell growth.   Examples of
20   cancer include but are not limited to, carcinoma including
adenocarcinoma, lymphoma, blastoma, melanoma, sarcoma, and leukemia.
More particular examples of such cancers include squamous cell
cancer, small-cell lung cancer, non-small cell lung cancer,
gastrointestinal cancer, Hodgkin's and non-Hodgkin's lymphoma,
25   pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer,
liver cancer such as hepatic carcinoma and hepatoma, bladder cancer,
breast cancer, colon cancer, colorectal cancer, endometrial
carcinoma, myeloma (such as multiple myeloma), salivary gland
carcinoma, kidney cancer such as renal cell carcinoma and Wilms'
30   tumors, basal cell carcinoma, melanoma, prostate cancer, vulval
cancer, thyroid cancer, testicular cancer, esophageal cancer, and
various types of head and neck cancer.   The preferred cancers for
treatment herein include breast cancer, gastric cancer, lung cancer,
colon or colorectal cancer, glioma and glioblastoma.

35   The term "prodrug" as used in this application refers to a
precursor or derivative form of a pharmaceutically active substance
that is less cytotoxic to cancer cells compared to the parent drug
and is capable of being enzymatically activated or converted into the
more active parent form.   See, e.g., Wilman, "Prodrugs in Cancer
40   Chemotherapy" Biochemical Society Transactions, 14, pp. 375-382,
615th Meeting Belfast (1986) and Stella et al., "Prodrugs: A

Chemical Approach to Targeted Drug Delivery," *Directed Drug Delivery*,
Borchardt *et al.*, (ed.), pp. 247-267, Humana Press (1985). The
prodrugs of this invention include, but are not limited to,
phosphate-containing prodrugs, thiophosphate-containing prodrugs,

5   sulfate-containing prodrugs, peptide-containing prodrugs, D-amino
acid-modified prodrugs, glycosylated prodrugs, beta-lactam-containing
prodrugs, optionally substituted phenoxyacetamide-containing prodrugs
or optionally substituted phenylacetamide-containing prodrugs, 5-
fluorocytosine and other 5-fluorouridine prodrugs which can be

10 converted into the more active cytotoxic free drug. Examples of
cytotoxic drugs that can be derivatized into a prodrug form for use
in this invention include, but are not limited to, those
chemotherapeutic agents described below.

The term "cytotoxic agent" as used herein refers to a substance

15 that inhibits or prevents the function of cells and/or causes
destruction of cells. The term is intended to include radioactive
isotopes (*e.g.* At^{211}, I^{131}, I^{125}, Y^{90}, Re^{186}, Re^{188}, Sm^{153}, Bi^{212}, P^{32} and
radioactive isotopes of Lu), chemotherapeutic agents, and toxins such
as small molecule toxins or enzymatically active toxins of bacterial,

20 fungal, plant or animal origin, including fragments and/or variants
thereof.

A "chemotherapeutic agent" is a chemical compound useful in the
treatment of conditions like cancer. Examples of chemotherapeutic
agents include alkylating agents such as thiotepa and

25 cyclosphosphamide (CYTOXAN™); alkyl sulfonates such as busulfan,
improsulfan and piposulfan; aziridines such as benzodopa, carboquone,
meturedopa, and uredopa; ethylenimines and methylamelamines including
altretamine, triethylenemelamine, trietylenephosphoramide,
triethylenethiophosphaoramide and trimethylolomelamine; acetogenins

30 (especially bullatacin and bullatacinone); a camptothecin (including
the synthetic analogue topotecan); bryostatin; callystatin; CC-1065
(including its adozelesin, carzelesin and bizelesin synthetic
analogues); cryptophycins (particularly cryptophycin 1 and
cryptophycin 8); dolastatin; duocarmycin (including the synthetic

35 analogues, KW-2189 and CBI-TMI); eleutherobin; pancratistatin; a
sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil,
chlornaphazine, cholophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,
novembichin, phenesterine, prednimustine, trofosfamide, uracil

40 mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine,
lomustine, nimustine, ranimustine; antibiotics such as the enediyne

antibiotics (e.g. calicheamicin, especially calicheamicin γ_1^I and calicheamicin θ_1^I, see, e.g., Agnew Chem Intl. Ed. Engl., 33:183-186 (1994); dynemicin, including dynemicin A; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne

5   antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and

10   deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic

15   acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as

20   calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine;

25   diaziquone; elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine;

30   PSK®; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2, 2',2''-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");

35   cyclophosphamide; thiotepa; taxoids, e.g. paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, NJ) and doxetaxel (TAXOTERE®, Rhône-Poulenc Rorer, Antony, France); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum;

40   etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide;

daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Also included in this definition

5   are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide,

10   nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.

     A "growth inhibitory agent" when used herein refers to a compound or composition which inhibits growth of a cell, either *in*

15   *vitro* or *in vivo*. Thus, the growth inhibitory agent is one which significantly reduces the percentage of cells overexpressing such genes in S phase. Examples of growth inhibitory agents include agents that block cell cycle progression (at a place other than S phase), such as agents that induce G1 arrest and M-phase arrest.

20   Classical M-phase blockers include the vincas (vincristine and vinblastine), taxol, and topo II inhibitors such as doxorubicin, epirubicin, daunorubicin, etoposide, and bleomycin. Those agents that arrest G1 also spill over into S-phase arrest, for example, DNA alkylating agents such as tamoxifen, prednisone, dacarbazine,

25   mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.

    Further information can be found in *The Molecular Basis of Cancer*, Mendelsohn and Israel, eds., Chapter 1, entitled "Cell cycle regulation, oncogens, and antineoplastic drugs" by Murakami *et al.* (WB Saunders: Philadelphia, 1995), especially p. 13.

30   The term "cytokine" is a generic term for proteins released by one cell population which act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormone such as human growth hormone, N-methionyl human

35   growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor; fibroblast growth factor; prolactin; placental

40   lactogen; tumor necrosis factor-α and -β; Apo-2 ligand (also referred

to as TRAIL); mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors; platelet-growth factor; transforming growth factors (TGFs) such as

5   TGF-α and TGF-β; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon-α, -β, and -gamma; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6,

10   IL-7, IL-8, IL-9, IL-11, IL-12; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture and biologically active equivalents of the native sequence cytokines.

15   "Treatment" is an intervention performed with the intention of preventing the development or altering the pathology of a disorder. Accordingly, "treatment" refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) the targeted pathological condition or

20   disorder. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented. In treatment of a disorder, a therapeutic agent may directly decrease or increase the magnitude of response of a pathological component of the disorder, or render the disease more susceptible to treatment by

25   other therapeutic agents, e.g. antibiotics, antifungals, anti-inflammatory agents, chemotherapeutics, etc.

The term "effective amount" is the minimum concentration of WISP-1 antagonist which causes, induces or results in either a detectable improvement or reduction of a pathological condition. In

30   a method of treating cancer, an effective amount is one which causes, induces, or results in reduction of cancer cell number or tumor volume. Furthermore a "therapeutically effective amount" is the minimum concentration (amount) of WISP-1 antagonist administered to a mammal which would be effective in at least attenuating a

35   pathological symptom.

"Chronic" administration refers to administration of the factor(s) in a continuous mode as opposed to an acute mode, so as to maintain the initial therapeutic effect (activity) for an extended period of time. "Intermittent" administration is treatment that is

done not consecutively without interruption, but rather is cyclic in nature.

"Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans, domestic and farm animals, and zoo, sports, or pet animals, such as dogs, horses, cats, cattle, pigs, hamsters, etc. Preferably, the mammal is human.

Administration "in combination with" one or more further therapeutic agents includes simultaneous (concurrent) and consecutive administration in any order.

"Carriers" as used herein include pharmaceutically acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically acceptable carrier is an aqueous pH buffered solution. Examples of physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptide; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®, hyaluronic acid (HA).

II. Methods and Compositions of the Invention

As described further in the Examples below, Applicant has surprisingly found that ectopic expression of WISP-1 in fibroblasts triggered HA production, namely increased HA production induced its accumulation at the cell surface and in the culture media. It is believed that cell surface HA can enhance anchorage-independent growth and tumorigenicity (Kosaki et al., Cancer Res., 59:1141-1145 (1999)) and may diminish contact inhibition of cell proliferation, thereby promoting cell migration (Ichikawa et al., J. Invest. Dermatol., 113:935-939 (1999); Itano et al., Proc. Natl. Acad. Sci., 99:3609-3614 (2002)). Hyaluronan coat formation has also been correlated with cellular metastatic potential (Zhang et al., Cancer Res., 55:428-433 (1995); Toole et al., J. Biol. Chem., 277:4593-4596 (2002)). Analysis of HA synthases (HAS1, HAS2, and HAS3) expression revealed that WISP-1 promoted *HAS2* induction whereas *HAS1* and *HAS3*

mRNA levels remained unchanged. *HAS2* is the main target of growth
factor and cytokine up-regulated HA synthesis (Pienimaki et al., J.
Biol. Chem., 276:20428-20435 (2001)). Ectopic expression of *HAS2*
increases HA secretion and induces hyaluronan coat formation (Kosaki

5   et al., supra). Moreover, HAS2 is believed to be important for
hyaluronan-mediated transformation of epithelium to mesenchyme during
cardiac morphogenesis (Camenisch et al., J. Clin. Invest., 106:349-
360 (2000)). Because epithelial to mesenchymal transition is also
important for tumor invasion and metastasis, HAS2 is postulated to

10 play an important role in epithelial tumor progression (Boyer et al.,
Biochem. Pharmacol., 60:1091-1099 (2000); Hay, Acta Anat., 154:8-20
(1995); Arias, Cell, 105:425-431 (2001)). These results indicate
that HA secretion induced by WISP-1 may be important for tumor
invasion and metastasis.

15   WISP-1 also induced the expression of two HA receptors, CD44
and RHAMM. By inducing HA receptor expression and increasing HA
production, WISP-1 may activate an autocrine and/or paracrine loop.
Hyaluronan interaction with CD44 and RHAMM promotes cell locomotion
and proliferation *in vitro* and tumor growth and metastasis *in vivo*

20 (Turley et al., J. Biol. Chem., 277:4589-4592 (2002); Sy et al.,
Curr. Top. Microbiol. Immunol., 213:129-153 (1996); Hall et al., J.
Neurooncol., 26:221-229 (1995)).

        The effects of WISP-1 on cell migration were analyzed in a cell
wound healing assay and by time lapse microscopy, and the data showed

25 that WISP-1 expression promoted cell motility. Further, isolated
cells showed increased migration suggesting that WISP-1 could act
through an autocrine mechanism. Purified recombinant WISP-1 promoted
HAS2 and CD44 expression, though, when attached to a surface. This
induction was further increased when WISP-1 was tethered through its

30 interaction with decorin. Similarly, WISP-1 promoted cell motility
when surface bound, suggesting that WISP-1 may also act through a
paracrine mechanism when tethered to a substrate. The Examples
herein show that WISP-1 induced cell motility was mediated by CD44,
by abolishing migration with an anti-CD44 antibody. WISP-1 induced

35 cell motility was also inhibited by WISP-1 antibodies. Moreover,
WISP-1 haptotactic activity was not restricted to a single cell type
as it induced both normal fibroblast and colon adenocarcinoma cell
migration.

        Because WISP-1 is believed to be a Wnt-1 downstream effector,

40 the C57MG/Wnt-1 cell line was analyzed for phenotypes found in
NRK/WISP-1 cells. Consistent with a role for WISP-1 downstream of

Wnt-1, C57MG/Wnt-1 cells overexpressed HAS2 and CD44 and had higher
CD44 protein content compared to the parental cell line. In addition,
C57/Wnt-1 cells spontaneously scattered in culture and demonstrated a
de-differentiated spindloid morphology similar to NRK/WISP-1H cells.

5   Expression analysis was also performed on a group of MMTV-Wnt-1
mammary tumors, and elevated CD44 and HAS2 expression was detected in
all mammary tumors from the MMTV-Wnt-1 transgenic mice. In these
tumors, WISP-1 expression was localized to the stromal fibroblasts
whereas CD44 and HAS2 were expressed by tumor epithelial cells.

10   Although negative for HAS2 expression, the peritumoral stroma
contained high levels of HA whereas the tumor parenchyma stained only
weakly for HA. Although it is generally accepted that fibroblasts
are responsible for HA production, the origin of stromal HA is not
definitely known. Because HAS2 expression was found only in the

15   parenchyma, the experimental results disclosed herein suggest that
the tumor cells are responsible for the HA synthesis and deposition
in the stroma. Hyaluronan accumulation in the peritumoral stroma is
frequently encountered in several tumor types and was previously
reported for ovary, breast, prostate and colon adenocarcinomas

20   (Ropponen et al., Cancer Res., 58:342-347 (1998); Lipponen et al.,
Eur. J. Cancer, 37:849-856 (2001); Auvinen et al., Am. J. Pathol.,
156:529-536 (2000); Anttila et al., Cancer Res., 60:150-155 (2000)).
 Moreover, a high stromal level of HA was associated with poor
differentiation, metastatic behavior and unfavorable prognosis.

25   Because HA and CD44 are associated with tumor invasion, the
metastatic potential of WISP-1 expressing cells was evaluated in
vivo. After tail inoculation, NRK/WISP-1 cells readily colonized the
lungs of injected mice and formed invasive tumors. NRK/WISP-1 cells
exhibited a significant metastatic potential while NRK cells did not.

30   Histological observation revealed that NRK/WISP-1 cells populated
the vasculature and invaded the pulmonary airways. The lung
colonization was proportional to the number of cells injected, the
time after injection and the WISP-1 expression. In addition,
Applicant found the metastatic potential to be proportional to CD44

35   and HAS2 expression levels, and the treatment of mice inoculated with
NRK/WISP-1H cells with CD44 antibody or WISP-1 antibody greatly
diminished the number and size of the tumors in the lung. Thus, it
is likely that levels of WISP-1 promoted lung colonization through a
hyaluronan-CD44 mechanism. This is consistent with previous reports

40   demonstrating the importance of CD44 and its interaction with HA for
tumor growth, metastasis and the retention of metastatic cells to the

lung vasculature (Sy et al., supra; Kogerman et al., Proc. Natl.
Acad. Sci., 94:13233-13238 (1997)).

Although activation of the Wnt pathway by APC or β-catenin
mutations may typically be associated with colorectal cancer, several
lines of evidence suggest that it also plays a role in other types of
cancer including mammary adenocarcinoma (Polakis, Genes Dev.,
14:1837-1851 (2000); Brown, Breast Cancer Res., 3:351-355 (2001)).
APC truncation and increased β-catenin levels were found in human
breast cancer cell lines (Schlosshauer et al., Carcinogenesis,
21:1453-1456 (2000)). Somatic mutations of the APC gene were found
in primary breast cancers (Furuuchi et al., Am. J. Pathol., 156:1997-
2005 (2000)). In addition, β-catenin activating mutations promote
mouse mammary adenocarcinomas Michaelson et al., Oncogene, 20:5525-
5532 (2001)). Elevated levels of Wnt-1 and β-catenin were found in
invasive ductal breast carcinomas and correlated with poor prognosis
(Lin et al., Proc. Natl. Acad. Sci., 97:4262-4266 (2000)). It is
therefore possible that WISP-1 expression found in certain breast
adenocarcinomas resulted from Wnt pathway activation. Applicants
have also found, by Taqman analysis, that WISP-1 is overexpressed in
cancers such as breast and glial tumors.

For at least these reasons, it is believed that WISP-1
antgonists will be particularly useful in treating and diagnosing
various pathological disorders, such as cancer. The present invention
accordingly provides methods for modulating, blocking or neutralizing
WISP-1 activity in mammalian cells which comprise exposing the cells
to a desired amount of WISP-1 antagonist. Preferably, the amount of
WISP-1 antagonist employed will be an amount effective to reduce or
inhibit cancer cell growth, metastasis or motility. This can be
accomplished in vivo or ex vivo in accordance, for instance, with the
methods described below and in the Examples. Exemplary conditions or
disorders to be treated with such WISP-1 antagonists include
conditions in mammals clinically referred to as cancer.

Diagnostic methods are also provided herein. For instance, the
antagonists may be employed to detect invasive or metastatic cancers.
The antagonist molecule may be used, e.g., in assays to detect or
quantitate metastatic cancer cells in a sample. A sample, such as
cells obtained from a mammal, can be incubated in the presence of a
labeled antagonist, and detection of the labeled antagonist bound in
the sample can be performed.

The antagonists which can be employed in the methods include, but are not limited to, WISP-1 immunoadhesins, fusion proteins comprising WISP-1, covalently modified forms of WISP-1, WISP-1 variants, fusion proteins thereof, and WISP-1 antibodies. Various techniques that can be employed for making the antagonists are described herein. For instance, methods and techniques for preparing WISP-1 polypeptides are described. Further modifications of the polypeptides, and antibodies to WISP-1 are also described.

In addition to the full-length native sequence WISP-1 polypeptide described herein, it is contemplated that WISP-1 polypeptide variants can be prepared. WISP-1 variants can be prepared by introducing appropriate nucleotide changes into the encoding DNA, and/or by synthesis of the desired polypeptide. Those skilled in the art will appreciate that amino acid changes may alter post-translational processes of the WISP-1 polypeptide, such as changing the number or position of glycosylation sites or altering the membrane anchoring characteristics.

Variations in the WISP-1 polypeptides described herein, can be made, for example, using any of the techniques and guidelines for conservative and non-conservative mutations set forth, for instance, in U.S. Patent No. 5,364,934. Variations may be a substitution, deletion or insertion of one or more codons encoding the polypeptide that results in a change in the amino acid sequence as compared with the native sequence polypeptide. Optionally the variation is by substitution of at least one amino acid with any other amino acid in one or more of the domains of the WISP-1 polypeptide. Guidance in determining which amino acid residue may be inserted, substituted or deleted without adversely affecting the desired activity may be found by comparing the sequence of the WISP-1 polypeptide with that of homologous known protein molecules and minimizing the number of amino acid sequence changes made in regions of high homology. Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Insertions or deletions may optionally be in the range of about 1 to 5 amino acids. The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.

WISP-1 polypeptide fragments are provided herein. Such
fragments may be truncated at the N-terminus or C-terminus, or may
lack internal residues, for example, when compared with a full length
native protein. Certain fragments lack amino acid residues that are
5 not essential for a desired biological activity of the WISP-1
polypeptide.

WISP-1 polypeptide fragments may be prepared by any of a number
of conventional techniques. Desired peptide fragments may be
chemically synthesized. An alternative approach involves generating
10 polypeptide fragments by enzymatic digestion, e.g., by treating the
protein with an enzyme known to cleave proteins at sites defined by
particular amino acid residues, or by digesting the DNA with suitable
restriction enzymes and isolating the desired fragment. Yet another
suitable technique involves isolating and amplifying a DNA fragment
15 encoding a desired polypeptide fragment, by polymerase chain reaction
(PCR). Oligonucleotides that define the desired termini of the DNA
fragment are employed at the 5' and 3' primers in the PCR.

In particular embodiments, conservative substitutions of
interest are shown in the Table below under the heading of preferred
20 substitutions. If such substitutions result in a change in
biological activity, then more substantial changes, denominated
exemplary substitutions in the Table, or as further described below
in reference to amino acid classes, are introduced and the products
screened.

25 Table

Original	Exemplary	Preferred
Residue	Substitutions	
Substitutions		
Ala (A)	val; leu; ile	val
Arg (R)	lys; gln; asn	lys
Asn (N)	gln; his; lys; arg	gln
Asp (D)	glu	glu
Cys (C)	ser	ser
Gln (Q)	asn	asn
Glu (E)	asp	asp
Gly (G)	pro; ala	ala
His (H)	asn; gln; lys; arg	arg
Ile (I)	leu; val; met; ala; phe; norleucine	leu

30

35

40

Leu (L)	norleucine; ile; val;	
	met; ala; phe	ile
Lys (K)	arg; gln; asn	arg
Met (M)	leu; phe; ile	leu
Phe (F)	leu; val; ile; ala; tyr	leu
Pro (P)	ala	ala
Ser (S)	thr	thr
Thr (T)	ser	ser
Trp (W)	tyr; phe	tyr
Tyr (Y)	trp; phe; thr; ser	phe
Val (V)	ile; leu; met; phe;	
	ala; norleucine	leu

Substantial modifications in function or immunological identity of the WISP-1 polypeptide are accomplished by selecting substitutions that differ significantly in their effect on maintaining (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) the bulk of the side chain. Naturally occurring residues are divided into groups based on common side-chain properties:

(1) hydrophobic: norleucine, met, ala, val, leu, ile;

(2) neutral hydrophilic: cys, ser, thr;

(3) acidic: asp, glu;

(4) basic: asn, gln, his, lys, arg;

(5) residues that influence chain orientation: gly, pro; and

(6) aromatic: trp, tyr, phe.

Non-conservative substitutions will entail exchanging a member of one of these classes for another class. Such substituted residues also may be introduced into the conservative substitution sites or, more preferably, into the remaining (non-conserved) sites.

The variations can be made using methods known in the art such as oligonucleotide-mediated (site-directed) mutagenesis, alanine scanning, and PCR mutagenesis. Site-directed mutagenesis [Carter et al., Nucl. Acids Res., 13:4331 (1986); Zoller et al., Nucl. Acids Res., 10:6487 (1987)], cassette mutagenesis [Wells et al., Gene, 34:315 (1985)], restriction selection mutagenesis [Wells et al., Philos. Trans. R. Soc. London SerA, 317:415 (1986)] or other known techniques can be performed on the cloned DNA to produce the WISP-1 polypeptide variant DNA.

Scanning amino acid analysis can also be employed to identify one or more amino acids along a contiguous sequence. Among the preferred scanning amino acids are relatively small, neutral amino acids. Such amino acids include alanine, glycine, serine, and cysteine. Alanine is typically a preferred scanning amino acid among this group because it eliminates the side-chain beyond the beta-carbon and is less likely to alter the main-chain conformation of the variant [Cunningham and Wells, Science, 244:1081-1085 (1989)]. Alanine is also typically preferred because it is the most common amino acid. Further, it is frequently found in both buried and exposed positions [Creighton, The Proteins, (W.H. Freeman & Co., N.Y.); Chothia, J. Mol. Biol., 150:1 (1976)]. If alanine substitution does not yield adequate amounts of variant, an isoteric amino acid can be used.

Any cysteine residue not involved in maintaining the proper conformation of the WISP-1 polypeptide also may be substituted, generally with serine, to improve the oxidative stability of the molecule and prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the WISP-1 polypeptide to improve its stability.

The description below relates primarily to production of WISP-1 polypeptides by culturing cells transformed or transfected with a vector containing WISP-1 polypeptide-encoding nucleic acid. It is, of course, contemplated that alternative methods, which are well known in the art, may be employed to prepare WISP-1 polypeptides. For instance, the appropriate amino acid sequence, or portions thereof, may be produced by direct peptide synthesis using solid-phase techniques [see, e.g., Stewart et al., Solid-Phase Peptide Synthesis, W.H. Freeman Co., San Francisco, CA (1969); Merrifield, J. Am. Chem. Soc., 85:2149-2154 (1963)]. In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, using an Applied Biosystems Peptide Synthesizer (Foster City, CA) using manufacturer's instructions. Various portions of the WISP-1 polypeptide may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the desired WISP-1 polypeptide. The methods and techniques described are similarly applicable to production of WISP-1 variants, modified forms of WISP-1 and WISP-1 antibodies.

1.   Isolation of DNA Encoding WISP-1 Polypeptide

DNA encoding WISP-1 polypeptide may be obtained from a cDNA library prepared from tissue believed to possess the WISP-1 polypeptide mRNA and to express it at a detectable level. 5 Accordingly, human WISP-1 polypeptide DNA can be conveniently obtained from a cDNA library prepared from human tissue. The WISP-1 polypeptide-encoding gene may also be obtained from a genomic library or by known synthetic procedures (e.g., automated nucleic acid synthesis).

10   Libraries can be screened with probes (such as oligonucleotides of at least about 20-80 bases) designed to identify the gene of interest or the protein encoded by it. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures, such as described in Sambrook et al., Molecular Cloning: 15 A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989). An alternative means to isolate the gene encoding WISP-1 polypeptide is to use PCR methodology [Sambrook et al., supra; Dieffenbach et al., PCR Primer: A Laboratory Manual (Cold Spring Harbor Laboratory Press, 1995)].

20   Techniques for screening a cDNA library are well known in the art. The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimized. The oligonucleotide is preferably labeled such that it can be detected upon hybridization to DNA in the library being 25 screened. Methods of labeling are well known in the art, and include the use of radiolabels like ^{32}P-labeled ATP, biotinylation or enzyme labeling. Hybridization conditions, including moderate stringency and high stringency, are provided in Sambrook et al., supra.

Sequences identified in such library screening methods can be 30 compared and aligned to other known sequences deposited and available in public databases such as GenBank or other private sequence databases. Sequence identity (at either the amino acid or nucleotide level) within defined regions of the molecule or across the full-length sequence can be determined using methods known in the art and 35 as described herein.

Nucleic acid having protein coding sequence may be obtained by screening selected cDNA or genomic libraries using the deduced amino acid sequence disclosed herein for the first time, and, if necessary, using conventional primer extension procedures as described in 40 Sambrook et al., supra, to detect precursors and processing

intermediates of mRNA that may not have been reverse-transcribed into cDNA.

2.   Selection and Transformation of Host Cells

Host cells are transfected or transformed with expression or
5   cloning vectors described herein for WISP-1 polypeptide production
and cultured in conventional nutrient media modified as appropriate
for inducing promoters, selecting transformants, or amplifying the
genes encoding the desired sequences. The culture conditions, such
as media, temperature, pH and the like, can be selected by the
10 skilled artisan without undue experimentation.   In general,
principles, protocols, and practical techniques for maximizing the
productivity of cell cultures can be found in Mammalian Cell
Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press,
1991) and Sambrook et al., supra.

15   Methods of eukaryotic cell transfection and prokaryotic cell
transformation are known to the ordinarily skilled artisan, for
example, CaCl₂, CaPO₄, liposome-mediated and electroporation.
Depending on the host cell used, transformation is performed using
standard techniques appropriate to such cells. The calcium treatment
20 employing calcium chloride, as described in Sambrook et al., supra,
or electroporation is generally used for prokaryotes. Infection with
Agrobacterium tumefaciens is used for transformation of certain plant
cells, as described by Shaw et al., Gene, 23:315 (1983) and WO
89/05859 published 29 June 1989. For mammalian cells without such
25 cell walls, the calcium phosphate precipitation method of Graham and
van der Eb, Virology, 52:456-457 (1978) can be employed. General
aspects of mammalian cell host system transfections have been
described in U.S. Patent No. 4,399,216. Transformations into yeast
are typically carried out according to the method of Van Solingen et
30 al., J. Bact., 130:946 (1977) and Hsiao et al., Proc. Natl. Acad.
Sci. (USA), 76:3829 (1979). However, other methods for introducing
DNA into cells, such as by nuclear microinjection, electroporation,
bacterial protoplast fusion with intact cells, or polycations, e.g.,
polybrene, polyornithine, may also be used. For various techniques
35 for transforming mammalian cells, see Keown et al., Methods in
Enzymology, 185:527-537 (1990) and Mansour et al., Nature, 336:348-
352 (1988).

Suitable host cells for cloning or expressing the DNA in the
vectors herein include prokaryote, yeast, or higher eukaryote cells.
40 Suitable prokaryotes include but are not limited to eubacteria, such
as Gram-negative or Gram-positive organisms, for example,

Enterobacteriaceae such as *E. coli*.   Various *E. coli* strains are
publicly available, such as *E. coli* K12 strain MM294 (ATCC 31,446);
E. coli X1776 (ATCC 31,537); *E. coli* strain W3110 (ATCC 27,325) and
K5 772 (ATCC 53,635).   Other suitable prokaryotic host cells include

5   Enterobacteriaceae such as *Escherichia*, e.g., *E. coli*, *Enterobacter*,
Erwinia,   *Klebsiella*,   *Proteus*,   *Salmonella*,   e.g.,   *Salmonella*
typhimurium, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as
well as *Bacilli* such as *B. subtilis* and *B. licheniformis* (e.g., *B.*
licheniformis 41P disclosed in DD 266,710 published 12 April 1989),

10   *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*.   These examples
are   illustrative   rather   than   limiting.   Strain   W3110   is   one
particularly preferred host or parent host because it is a common
host strain for recombinant DNA product fermentations.   Preferably,
the host cell secretes minimal amounts of proteolytic enzymes.   For

15   example, strain W3110 may be modified to effect a genetic mutation in
the genes encoding proteins endogenous to the host, with examples of
such hosts including *E. coli* W3110 strain 1A2, which has the complete
genotype *tonA* ;   *E. coli* W3110 strain 9E4, which has the complete
genotype *tonA* *ptr3*; *E. coli* W3110 strain 27C7 (ATCC 55,244), which

20   has the complete genotype *tonA ptr3 phoA E15* *(argF-lac)169 degP ompT*
kan^r; *E. coli* W3110 strain 37D6, which has the complete genotype *tonA*
ptr3 phoA E15 *(argF-lac)169* *degP* *ompT* *rbs7 ilvG kan*^{r}; *E. coli*
W3110   strain   40B4,   which   is   strain   37D6   with   a   non-kanamycin
resistant *degP* deletion mutation; and an *E. coli* strain having mutant

25   periplasmic protease disclosed in U.S. Patent No. 4,946,783 issued 7
August 1990.   Alternatively, *in vitro* methods of cloning, e.g., PCR
or other nucleic acid polymerase reactions, are suitable.

In   addition   to   prokaryotes,   eukaryotic   microbes   such   as
filamentous fungi or yeast are suitable cloning or expression hosts

30   for WISP-1 polypeptide-encoding vectors.   *Saccharomyces cerevisiae* is
a commonly used lower eukaryotic host microorganism.   Others include
Schizosaccharomyces pombe (Beach and Nurse, Nature, 290: 140 [1981];
EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Patent
No. 4,943,529; Fleer et al., Bio/Technology, 9:968-975 (1991)) such

35   as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt et al., J.
Bacteriol., 154(2):737-742 [1983]), *K. fragilis* (ATCC 12,424), *K.*
bulgaricus (ATCC 16,045), *K. wickeramii* (ATCC 24,178), *K. waltii*
(ATCC 56,500), *K. drosophilarum* (ATCC 36,906; Van den Berg et al.,
Bio/Technology, 8:135 (1990)), *K. thermotolerans*, and *K. marxianus;*

40   *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna et
al., J. Basic Microbiol., 28:265-278 [1988]); *Candida; Trichoderma*

reesia (EP 244,234); *Neurospora crassa* (Case et al., <u>Proc. Natl.</u> <u>Acad. Sci. USA</u>, 76:5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31 October 1990); and filamentous fungi such as, e.g., *Neurospora, Penicillium,*
5 *Tolypocladium* (WO 91/00357 published 10 January 1991), and *Aspergillus* hosts such as *A. nidulans* (Ballance et al., <u>Biochem.</u> <u>Biophys. Res. Commun.</u>, 112:284-289 [1983]; Tilburn et al., <u>Gene,</u> 26:205-221 [1983]; Yelton et al., <u>Proc. Natl. Acad. Sci. USA</u>, 81: 1470-1474 [1984]) and *A. niger* (Kelly and Hynes, <u>EMBO J.</u>, 4:475-479
10 [1985]). Methylotropic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of *Hansenula, Candida, Kloeckera, Pichia, Saccharomyces, Torulopsis,* and *Rhodotorula.* A list of specific species that are exemplary of this class of yeasts may be found in C.
15 Anthony, <u>The Biochemistry of Methylotrophs</u>, 269 (1982).

Suitable host cells for the expression of glycosylated WISP-1 polypeptide are derived from multicellular organisms. Examples of invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells, such as cell cultures of
20 cotton, corn, potato, soybean, petunia, tomato, and tobacco. Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts such as *Spodoptera frugiperda* (caterpillar), *Aedes aegypti* (mosquito), *Aedes albopictus* (mosquito), *Drosophila melanogaster* (fruitfly), and *Bombyx mori* have been
25 identified. A variety of viral strains for transfection are publicly available, e.g., the L-1 variant of *Autographa californica* NPV and the Bm-5 strain of *Bombyx mori* NPV, and such viruses may be used as the virus herein according to the present invention, particularly for transfection of *Spodoptera frugiperda* cells.

30 However, interest has been greatest in vertebrate cells, and propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for
35 growth in suspension culture, Graham et al., <u>J. Gen Virol.</u> 36:59 (1977)); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO, Urlaub et al., <u>Proc. Natl. Acad. Sci.</u> <u>USA</u> 77:4216 (1980)); mouse sertoli cells (TM4, Mather, <u>Biol. Reprod.</u> 23:243-251 (1980)); monkey kidney cells (CV1 ATCC CCL 70); African
40 green monkey kidney cells (VERO-76, ATCC CRL-1587); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC

CCL 34); buffalo rat liver cells (BRL 3A, ATCC CRL 1442); human lung

cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); mouse

mammary tumor (MMT 060562, ATCC CCL51); TRI cells (Mather et al.,

Annals N.Y. Acad. Sci. 383:44-68 (1982)); MRC 5 cells; FS4 cells; and

5   a human hepatoma line (Hep G2).

Host cells are transformed with the above-described expression

or cloning vectors for WISP-1 polypeptide production and cultured in

conventional nutrient media modified as appropriate for inducing

promoters, selecting transformants, or amplifying the genes encoding

10   the desired sequences.

3.   Selection and Use of a Replicable Vector

The nucleic acid (e.g., cDNA or genomic DNA) encoding WISP-1

polypeptide may be inserted into a replicable vector for cloning

(amplification of the DNA) or for expression. Various vectors are

15   publicly available. The vector may, for example, be in the form of a

plasmid, cosmid, viral particle, or phage. The appropriate nucleic

acid sequence may be inserted into the vector by a variety of

procedures. In general, DNA is inserted into an appropriate

restriction endonuclease site(s) using techniques known in the art.

20   Vector components generally include, but are not limited to, one or

more of a signal sequence, an origin of replication, one or more

marker genes, an enhancer element, a promoter, and a transcription

termination sequence. Construction of suitable vectors containing

one or more of these components employs standard ligation techniques

25   which are known to the skilled artisan.

The WISP-1 may be produced recombinantly not only directly, but

also as a fusion polypeptide with a heterologous polypeptide, which

may be a signal sequence or other polypeptide having a specific

cleavage site at the N-terminus of the mature protein or polypeptide.

30   In general, the signal sequence may be a component of the vector, or

it may be a part of the WISP-1 polypeptide-encoding DNA that is

inserted into the vector. The signal sequence may be a prokaryotic

signal sequence selected, for example, from the group of the alkaline

phosphatase, penicillinase, lpp, or heat-stable enterotoxin II

35   leaders. For yeast secretion the signal sequence may be, e.g., the

yeast invertase leader, alpha factor leader (including *Saccharomyces*

and *Kluyveromyces* α-factor leaders, the latter described in U.S.

Patent No. 5,010,182), or acid phosphatase leader, the *C. albicans*

glucoamylase leader (EP 362,179 published 4 April 1990), or the

40   signal described in WO 90/13646 published 15 November 1990.   In

mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

5   Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2μ plasmid

10   origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV or BPV) are useful for cloning vectors in mammalian cells.

        Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection

15   genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b) complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for *Bacilli*.

20   An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the WISP-1 polypeptide-encoding nucleic acid, such as DHFR or thymidine kinase. An appropriate host cell when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared

25   and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980). A suitable selection gene for use in yeast is the *trp1* gene present in the yeast plasmid YRp7 [Stinchcomb et al., Nature, 282:39 (1979); Kingsman et al., Gene, 7:141 (1979); Tschemper et al., Gene, 10:157 (1980)]. The *trp1* gene provides a selection

30   marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1 [Jones, Genetics, 85:12 (1977)].

        Expression and cloning vectors usually contain a promoter operably linked to the WISP-1 polypeptide-encoding nucleic acid

35   sequence to direct mRNA synthesis. Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the β-lactamase and lactose promoter systems [Chang et al., Nature, 275:615 (1978); Goeddel et al., Nature, 281:544 (1979)], alkaline phosphatase, a tryptophan (trp)

40   promoter system [Goeddel, Nucleic Acids Res., 8:4057 (1980); EP

36,776], and hybrid promoters such as the tac promoter [deBoer et al., Proc. Natl. Acad. Sci. USA, 80:21-25 (1983)]. Promoters for use in bacterial systems also will contain a Shine-Dalgarno (S.D.) sequence operably linked to the DNA encoding WISP polypeptide.

5   Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [Hitzeman et al., J. Biol. Chem., 255:2073 (1980)] or other glycolytic enzymes [Hess et al., J. Adv. Enzyme Reg., 7:149 (1968); Holland, Biochemistry, 17:4900 (1978)], such as enolase, glyceraldehyde-3-

10   phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

Other yeast promoters, which are inducible promoters having the

15   additional advantage of transcription controlled by growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose

20   utilization. Suitable vectors and promoters for use in yeast expression are further described in EP 73,657.

WISP polypeptide transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowlpox virus (UK 2,211,504

25   published 5 July 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus and Simian Virus 40 (SV40), from heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter, and from heat-shock promoters, provided such promoters are

30   compatible with the host cell systems.

Transcription of a DNA encoding the WISP-1 polypeptide by higher eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its

35   transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovirus early promoter

40   enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into

46

the vector at a position 5' or 3' to the WISP-1 polypeptide coding sequence, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding WISP-1 polypeptide.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of WISP polypeptide in recombinant vertebrate cell culture are described in Gething et al., Nature, 293:620-625 (1981); Mantei et al., Nature, 281:40-46 (1979); EP 117,060; and EP 117,058.

4.   Culturing the Host Cells

The host cells used to produce the WISP polypeptide of this invention may be cultured in a variety of media. Commercially available media such as Ham's F10 (Sigma), Minimal Essential Medium ((MEM), (Sigma), RPMI-1640 (Sigma), and Dulbecco's Modified Eagle's Medium ((DMEM), Sigma) are suitable for culturing the host cells. In addition, any of the media described in Ham et al., Meth. Enz. 58:44 (1979), Barnes et al., Anal. Biochem.102:255 (1980), U.S. Pat. Nos. 4,767,704; 4,657,866; 4,927,762; 4,560,655; or 5,122,469; WO 90/03430; WO 87/00195; or U.S. Patent Re. 30,985 may be used as culture media for the host cells. Any of these media may be supplemented as necessary with hormones and/or other growth factors (such as insulin, transferrin, or epidermal growth factor), salts (such as sodium chloride, calcium, magnesium, and phosphate), buffers (such as HEPES), nucleotides (such as adenosine and thymidine), antibiotics (such as GENTAMYCIN™ drug), trace elements (defined as inorganic compounds usually present at final concentrations in the micromolar range), and glucose or an equivalent energy source. Any other necessary supplements may also be included at appropriate concentrations that would be known to those skilled in the art. The culture conditions, such as temperature, pH, and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

5.   Detecting Gene Amplification/Expression

Gene amplification and/or expression may be measured in a sample directly, for example, by conventional Southern blotting, Northern blotting to quantitate the transcription of mRNA [Thomas, Proc. Natl. Acad. Sci. USA, 77:5201-5205 (1980)], dot blotting (DNA analysis), or in situ hybridization, using an appropriately labeled probe, based on the sequences provided herein. Alternatively, antibodies may be employed that can recognize specific duplexes, including DNA duplexes, RNA duplexes, and DNA-RNA hybrid duplexes or DNA-protein duplexes. The antibodies in turn may be labeled and the assay may be carried out where the duplex is bound to a surface, so that upon the formation of duplex on the surface, the presence of antibody bound to the duplex can be detected.

Gene expression, alternatively, may be measured by immunological methods, such as immunohistochemical staining of cells or tissue sections and assay of cell culture or body fluids, to quantitate directly the expression of gene product. Antibodies useful for immunohistochemical staining and/or assay of sample fluids may be either monoclonal or polyclonal, and may be prepared in any mammal. Conveniently, the antibodies may be prepared against a native sequence WISP polypeptide or against a synthetic peptide based on the DNA sequences provided herein or against exogenous sequence fused to WISP DNA and encoding a specific antibody epitope.

6.   Purification of WISP Polypeptide

Forms of WISP polypeptide may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g. Triton-X 100) or by enzymatic cleavage. Cells employed in expression of WISP-1 polypeptide can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell lysing agents.

It may be desired to purify WISP-1 polypeptide from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the WISP-1 polypeptide. Various methods of protein purification may be employed and such

methods are known in the art and described for example in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice, Springer-Verlag, New York (1982). The purification step(s) selected will depend, for example, on the nature
5   of the production process used and the particular WISP-1 polypeptide produced.

Soluble forms of WISP-1 may be employed as antagonists in the methods of the invention. Such soluble forms of WISP-1 may comprise modifications, as described below (such as by fusing to an
10 immunoglobulin, epitope tag or leucine zipper). Immunoadhesin molecules are further contemplated for use in the methods herein. WISP-1 immunoadhesins may comprise various forms of WISP-1, such as the full length polypeptide as well as soluble forms of the WISP-1 or a fragment thereof. In particular embodiments, the molecule may
15 comprise a fusion of the WISP-1 polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the immunoadhesin, such a fusion could be to the Fc region of an IgG molecule. The Ig fusions preferably include the substitution of a soluble (transmembrane domain deleted or inactivated) form of the
20 polypeptide in place of at least one variable region within an Ig molecule. In a particularly preferred embodiment, the immunoglobulin fusion includes the hinge, CH2 and CH3, or the hinge, CH1, CH2 and CH3 regions of an IgG1 molecule. For the production of immunoglobulin fusions, see also US Patent No. 5,428,130 issued June
25 27, 1995 and Chamow et al., TIBTECH, 14:52-60 (1996).

The simplest and most straightforward immunoadhesin design combines the binding domain(s) of the adhesin (e.g. the WISP-1) with the Fc region of an immunoglobulin heavy chain. Ordinarily, when preparing the immunoadhesins of the present invention, nucleic acid
30 encoding the binding domain of the adhesin will be fused C-terminally to nucleic acid encoding the N-terminus of an immunoglobulin constant domain sequence, however N-terminal fusions are also possible.

Typically, in such fusions the encoded chimeric polypeptide will retain at least functionally active hinge, C_H2 and C_H3 domains
35 of the constant region of an immunoglobulin heavy chain. Fusions are also made to the C-terminus of the Fc portion of a constant domain, or immediately N-terminal to the C_H1 of the heavy chain or the corresponding region of the light chain. The precise site at which the fusion is made is not critical; particular sites are well known
40 and may be selected in order to optimize the biological activity, secretion, or binding characteristics of the immunoadhesin.

In a preferred embodiment, the adhesin sequence is fused to the N-terminus of the Fc region of immunoglobulin G_1 (IgG_1). It is possible to fuse the entire heavy chain constant region to the adhesin sequence. However, more preferably, a sequence beginning in the hinge region just upstream of the papain cleavage site which defines IgG Fc chemically (i.e. residue 216, taking the first residue of heavy chain constant region to be 114), or analogous sites of other immunoglobulins is used in the fusion. In a particularly preferred embodiment, the adhesin amino acid sequence is fused to (a) the hinge region and C_H2 and C_H3 or (b) the C_H1, hinge, C_H2 and C_H3 domains, of an IgG heavy chain.

For bispecific immunoadhesins, the immunoadhesins are assembled as multimers, and particularly as heterodimers or heterotetramers. Generally, these assembled immunoglobulins will have known unit structures. A basic four chain structural unit is the form in which IgG, IgD, and IgE exist. A four chain unit is repeated in the higher molecular weight immunoglobulins; IgM generally exists as a pentamer of four basic units held together by disulfide bonds. IgA globulin, and occasionally IgG globulin, may also exist in multimeric form in serum. In the case of multimer, each of the four units may be the same or different.

Various exemplary assembled immunoadhesins within the scope herein are schematically diagrammed below:

    (a) AC_L-AC_L;

    (b) AC_H-(AC_H, AC_L-AC_H, $AC_L-V_HC_H$, or $V_LC_L-AC_H$);

    (c) AC_L-AC_H-(AC_L-AC_H, $AC_L-V_HC_H$, $V_LC_L-AC_H$, or $V_LC_L-V_HC_H$)

    (d) $AC_L-V_HC_H-$(AC_H, or $AC_L-V_HC_H$, or $V_LC_L-AC_H$);

    (e) $V_LC_L-AC_H-$($AC_L-V_HC_H$, or $V_LC_L-AC_H$); and

    (f) $(A-Y)_n-$($V_LC_L-V_HC_H$)$_2$,

wherein each A represents identical or different adhesin amino acid sequences;

    V_L is an immunoglobulin light chain variable domain;

    V_H is an immunoglobulin heavy chain variable domain;

    C_L is an immunoglobulin light chain constant domain;

    C_H is an immunoglobulin heavy chain constant domain;

    n is an integer greater than 1;

    Y designates the residue of a covalent cross-linking agent.

In the interests of brevity, the foregoing structures only show key features; they do not indicate joining (J) or other domains of the immunoglobulins, nor are disulfide bonds shown. However, where such domains are required for binding activity, they shall be

constructed to be present in the ordinary locations which they occupy in the immunoglobulin molecules.

Alternatively, the adhesin sequences can be inserted between immunoglobulin heavy chain and light chain sequences, such that an

5   immunoglobulin comprising a chimeric heavy chain is obtained.   In this embodiment, the adhesin sequences are fused to the 3' end of an immunoglobulin heavy chain in each arm of an immunoglobulin, either between the hinge and the C_H2 domain, or between the C_H2 and C_H3 domains.   Similar constructs have been reported by Hoogenboom et al.,

10 Mol. Immunol., 28:1027-1037 (1991).

Although the presence of an immunoglobulin light chain is not required in the immunoadhesins of the present invention, an immunoglobulin light chain might be present either covalently associated to an adhesin-immunoglobulin heavy chain fusion

15 polypeptide, or directly fused to the adhesin.   In the former case, DNA encoding an immunoglobulin light chain is typically coexpressed with the DNA encoding the adhesin-immunoglobulin heavy chain fusion protein.   Upon secretion, the hybrid heavy chain and the light chain will be covalently associated to provide an immunoglobulin-like

20 structure comprising two disulfide-linked immunoglobulin heavy chain-light chain pairs.   Methods suitable for the preparation of such structures are, for example, disclosed in U.S. Patent No. 4,816,567, issued 28 March 1989.   Immunoadhesins are most conveniently constructed by fusing the cDNA sequence encoding the adhesin portion

25 in-frame to an immunoglobulin cDNA sequence.   However, fusion to genomic immunoglobulin fragments can also be used (see, e.g. Aruffo et al., Cell, 61:1303-1313 (1990); and Stamenkovic et al., Cell, 66:1133-1144 (1991)).   The latter type of fusion requires the presence of Ig regulatory sequences for expression.   cDNAs encoding

30 IgG heavy-chain constant regions can be isolated based on published sequences from cDNA libraries derived from spleen or peripheral blood lymphocytes, by hybridization or by polymerase chain reaction (PCR) techniques.   The cDNAs encoding the "adhesin" and the immunoglobulin parts of the immunoadhesin are inserted in tandem into a plasmid

35 vector that directs efficient expression in the chosen host cells.

In another embodiment, the WISP-1 or WISP-1 antagonist may be covalently modified by linking the receptor polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (PEG), polypropylene glycol, or polyoxyalkylenes, in the manner set

40 forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337, or other like molecules such as

polyglutamate. Such pegylated forms may be prepared using techniques
known in the art.

        Leucine zipper forms of these molecules are also contemplated
by the invention. "Leucine zipper" is a term in the art used to
5   refer to a leucine rich sequence that enhances, promotes, or drives
dimerization or trimerization of its fusion partner (e.g., the
sequence or molecule to which the leucine zipper is fused or linked
to). Various leucine zipper polypeptides have been described in the
art. See, e.g., Landschulz et al., Science, 240:1759 (1988); US
10 Patent 5,716,805; WO 94/10308; Hoppe et al., FEBS Letters, 344:1991
(1994); Maniatis et al., Nature, 341:24 (1989). Those skilled in the
art will appreciate that a leucine zipper sequence may be fused at
either the 5' or 3' end of the WISP-1 or WISP-1 antagonist molecule.

        The WISP-1 polypeptides of the present invention may also be
15 modified in a way to form chimeric molecules by fusing the
polypeptide to another, heterologous polypeptide or amino acid
sequence. Preferably, such heterologous polypeptide or amino acid
sequence is one which acts to oligimerize the chimeric molecule. In
one embodiment, such a chimeric molecule comprises a fusion of the
20 WISP-1 polypeptide with a tag polypeptide which provides an epitope
to which an anti-tag antibody can selectively bind. The epitope tag
is generally placed at the amino- or carboxyl- terminus of the
polypeptide. The presence of such epitope-tagged forms of the
polypeptide can be detected using an antibody against the tag
25 polypeptide. Also, provision of the epitope tag enables the
polypeptide to be readily purified by affinity purification using an
anti-tag antibody or another type of affinity matrix that binds to
the epitope tag. Various tag polypeptides and their respective
antibodies are well known in the art. Examples include poly-
30 histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags;
the flu HA tag polypeptide and its antibody 12CA5 [Field et al., Mol.
Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7,
6E10, G4, B7 and 9E10 antibodies thereto [Evan et al., Molecular and
Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus
35 glycoprotein D (gD) tag and its antibody [Paborsky et al., Protein
Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include
the Flag-peptide [Hopp et al., BioTechnology, 6:1204-1210 (1988)];
the KT3 epitope peptide [Martin et al., Science, 255:192-194 (1992)];
an .-tubulin epitope peptide [Skinner et al., J. Biol. Chem.,
40 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag

[Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397
(1990)].

It is contemplated that anti-WISP-1 antibodies may also be
employed in the presently disclosed methods. Examples of such
5   molecules include neutralizing or blocking antibodies which can
reduce cancer cell growth, metastasis or motility. The anti-WISP-1
may be monoclonal antibodies.

Monoclonal antibodies may be prepared using hybridoma methods,
such as those described by Kohler and Milstein, Nature, 256:495
10 (1975). In a hybridoma method, a mouse, hamster, or other appropriate
host animal, is typically immunized with an immunizing agent to elicit
lymphocytes that produce or are capable of producing antibodies that
will specifically bind to the immunizing agent. Alternatively, the
lymphocytes may be immunized in vitro.

15 The immunizing agent will typically include a WISP-1 polypeptide
or a fusion protein thereof, such as a WISP-1-IgG fusion protein.

Generally, either peripheral blood lymphocytes ("PBLs") are used
if cells of human origin are desired, or spleen cells or lymph node
cells are used if non-human mammalian sources are desired. The
20 lymphocytes are then fused with an immortalized cell line using a
suitable fusing agent, such as polyethylene glycol, to form a
hybridoma cell [Goding, Monoclonal Antibodies: Principles and
Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines
are usually transformed mammalian cells, particularly myeloma cells of
25 rodent, bovine and human origin. Usually, rat or mouse myeloma cell
lines are employed. The hybridoma cells may be cultured in a suitable
culture medium that preferably contains one or more substances that
inhibit the growth or survival of the unfused, immortalized cells.
For example, if the parental cells lack the enzyme hypoxanthine
30 guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium
for the hybridomas typically will include hypoxanthine, aminopterin,
and thymidine ("HAT medium"), which substances prevent the growth of
HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse
35 efficiently, support stable high level expression of antibody by the
selected antibody-producing cells, and are sensitive to a medium such
as HAT medium. More preferred immortalized cell lines are murine
myeloma lines, which can be obtained, for instance, from the Salk
Institute Cell Distribution Center, San Diego, California and the
40 American Type Culture Collection, Manassas, Virginia. Human myeloma
and mouse-human heteromyeloma cell lines also have been described for

the production of human monoclonal antibodies [Kozbor, J. Immunol.,
133:3001 (1984); Brodeur et al., Monoclonal Antibody Production
Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp.
51-63].

5   The culture medium in which the hybridoma cells are cultured can
then be assayed for the presence of monoclonal antibodies directed
against WISP-1. Preferably, the binding specificity of monoclonal
antibodies produced by the hybridoma cells is determined by
immunoprecipitation or by an in vitro binding assay, such as
10   radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
Such techniques and assays are known in the art. The binding
affinity of the monoclonal antibody can, for example, be determined by
the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220
(1980).

15   After the desired hybridoma cells are identified, the clones may
be subcloned by limiting dilution procedures and grown by standard
methods [Goding, supra]. Suitable culture media for this purpose
include, for example, Dulbecco's Modified Eagle's Medium or RPMI-1640
medium. Alternatively, the hybridoma cells may be grown in vivo as
20   ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be
isolated or purified from the culture medium or ascites fluid by
conventional immunoglobulin purification procedures such as, for
example, protein A-Sepharose, hydroxylapatite chromatography, gel
25   electrophoresis, dialysis, or affinity chromatography.

The monoclonal antibodies may also be made by recombinant DNA
methods, such as those described in U.S. Patent No. 4,816,567. DNA
encoding the monoclonal antibodies is readily isolated and sequenced
using conventional procedures (e.g., by using oligonucleotide probes
30   that are capable of binding specifically to genes encoding the heavy
and light chains of the monoclonal antibodies). The hybridoma cells
serve as a preferred source of such DNA. Once isolated, the DNA may
be placed into expression vectors, which are then transfected into
host cells such as E. coli cells, simian COS cells, Chinese hamster
35   ovary (CHO) cells, or myeloma cells that do not otherwise produce
immunoglobulin protein, to obtain the synthesis of monoclonal
antibodies in the recombinant host cells. The DNA also may be
modified, for example, by substituting the coding sequence for human
heavy and light chain constant domains in place of the homologous
40   murine sequences, Morrison, et al., Proc. Nat. Acad. Sci. 81, 6851
(1984), or by covalently joining to the immunoglobulin coding

sequence all or part of the coding sequence for a non-immunoglobulin
polypeptide.

Typically such non-immunoglobulin polypeptides are substituted
for the constant domains of an antibody of the invention, or they are
5   substituted for the variable domains of one antigen-combining site of
an antibody of the invention to create a chimeric bivalent antibody
comprising one antigen-combining site having specificity for WISP-1
and another antigen-combining site having specificity for a different
antigen.

10   Chimeric or hybrid antibodies also may be prepared in vitro
using known methods in synthetic protein chemistry, including those
involving crosslinking agents. For example, immunotoxins may be
constructed using a disulfide exchange reaction or by forming a
thioether bond. Examples of suitable reagents for this purpose
15   include iminothiolate and methyl-4-mercaptobutyrimidate.

Single chain Fv fragments may also be produced, such as
described in Iliades et al., FEBS Letters, 409:437-441 (1997).
Coupling of such single chain fragments using various linkers is
described in Kortt et al., Protein Engineering, 10:423-433 (1997). A
20   variety of techniques for the recombinant production and
manipulation of antibodies are well known in the art. Illustrative
examples of such techniques that are typically utilized by skilled
artisans are described in greater detail below.

(i)   Humanized antibodies
25   Generally, a humanized antibody has one or more amino acid
residues introduced into it from a non-human source. These non-human
amino acid residues are often referred to as "import" residues, which
are typically taken from an "import" variable domain. Humanization
can be essentially performed following the method of Winter and
30   co-workers [Jones et al., Nature, 321:522-525 (1986); Riechmann et
al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-
1536 (1988)], by substituting rodent CDRs or CDR sequences for the
corresponding sequences of a human antibody.

Accordingly, such "humanized" antibodies are chimeric
35   antibodies wherein substantially less than an intact human variable
domain has been substituted by the corresponding sequence from a non-
human species. In practice, humanized antibodies are typically human
antibodies in which some CDR residues and possibly some FR residues
are substituted by residues from analogous sites in rodent
40   antibodies.

It is important that antibodies be humanized with retention of
high affinity for the antigen and other favorable biological
properties. To achieve this goal, according to a preferred method,
humanized antibodies are prepared by a process of analysis of the
5   parental sequences and various conceptual humanized products using
three dimensional models of the parental and humanized sequences.
Three dimensional immunoglobulin models are commonly available and
are familiar to those skilled in the art. Computer programs are
available which illustrate and display probable three-dimensional
10   conformational structures of selected candidate immunoglobulin
sequences. Inspection of these displays permits analysis of the
likely role of the residues in the functioning of the candidate
immunoglobulin sequence, i.e. the analysis of residues that influence
the ability of the candidate immunoglobulin to bind its antigen. In
15   this way, FR residues can be selected and combined from the consensus
and import sequence so that the desired antibody characteristic, such
as increased affinity for the target antigen(s), is achieved. In
general, the CDR residues are directly and most substantially
involved in influencing antigen binding.
20   *(ii)   Human antibodies*
     Human monoclonal antibodies can be made by the hybridoma
method. Human myeloma and mouse-human heteromyeloma cell lines for
the production of human monoclonal antibodies have been described,
for example, by Kozbor, <u>J. Immunol.</u> <u>133</u>, 3001 (1984), and Brodeur, *et*
25   *al.,* <u>Monoclonal Antibody Production Techniques and Applications,</u>
pp.51-63 (Marcel Dekker, Inc., New York, 1987).
     It is now possible to produce transgenic animals (e.g. mice) that
are capable, upon immunization, of producing a repertoire of human
antibodies in the absence of endogenous immunoglobulin production.
30   For example, it has been described that the homozygous deletion of
the antibody heavy chain joining region (J_H) gene in chimeric and
germ-line mutant mice results in complete inhibition of endogenous
antibody production. Transfer of the human germ-line immunoglobulin
gene array in such germ-line mutant mice will result in the
35   production of human antibodies upon antigen challenge. See, e.g.
Jakobovits *et al.,* <u>Proc. Natl. Acad. Sci. USA</u> <u>90</u>, 2551-255 (1993);
Jakobovits *et al.,* <u>Nature</u> <u>362</u>, 255-258 (1993).
     Mendez *et al.* (*Nature Genetics* 15: 146-156 [1997]) have further
improved the technology and have generated a line of transgenic mice
40   designated as "Xenomouse II" that, when challenged with an antigen,
generates high affinity fully human antibodies. This was achieved by

germ-line integration of megabase human heavy chain and light chain
loci into mice with deletion into endogenous J_H segment as described
above. The Xenomouse II harbors 1,020 kb of human heavy chain locus
containing approximately 66 V_H genes, complete D_H and J_H regions and

5   three different constant regions (μ, δ and χ), and also harbors 800
kb of human κ locus containing 32 $V\kappa$ genes, $J\kappa$ segments and $C\kappa$ genes.
The antibodies produced in these mice closely resemble that seen in
humans in all respects, including gene rearrangement, assembly, and
repertoire. The human antibodies are preferentially expressed over

10   endogenous antibodies due to deletion in endogenous J_H segment that
prevents gene rearrangement in the murine locus.

Alternatively, the phage display technology (McCafferty et al.,
Nature 348, 552-553 [1990]) can be used to produce human antibodies
and antibody fragments in vitro, from immunoglobulin variable (V)

15   domain gene repertoires from unimmunized donors. According to this
technique, antibody V domain genes are cloned in-frame into either a
major or minor coat protein gene of a filamentous bacteriophage, such
as M13 or fd, and displayed as functional antibody fragments on the
surface of the phage particle. Because the filamentous particle

20   contains a single-stranded DNA copy of the phage genome, selections
based on the functional properties of the antibody also result in
selection of the gene encoding the antibody exhibiting those
properties. Thus, the phage mimicks some of the properties of the B-
cell. Phage display can be performed in a variety of formats; for

25   their review see, e.g. Johnson, Kevin S. and Chiswell, David J.,
Current Opinion in Structural Biology 3, 564-571 (1993). Several
sources of V-gene segments can be used for phage display. Clackson
et al., Nature 352, 624-628 (1991) isolated a diverse array of anti-
oxazolone antibodies from a small random combinatorial library of V

30   genes derived from the spleens of immunized mice. A repertoire of V
genes from unimmunized human donors can be constructed and antibodies
to a diverse array of antigens (including self-antigens) can be
isolated essentially following the techniques described by Marks et
al., J. Mol. Biol. 222, 581-597 (1991), or Griffith et al., EMBO J.

35   12, 725-734 (1993). In a natural immune response, antibody genes
accumulate mutations at a high rate (somatic hypermutation). Some of
the changes introduced will confer higher affinity, and B cells
displaying high-affinity surface immunoglobulin are preferentially
replicated and differentiated during subsequent antigen challenge.

40   This natural process can be mimicked by employing the technique known

as "chain shuffling" (Marks *et al.*, <u>Bio/Technol.</u> <u>10</u>, 779-783 [1992]).

In this method, the affinity of "primary" human antibodies obtained
by phage display can be improved by sequentially replacing the heavy
and light chain V region genes with repertoires of naturally

5   occurring variants (repertoires) of V domain genes obtained from
unimmunized donors. This technique allows the production of
antibodies and antibody fragments with affinities in the nM range. A
strategy for making very large phage antibody repertoires (also known
as "the mother-of-all libraries") has been described by Waterhouse *et*

10   *al.*, <u>Nucl. Acids Res.</u> <u>21</u>, 2265-2266 (1993). Gene shuffling can also
be used to derive human antibodies from rodent antibodies, where the
human antibody has similar affinities and specificities to the
starting rodent antibody. According to this method, which is also
referred to as "epitope imprinting", the heavy or light chain V

15   domain gene of rodent antibodies obtained by phage display technique
is replaced with a repertoire of human V domain genes, creating
rodent-human chimeras. Selection on antigen results in isolation of
human variable capable of restoring a functional antigen-binding
site, i.e. the epitope governs (imprints) the choice of partner.

20   When the process is repeated in order to replace the remaining rodent
V domain, a human antibody is obtained (see PCT patent application WO
93/06213, published 1 April 1993). Unlike traditional humanization
of rodent antibodies by CDR grafting, this technique provides
completely human antibodies, which have no framework or CDR residues

25   of rodent origin.

As discussed below, the antibodies of the invention may
optionally comprise monomeric, antibodies, dimeric antibodies, as well
as multivalent forms of antibodies. Those skilled in the art may
construct such dimers or multivalent forms by techniques known in the

30   art. Methods for preparing monovalent antibodies are also well known
in the art. For example, one method involves recombinant expression
of immunoglobulin light chain and modified heavy chain. The heavy
chain is truncated generally at any point in the Fc region so as to
prevent heavy chain crosslinking. Alternatively, the relevant

35   cysteine residues are substituted with another amino acid residue or
are deleted so as to prevent crosslinking.

(iii) *Bispecific antibodies*

Bispecific antibodies are monoclonal, preferably human or
humanized, antibodies that have binding specificities for at least

40   two different antigens. In the present case, one of the binding
specificities is for WISP-1. For example, bispecific antibodies

specifically binding WISP-1 or WISP-1 variants and another CNN family
member (e.g., WISP-2, WISP-3, CTGF, Cyr61, or Nov) or other molecules
such as CD44 are within the scope of the present invention.

Methods for making bispecific antibodies are known in the art.

5   Traditionally, the recombinant production of bispecific antibodies is
based on the coexpression of two immunoglobulin heavy chain-light
chain pairs, where the two heavy chains have different specificities
(Millstein and Cuello, Nature 305, 537-539 (1983)). Because of the
random assortment of immunoglobulin heavy and light chains, these

10 hybridomas (quadromas) produce a potential mixture of 10 different
antibody molecules, of which only one has the correct bispecific
structure. The purification of the correct molecule, which is
usually done by affinity chromatography steps, is rather cumbersome,
and the product yields are low. Similar procedures are disclosed in

15 PCT application publication No. WO 93/08829 (published 13 May 1993),
and in Traunecker et al., EMBO 10, 3655-3659 (1991).

According to a different and more preferred approach, antibody
variable domains with the desired binding specificities (antibody-
antigen combining sites) are fused to immunoglobulin constant domain

20 sequences. The fusion preferably is with an immunoglobulin heavy
chain constant domain, comprising at least part of the hinge, CH2 and
CH3 regions. It is preferred to have the first heavy chain constant
region (CH1) containing the site necessary for light chain binding,
present in at least one of the fusions. DNAs encoding the

25 immunoglobulin heavy chain fusions and, if desired, the
immunoglobulin light chain, are inserted into separate expression
vectors, and are cotransfected into a suitable host organism. This
provides for great flexibility in adjusting the mutual proportions of
the three polypeptide fragments in embodiments when unequal ratios of

30 the three polypeptide chains used in the construction provide the
optimum yields. It is, however, possible to insert the coding
sequences for two or all three polypeptide chains in one expression
vector when the expression of at least two polypeptide chains in
equal ratios results in high yields or when the ratios are of no

35 particular significance. In a preferred embodiment of this approach,
the bispecific antibodies are composed of a hybrid immunoglobulin
heavy chain with a first binding specificity in one arm, and a hybrid
immunoglobulin heavy chain-light chain pair (providing a second
binding specificity) in the other arm. It was found that this

40 asymmetric structure facilitates the separation of the desired
bispecific compound from unwanted immunoglobulin chain combinations,

as the presence of an immunoglobulin light chain in only one half of
the bispecific molecule provides for a facile way of separation.
This approach is disclosed in PCT Publication No. WO 94/04690,
published on March 3, 1994.

5   For further details of generating bispecific antibodies see,
for example, Suresh et al., Methods in Enzymology 121, 210 (1986).
           (iv) Heteroconjugate antibodies
           Heteroconjugate antibodies are also within the scope of the
present invention. Heteroconjugate antibodies are composed of two

10   covalently joined antibodies. Such antibodies have, for example,
been proposed to target immune system cells to unwanted cells (U.S.
Patent No. 4,676,980), and for treatment of HIV infection (PCT
application publication Nos. WO 91/00360 and WO 92/200373; EP 03089).
Heteroconjugate antibodies may be made using any convenient cross-

15   linking methods. Suitable cross-linking agents are well known in the
art, and are disclosed in U.S. Patent No. 4,676,980, along with a
number of cross-linking techniques.
           (v)   Antibody fragments
           In certain embodiments, the anti-WISP-1 antibody (including

20   murine, human and humanized antibodies, and antibody variants) is an
antibody fragment. Various techniques have been developed for the
production of antibody fragments. Traditionally, these fragments
were derived via proteolytic digestion of intact antibodies (see,
e.g., Morimoto et al., J. Biochem. Biophys. Methods 24:107-117 (1992)

25   and Brennan et al., Science 229:81 (1985)). However, these fragments
can now be produced directly by recombinant host cells. For example,
Fab'-SH fragments can be directly recovered from E. coli and
chemically coupled to form $F(ab')_2$ fragments (Carter et al.,
Bio/Technology 10:163-167 (1992)). In another embodiment, the $F(ab')_2$

30   is formed using the leucine zipper GCN4 to promote assembly of the
$F(ab')_2$ molecule. According to another approach, Fv, Fab or $F(ab')_2$
fragments can be isolated directly from recombinant host cell
culture. A variety of techniques for the production of antibody
fragments will be apparent to the skilled practitioner. For

35   instance, digestion can be performed using papain. Examples of papain
digestion are described in WO 94/29348 published 12/22/94 and U.S.
Patent No. 4,342,566. Papain digestion of antibodies typically
produces two identical antigen binding fragments, called Fab
fragments, each with a single antigen binding site, and a residual Fc

40   fragment. Pepsin treatment yields an $F(ab')_2$ fragment that has two

antigen combining sites and is still capable of cross-linking antigen.

The Fab fragments produced in the antibody digestion also
contain the constant domains of the light chain and the first constant
5   domain (CH$_1$) of the heavy chain. Fab' fragments differ from Fab
fragments by the addition of a few residues at the carboxy terminus of
the heavy chain CH$_1$ domain including one or more cysteines from the
antibody hinge region. Fab'-SH is the designation herein for Fab' in
which the cysteine residue(s) of the constant domains bear a free
10   thiol group. F(ab')$_2$ antibody fragments originally were produced as
pairs of Fab' fragments which have hinge cysteines between them.
Other chemical couplings of antibody fragments are also known.
       Antibodies are glycosylated at conserved positions in their
constant regions (Jefferis and Lund, Chem. Immunol. 65:111-128
15   [1997]; Wright and Morrison, TibTECH 15:26-32 [1997]). The
oligosaccharide side chains of the immunoglobulins affect the
protein's function (Boyd et al., Mol. Immunol. 32:1311-1318 [1996];
Wittwe and Howard, Biochem. 29:4175-4180 [1990]), and the
intramolecular interaction between portions of the glycoprotein
20   which can affect the conformation and presented three-dimensional
surface of the glycoprotein (Hefferis and Lund, supra; Wyss and
Wagner, Current Opin. Biotech. 7:409-416 [1996]). Oligosaccharides
may also serve to target a given glycoprotein to certain molecules
based upon specific recognition structures. For example, it has
25   been reported that in agalactosylated IgG, the oligosaccharide
moiety 'flips' out of the inter-CH2 space and terminal N-
acetylglucosamine residues become available to bind mannose binding
protein (Malhotra et al., Nature Med. 1:237-243 [1995]). Removal by
glycopeptidase of the oligosaccharides from CAMPATH-1H (a
30   recombinant humanized murine monoclonal IgG1 antibody which
recognizes the CDw52 antigen of human lymphocytes) produced in
Chinese Hamster Ovary (CHO) cells resulted in a complete reduction
in complement mediated lysis (CMCL) (Boyd et al., Mol. Immunol.
32:1311-1318 [1996]), while selective removal of sialic acid
35   residues using neuraminidase resulted in no loss of DMCL.
Glycosylation of antibodies has also been reported to affect
antibody-dependent cellular cytotoxicity (ADCC). In particular, CHO
cells with tetracycline-regulated expression of $\beta(1,4)$-N-
acetylglucosaminyltransferase III (GnTIII), a glycosyltransferase
40   catalyzing formation of bisecting GlcNAc, was reported to have

61

improved ADCC activity (Umana *et al.*, *Mature Biotech.* 17:176-180
[1999]).

Glycosylation variants of antibodies are variants in which the
glycosylation pattern of an antibody is altered. By altering is
5   meant deleting one or more carbohydrate moieties found in the
antibody, adding one or more carbohydrate moieties to the antibody,
changing the composition of glycosylation (glycosylation pattern),
the extent of glycosylation, etc. Glycosylation variants may, for
example, be prepared by removing, changing and/or adding one or more
10   glycosylation sites in the nucleic acid sequence encoding the
antibody.

Glycosylation of antibodies is typically either N-linked or O-
linked. N-linked refers to the attachment of the carbohydrate
moiety to the side chain of an asparagine residue. The tripeptide
15   sequences asparagine-X-serine and asparagine-X-threonine, where X is
any amino acid except proline, are the recognition sequences for
enzymatic attachment of the carbohydrate moiety to the asparagine
side chain. Thus, the presence of either of these tripeptide
sequences in a polypeptide creates a potential glycosylation site.
20   O-linked glycosylation refers to the attachment of one of the sugars
N-aceylgalactosamine, galactose, or xylose to a hydroxyamino acid,
most commonly serine or threonine, although 5-hydroxyproline or 5-
hydroxylysine may also be used.

Addition of glycosylation sites to the antibody is
25   conveniently accomplished by altering the amino acid sequence such
that it contains one or more of the above-described tripeptide
sequences (for N-linked glycosylation sites). The alteration may
also be made by the addition of, or substitution by, one or more
serine or threonine residues to the sequence of the original
30   antibody (for O-linked glycosylation sites).

The glycosylation (including glycosylation pattern) of
antibodies may also be altered without altering the underlying
nucleotide sequence. Glycosylation largely depends on the host cell
used to express the antibody.   Since the cell type used for
35   expression of recombinant glycoproteins, e.g. antibodies, as
potential therapeutics is rarely the native cell, significant
variations in the glycosylation pattern of the antibodies can be
expected (see, e.g. Hse *et al.*, *J. Biol. Chem.* 272:9062-9070
[1997]). In addition to the choice of host cells, factors which
40   affect glycosylation during recombinant production of antibodies
include growth mode, media formulation, culture density,

oxygenation, pH, purification schemes and the like. Various methods have been proposed to alter the glycosylation pattern achieved in a particular host organism including introducing or overexpressing certain enzymes involved in oligosaccharide production (U. S. Patent Nos. 5,047,335; 5,510,261 and 5.278,299). Glycosylation, or certain types of glycosylation, can be enzymatically removed from the glycoprotein, for example using endoglycosidase H (Endo H). In addition, the recombinant host cell can be genetically engineered, e.g. make defective in processing certain types of polysaccharides. These and similar techniques are well known in the art.

The glycosylation structure of antibodies can be readily analyzed by conventional techniques of carbohydrate analysis, including lectin chromatography, NMR, Mass spectrometry, HPLC, GPC, monosaccharide compositional analysis, sequential enzymatic digestion, and HPAEC-PAD, which uses high pH anion exchange chromatography to separate oligosaccharides based on charge. Methods for releasing oligosaccharides for analytical purposes are also known, and include, without limitation, enzymatic treatment (commonly performed using peptide-N-glycosidase F/endo-β-galactosidase), elimination using harsh alkaline environment to release mainly O-linked structures, and chemical methods using anhydrous hydrazine to release both N- and O-linked oligosaccharides.

Triabodies are also within the scope of the invention. Such antibodies are described for instance in Iliades et al., supra and Kortt et al., supra.

The antibodies of the present invention may be modified by conjugating the antibody to a cytotoxic agent (like a toxin molecule) or a prodrug-activating enzyme which converts a prodrug (e.g. a peptidyl chemotherapeutic agent, see WO81/01145) to an active anti-cancer drug. See, for example, WO 88/07378 and U.S. Patent No. 4,975,278. This technology is also referred to as "Antibody Dependent Enzyme Mediated Prodrug Therapy" (ADEPT).

The enzyme component of the immunoconjugate useful for ADEPT includes any enzyme capable of acting on a prodrug in such a way so as to covert it into its more active, cytotoxic form. Enzymes that are useful in the method of this invention include, but are not limited to, alkaline phosphatase useful for converting phosphate-containing prodrugs into free drugs; arylsulfatase useful for converting sulfate-containing prodrugs into free drugs; cytosine deaminase useful for converting non-toxic 5-fluorocytosine into the

anti-cancer drug, 5-fluorouracil; proteases, such as serratia protease, thermolysin, subtilisin, carboxypeptidases and cathepsins (such as cathepsins B and L), that are useful for converting peptide-containing prodrugs into free drugs; caspases such as caspase-3; D-alanylcarboxypeptidases, useful for converting prodrugs that contain D-amino acid substituents; carbohydrate-cleaving enzymes such as beta-galactosidase and neuraminidase useful for converting glycosylated prodrugs into free drugs; beta-lactamase useful for converting drugs derivatized with beta-lactams into free drugs; and penicillin amidases, such as penicillin V amidase or penicillin G amidase, useful for converting drugs derivatized at their amine nitrogens with phenoxyacetyl or phenylacetyl groups, respectively, into free drugs. Alternatively, antibodies with enzymatic activity, also known in the art as "abzymes", can be used to convert the prodrugs of the invention into free active drugs (see, *e.g.*, Massey, *Nature* 328: 457-458 (1987)). Antibody-abzyme conjugates can be prepared as described herein for delivery of the abzyme to a tumor cell population.

The enzymes can be covalently bound to the antibodies by techniques well known in the art such as the use of heterobifunctional crosslinking reagents. Alternatively, fusion proteins comprising at least the antigen binding region of an antibody of the invention linked to at least a functionally active portion of an enzyme of the invention can be constructed using recombinant DNA techniques well known in the art (see, *e.g.*, Neuberger *et al.*, *Nature*, 312: 604-608 (1984).

Further antibody modifications are contemplated. For example, the antibody may be linked to one of a variety of nonproteinaceous polymers, *e.g.*, polyethylene glycol, polypropylene glycol, polyoxyalkylenes, or copolymers of polyethylene glycol and polypropylene glycol, or other molecules such as polyglutamate. The antibody also may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively), in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules), or in macroemulsions. Such techniques are disclosed in *Remington's Pharmaceutical Sciences*, 16th edition, Osol, A., Ed., (1980). To increase the serum half life of the antibody, one may incorporate a salvage receptor binding epitope into the antibody (especially an

antibody fragment) as described in U.S. Patent 5,739,277, for example. As used herein, the term "salvage receptor binding epitope" refers to an epitope of the Fc region of an IgG molecule (e.g., IgG$_1$, IgG$_2$, IgG$_3$, or IgG$_4$) that is responsible for increasing the *in vivo* serum half-life of the IgG molecule.

FORMULATIONS

The WISP-1 antagonists described herein, are optionally employed in a carrier. Suitable carriers and their formulations are described in Remington's Pharmaceutical Sciences, 16th ed., 1980, Mack Publishing Co., edited by Osol et al. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the carrier to render the formulation isotonic. Examples of the carrier include saline, Ringer's solution and dextrose solution. The pH of the carrier is preferably from about 5 to about 8, and more preferably from about 7.4 to about 7.8. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of active agent being administered. The carrier may be in the form of a lyophilized formulation or aqueous solution.

Acceptable carriers, excipients, or stabilizers are preferably nontoxic to cells and/or recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; and/or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).

The formulation may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.

The antagonists described herein may also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules,

5   respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

10   The formulations to be used for in vivo administration should be sterile. This is readily accomplished by filtration through sterile filtration membranes.

Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable

15   matrices of solid hydrophobic polymers containing the active agent, which matrices are in the form of shaped articles, e.g. films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No.

20   3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3-hydroxybutyric acid. While

25   polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.

MODES OF THERAPY

The molecules described herein are useful in treating various

30   pathological conditions, such as cancer. These conditions can be treated by administration of one or more antagonists described herein.

Diagnosis in mammals of the various pathological conditions described herein can be made by the skilled practitioner. Diagnostic

35   techniques are available in the art which allow, e.g., for the diagnosis or detection of cancer or immune related disease in a mammal. For instance, cancers may be identified through techniques, including but not limited to, palpation, blood analysis, x-ray, NMR and the like.

40   The antagonist(s) can be administered in accord with known methods, such as intravenous administration as a bolus or by

continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, oral, topical, or inhalation routes. Optionally, administration may be performed through mini-pump infusion using various commercially available devices. The antagonists may also be employed using gene therapy techniques which have been described in the art.

Effective dosages and schedules for administering antagonists may be determined empirically, and making such determinations is within the skill in the art. Single or multiple dosages may be employed. It is presently believed that an effective dosage or amount of antagonist used alone may range from about 1 μg/kg to about 100 mg/kg of body weight or more per day. Interspecies scaling of dosages can be performed in a manner known in the art, e.g., as disclosed in Mordenti et al., Pharmaceut. Res., 8:1351 (1991).

When in vivo administration of an antagonist thereof is employed, normal dosage amounts may vary from about 10 ng/kg to up to 100 mg/kg of mammal body weight or more per day, preferably about 1 μg/kg/day to 10 mg/kg/day, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature; see, for example, U.S. Pat. Nos. 4,657,760; 5,206,344; or 5,225,212. It is anticipated that different formulations will be effective for different treatment compounds and different disorders, that administration targeting one organ or tissue, for example, may necessitate delivery in a manner different from that to another organ or tissue. Those skilled in the art will understand that the dosage of antagonist that must be administered will vary depending on, for example, the mammal which will receive the agonist or antagonist, the route of administration, and other drugs or therapies being administered to the mammal.

Depending on the type of cells and/or severity of the disease, about 1 μg/kg to 15 mg/kg (e.g. 0.1-20 mg/kg) of antagonist antibody is an initial candidate dosage for administration, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 μg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. However, other dosage regimens may be useful.

A single type of antagonist may be used in the methods of the invention. For example, a WISP-1 immunoadhesin molecule may be administered. Alternatively, the skilled practitioner may opt to employ a combination of antagonists in the methods, e.g., a
5   combination of a WISP-1 immunoadhesin and WISP-1 antibody. It   is contemplated that yet additional therapies may be employed in the methods. The one or more other therapies may include but are not limited to, administration of radiation therapy, cytokine(s), growth inhibitory agent(s), chemotherapeutic agent(s), cytotoxic agent(s),
10 tyrosine kinase inhibitors, ras farnesyl transferase inhibitors, angiogenesis inhibitors, and cyclin-dependent kinase inhibitors which are known in the art and defined further with particularity in Section I above. In addition, therapies based on therapeutic antibodies that target tumor antigens such as Rituxan™ or Herceptin™ as well as anti-
15 angiogenic antibodies such as anti-VEGF.

Preparation and dosing schedules for chemotherapeutic agents may be used according to manufacturers' instructions or as determined empirically by the skilled practitioner. Preparation and dosing schedules for such chemotherapy are also described in *Chemotherapy*
20 *Service* Ed., M.C. Perry, Williams & Wilkins, Baltimore, MD (1992). The chemotherapeutic agent may precede, or follow administration of, e.g. an antagonist, or may be given simultaneously therewith. The antagonist, for instance, may also be combined with an anti-oestrogen compound such as tamoxifen or an anti-progesterone such as
25 onapristone (see, EP 616812) in dosages known for such molecules.

It may be desirable to also administer antibodies against other antigens, such as antibodies which bind to CD20, CD11a, CD18, CD40, CD44, ErbB2, EGFR, ErbB3, ErbB4, vascular endothelial factor (VEGF), or other TNFR family members (such as DR4, DR5, OPG, TNFR1, TNFR2).
30 Alternatively, or in addition, two or more antibodies binding the same or two or more different antigens disclosed herein may be co-administered to the patient. Sometimes, it may be beneficial to also administer one or more cytokines to the patient. In one embodiment, the antagonists herein are co-administered with a growth inhibitory
35 agent. For example, the growth inhibitory agent may be administered first, followed by an antagonist of the present invention.

The antagonist and one or more other therapies may be administered concurrently or sequentially. Following administration of antagonist, treated cells *in vitro* can be analyzed. Where there
40 has been *in vivo* treatment, a treated mammal can be monitored in various ways well known to the skilled practitioner.

ARTICLES OF MANUFACTURE

In another embodiment of the invention, an article of manufacture containing materials useful for the treatment of the disorders described above is provided. The article of manufacture

5   comprises a container and a label. Suitable containers include, for example, bottles, vials, syringes, and test tubes. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is effective for treating the condition and may have a sterile access port (for example the

10   container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agents in the composition may comprise antagonist(s). The label on, or associated with, the container indicates that the composition is used for treating the condition of choice.   The article of

15   manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles,

20   syringes, and package inserts with instructions for use.

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

All patent and literature references cited in the present

25   specification are hereby incorporated by reference in their entirety.

EXAMPLES

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise

30   indicated. The source of those cells identified in the following examples, and throughout the specification, by ATCC accession numbers is the American Type Culture Collection, Manassas, VA. Unless otherwise noted, the present invention uses standard procedures of recombinant DNA technology, such as those described hereinabove and

35   in the following textbooks: Sambrook *et al., Molecular Cloning: A Laboratory Manual,* Cold Spring Harbor Press N.Y., 1989; Ausubel *et al., Current Protocols in Molecular Biology,* Green Publishing Associates and Wiley Interscience, N.Y., 1989; Innis *et al., PCR Protocols: A Guide to Methods and Applications,* Academic Press, Inc.,

40   N.Y., 1990; Harlow *et al., Antibodies: A Laboratory Manual,* Cold Spring Harbor Press, Cold Spring Harbor, 1988; Gait, M.J.,

Oligonucleotide Synthesis, IRL Press, Oxford, 1984; R.I. Freshney, *Animal Cell Culture*, 1987; Coligan et al., *Current Protocols in Immunology*, 1991.

5   A description of the assays and materials referred to in the following Examples is provided below:

Proteins and Antibodies: Full length human WISP-1-Fc fusion protein was expressed and purified as described previously (Desnoyers et al., J. Biol. Chem., 276:47599-47607 (2001)). Purified mouse anti-rat CD44 antibody (clone OX49) was from BD Bioscience (Bedford

10   MA). The mouse IgG2a isotype control antibody was from Pharmingen. The FITC conjugated mouse anti-rat CD44 was from Serotec (Raleigh, NC) and the FITC conjugated mouse IgG1 isotype control antibody was from DAKO (Denmark). The rat anti-mouse CD44 (clone KM114) was from Pharmingen. The actin antibody (clone C4) was from ICN biomedicals

15   (Aurora, OH). Murine anti- human WISP-1 monoclonal antibodies were generated and selected using WISP-1-Fc as an immunogen and the protocols and reagents described in the Examples of US Patent No. 6,387,657 issued May 14, 2002. Five such monoclonal antibodies have been deposited by Applicants with the ATCC, as noted below.

20   Cells and Tissue Specimens: NRK-49F and SW480 cell lines (ATCC, Manassas, VA) were maintained in High glucose Dulbecco's Modified Eagle's Medium (HGDMEM) supplemented with 10% fetal calf serum (FBS). Parental C57MG, C57MG expressing Wnt-1 (C57MG/Wnt-1), NRK-49F expressing high levels of hWISP-1 (NRK/WISP-1H), NRK-49F

25   expressing lower levels of hWISP-1 (NRK/WISP-1L) and NRK-49F containing an empty vector (NRK/control) were obtained from Arnold Levine (Princeton University, Princeton, NJ) and maintained in media containing 2.5 μg ml^{-1} puromycin (Xu et al., Genes Dev., 14:585-595 (2000)). Wnt-1 transgenic mice obtained from Harold Varmus (National

30   Cancer Institute, National Institutes of Health, Bethesda, MD) were bred with p53 null mice obtained from Jackson Laboratories (Bar Harbor, MA) to generate the Wnt-1 trangenic/p53 knock out mice. Specimens of breast tumor and mammary duct epithelium were excised from those mice for analysis.

35   Particle Exclusion Assay: The erythrocyte sedimentation assay was used as described previously, with minor modifications. (Knudson et al., J. Cell Sci., 99:227-235 (1991)). NRK/WISP-1 ((normal rat kidney fibroblasts transfected with WISP-1; see Xu et al., Genes Dev., 14:585-595 (2000)) and NRK/control cells (normal rat kidney

40   fibroblasts; obtained from Arnold Levine, Princeton University, Princeton, NJ) (1 X 10^5 cells/well) were seeded in Falcon 6 well

plates (Becton Dickinson, Franklin Lanes, NJ) and maintained in high
glucose Dulbecco's modified Eagle's Medium supplemented with 10%
fetal bovine serum (FBS) (Life Technologies, Gaithersburg, MD)
overnight at 37° C, 5% CO_2. The next day, the media was removed and

5   10^8 sheep RBCs (Inter-Cell Technologies, Hopewell, NJ) in 750μl
PBS/0.1% BSA (Boehringer Mannheim, Indianapolis, IN) were added and
allowed to settle for 15 minutes. The cells were observed using a
Nikon Diaphot 300 inverted microscope, and digital images were
acquired using a SONY DKC-5000 digital photo camera (Japan).

10   Hyaluronan Staining of Cultured Cells: Hyaluronan
Staining was performed as previously described, with minor
modifications (Pienimaki et al., J. Biol. Chem., 276:20428-20435
(2001)). NRK/WISP-1 and NRK/control cells (8-10 X 10^3) were plated
in 8 well plastic chamber slides and maintained (as described above)

15   overnight at 37°C, 5% CO_2. The next day the cells were washed with
phosphate buffered saline (PBS) and fixed with 4% paraformaldehyde in
PBS for 20 minutes at room temperature. The cells were washed with
PBS and the non-specific binding sites were saturated for 30 minutes
with distilled water containing 1% bovine serum albumin (BSA) and

20   0.1% Triton X-100 (Calbiochem, LaJolla, CA). Biotinylated HA binding
protein (HA-BP) (Seikagaku America, Falmouth, MA) (5μg/ml in PBS/3%
BSA) was added and incubated overnight at room temperature. The next
day the cells were washed with PBS and incubated for 30 minutes with
1:1000 FITC-conjugated streptavidin (DAKO, Carpinteria, CA) in TBS

25   and 1%/BSA. The cells were washed in PBS, mounted using Vectashield
(Burlingame, CA) containing 1 μg/ml Hoechst 33342 (Molecular Probes,
Eugene, OR) and visualized under a Nikon Eclipse 800 fluorescent
microscope. Images were acquired with a Photometrics 300 CCD camera
operated at -40°C interfaced with an Apple G3 computer. The same

30   procedure was also used to stain frozen sections of mammary tumors
from Wnt-1 transgenic mice).

           Real time RT-PCR: Relative RNA expression level was determined
using real-time RT-PCR as previously reported (Winer et al., Anal.
Biochem., 270:41-49 (1999)). Total RNA was extracted from cells with

35   Tri-Reagent using the manufacturer's protocol (Molecular Research
Center). Specific primers and fluorogenic probes were designed and
used to amplify and quantitate gene expression level. The genes'
specific signals were normalized to that of the glyceraldehyde-3-
phosphate dehydrogenase housekeeping gene. Triplicate sets of data

40   were averaged for each condition. All TaqMan RT-PCR reagents were
purchased from Applied Biosystems (Foster City, CA). To test the

effect of recombinant WISP-1 on gene expression, petri dishes (35 mm) were coated overnight at 4°C with 75 µg ml⁻¹ hWISP-1-Fc in PBS. The next day, cells (3 X 10⁵ cells/dish) were plated on the coated surface and the expression analysis was performed after 18 hours. In

5   certain cases the coated surface was washed and treated for an additional 2 hours at room temperature before cell were seeded.

FACS Analysis: Cells were harvested by trypsinization, washed with PBS and incubated in PBS 1% BSA/ 20% glucose containing 1 µg ml⁻¹ FITC conjugated anti-CD44 (Serotec, Raleigh, NC) or an isotype

10   control Ab (DAKO, Denmark) for 30 minutes at room temperature. Cells were washed with the same buffer and analyzed on an EPICS XL-MCL (Coulter, Miami, FL).

Western Blot: NRK/C and NRK/W1H were cultured to confluency in 10 cm² plates. The cells were washed with PBS and extracted with 300

15   µl of 1% Triton-X100 in TBS for 5 minutes. Proteins were precipitated by adding 10 volumes of acetone to the extract. Samples were reduced, denatured and loaded on a 4-20% gradient SDS polyacrylamide gel. The gel was transferred to PVDF membranes and probed with a anti-rat CD44 antibody (OX49) or an anti-mouse CD44

20   (KM114) at a 1 µg/ml concentration and detected using a HRP-conjugated anti-mouse IgG secondary antibody and the Amersham ECL detection reagents. Actin detection in the samples was used as loading control.

Scatter Assay: The cells were plated in 24 well plates at low

25   concentration (~1000 cells/well) and allowed to form colonies over 3 days. The cells were stained using Diff-Quik (Dade Behring, Newark, DE) and colonies were observed under the microscope.

Cell Wound Healing Assay: Cell migration was evaluated using a cell wound healing assay previously described with minor

30   modifications (Pienimaki et al., J. Biol. Chem., 276:20428-20435 (2001)). Briefly, cells were cultured until they reached confluency. One line (~1 mm) was drawn in the cell layer using a micropipette equipped with a disposable yellow tip. Cell migration over the cleared area was monitored by time lapse microscopy over 15 hours.

35   The area newly occupied by the cells after this period was measured using NIH image software calibrated with a stage micrometer.

Time Lapse Microscopy: Cells were plated in HGDMEM/10% FBS and their random migration was observed for 15 hours using time lapse microscopy. The distance covered by the cells was measured using NIH

40   image software calibrated with a stage micrometer.

Migration Assay: Haptotaxis was measured using a modified
Boyden chamber system as described previously (Bourguignon et al., J.
Biol. Chem., 275:1829-1838 (2000)). The underside of 8 μm porosity
24-well format PET membrane filters (Falcon) were coated overnight at
5   4°C with 50 μl of protein (50 μg ml^{-1}) in PBS. The coated inserts
were rinsed in serum-free media and 0.5 X 10^5 NRK cells in 0.5 ml
HGDMEM/10% FBS were added to the upper chamber. The lower chamber was
filled with 0.75 ml of the same media and the plates were incubated
overnight at 37°C. The next day the upper chamber was wiped with a
10   cotton swab and the cells that migrated to the lower side of the
insert were stained with the Diff-Quik Stain Kit (Dade Behring Inc.)
and counted under the microscope. Triplicate sets of data were
averaged for each condition.

In certain cases, the coated inserts were washed and treated for an
15   additional 2 hours at room temperature.

In situ Hybridization: PCR primers were designed to amplify
either a 740 bp fragment of murine WISP-1 spanning from nt 440-1180
of NM_018865 (upper- 5' GGCTGCCATCTGTGACCCA (SEQ ID NO:12) and lower-
5' CATAGGACCT GCCGGGAGAA A (SEQ ID NO:13)) or a 706 bp fragment of
20   murine WISP-1 spanning from nt 204-910 of NM_018865 (upper- 5'
GCCGTGGCAGTCCTGAGGG (SEQ ID NO:14) and lower- 5' CAGCACCGGG
CATTGACGTT A (SEQ ID NO:15)) or a 464 bp fragment of murine CD44
spanning from nt 144-608 of M27129 (upper- 5' TGGAGAAAAATGGCCGCTAC A
(SEQ ID NO:16))and lower-5' TGGGGTGCTC TTCTCGATGG (SEQ ID NO:17)) or
25   a 630 bp fragment of murine HAS2 spanning from nt 927-1557 of
NM_008216 (upper- 5' GGACAAATCGGCCACGTACA T (SEQ ID NO:18) and lower-
5' CTTGCTCCAT CGGGTCTGC (SEQ ID NO:19)) . Primers included
extensions encoding 27-nucleotide T7 or T3 RNA polymerase initiation
sites to allow in vitro transcription of sense or antisense probes,
30   respectively, from the amplified products. (Lu et al., Cell Vision,
1:169-176 (1994)). All tissues were fixed in 4% formalin and
paraffin-embedded. Sections 3-5 microns thick were deparaffinized,
deproteinated in 4 mg/ml of proteinase K for 30 minutes at 37 °C, and
further processed for in situ hybridization as previously described.
35   (Holcomb et al., EMBO J., Aug 2000 1;19(15):4046-55). ^{33}P-UTP
labeled sense and antisense probes were hybridized to the sections at
55°C overnight. Unhybridized probe was removed by incubation in
20mg/ml RNase A for 30 minutes at 37°C, followed by a high stringency
wash at 55 °C in 0.1 X SSC for 2 hours and dehydration through graded
40   ethanols. The slides were dipped in NBT2 nuclear track emulsion,

exposed in sealed plastic slide boxes containing dessicant for 4
weeks at 4 °C, developed and counterstained with hematoxylin and
eosin.

                              EXAMPLE 1
5
        Stable fibroblast cell lines expressing high (NRK/WISP-1H) or
low (NRK/WISP-1L) levels of WISP-1 and a control cell line containing
an empty vector (NRK/control) were used to evaluate the effect of
WISP-1 on HA production. As demonstrated by the particle exclusion
10   assay, NRK/WISP-1H cells accumulated a large hyaluronan pericellular
coat capable of excluding sedimenting erythrocytes (Fig. 1a).
NRK/WISP-1L accumulated a smaller pericellular matrix (Fig. 1b)
whereas no matrix surrounded NRK/control (Fig. 1c) or NRK/WISP-1H
cells treated with hyaluronidase (data not shown).
15   Accumulation of cell surface associated HA was also evaluated by
fluorescent staining using the biotinylated HA binding protein
(bHABP). The staining revealed HA accumulation at the NRK/WISP-1H
cell surface (Fig. 1d) whereas no staining was detected on NRK
control cells (Fig. 1e).
20   The effect of WISP-1 on HA secretion was evaluated by comparing
the accumulation of HA in the culture media of NRK/WISP-1H to
NRK/control cells over time. After 24 hours, HA concentration in the
NRK/WISP-1H media was 3.5 fold greater in NRK/control cell media and
gradually increased to 8 fold after 144 h (fig. 1f). Together these
25   results show that WISP-1 expression in NRK cells promotes HA
accumulation at the cell surface and in the culture media.

                              EXAMPLE 2
        To identify the enzyme responsible for the WISP-1 triggered HA
30   production, the expression of the known HA synthases (HAS1, HAS2 and
HAS3) in NRK/WISP-1H, NRK/WISP-1L and NRK/control cells was analyzed.
 HAS2 expression was increased up to 10 fold in WISP-1 producing
cells whereas HAS1 and HAS3 mRNA levels were identical to the control
(Fig. 2a). CD44 and RHAMM mRNA levels were also increased in
35   NRK/WISP-1 cell lines whereas hyaluronidase expression remained
unchanged (Fig 2a). Moreover, HAS2, CD44 and RHAMM mRNA levels were
proportional to WISP-1 expression. As demonstrated by FACS analysis
(Fig. 2b) and Western blot (Fig. 2c), the increase in CD44 mRNA
expression in the NRK/WISP-1H cells resulted in a 4- fold increase in
40   CD44 protein level.

EXAMPLE 3

    HA was shown to stimulate cell migration by interacting with
two cell surface receptors, CD44 and RHAMM (Hall et al., supra;
Bourguignon et al., supra). Because WISP-1 increased both HA

5   production and CD44 and RHAMM expression, the motility of WISP-1
expressing cells was evaluated. When plated at a low density,
NRK/control cells proliferated and formed well defined colonies (Fig
3a). Proliferating NRK/WISP-1L cells formed less defined groups as
some cells departed from the growing colonies (Fig 3b). No NRK/WISP-

10   1H colonies were seen, cells scattered in a random pattern (Fig 3c).
    Contrary to the control (Fig. 3d), WISP-1 expressing cells also
revealed a hyper elongated morphology with extended lamellipodia
characteristic of high motility (Fig. 3e). Using time lapse
microscopy, a 4 fold increase in the migration distance of NRK/WISP-

15   1H was observed compared to control cells (Fig. 3f). NRK/WISP-1H
also showed a 2.5 fold increase in migration area in a cell wound
healing assay (Fig. 3g). Together these results demonstrate that
WISP-1 expression may promote cell migration.

20   EXAMPLE 4

    To determine whether the ectopic addition of WISP-1 could
promote HAS2 expression and cell migration, an assay was conducted
using purified recombinant WISP-1-IgG (Desnoyers et al., supra).
WISP-1 addition to the culture media did not promote HAS2 expression

25   (data not shown). When NRK cells were plated onto a WISP-1-IgG
coated surface, HAS2 expression increased compared to cells plated
onto uncoated plastic or onto an irrelevant IgG chimeric protein
(TNFR-IgG) coated surface (Fig. 4a). Although decorin alone promoted
HAS2 expression, this induction was further increased three fold

30   after the coated surface was incubated with WISP-1. The effects of
ectopic WISP-1 addition on NRK cell migration were also examined. In
a transwell assay, WISP-1-IgG induced the haptotactic migration of
NRK cells when coated on the filter's lower surface (Fig. 4b).
Coating of an irrelevant IgG chimeric protein (TNFR-IgG) or addition

35   of WISP-1-IgG to the lower chamber did not promote migration. A CD44
or a WISP-1 antibody (Fig. 4b) inhibited the haptotactic migration
induced by WISP-1. Moreover, WISP-1 haptotactic activity was not
limited to fibroblasts as it also promoted the migration of SW480
cells, a colon adenocarcinoma cell line (Fig. 4c). Together these

40   results demonstrate that ectopic WISP-1 addition increases HAS2
expression and promotes cell migration through a CD44 mediated

mechanism.   It is believed, though not fully understood, that WISP-1
presentation may be important for migration as it may need to be
tethered to a substrate to elicit this activity.

5   EXAMPLE 5
        Because WISP-1 is believed to be a downstream effector of Wnt-
1, WISP-1, HAS2 and CD44 expression in a mammary epithelial cell line
stably transfected with Wnt-1 (C57MG/Wnt-1) were analyzed.   When
compared to the control cell line (C57MG), C57MG/Wnt-1 cells showed a
10   2.7, 5.8 and 3 fold increase in WISP-1, HAS2 and CD44 mRNA expression
respectively (Fig. 5a).   As demonstrated by Western blot, C57/Wnt-1
cells also showed a 6-fold increase in CD44 protein content (Fig.
5b).   Moreover, unlike the control cell line, Wnt-1 expressing cells
failed to form distinct colonies and scattered when put in culture at
15   low density (Fig. 5c).   These results show that HAS2 and CD44
expression and cell motility are elevated in cell lines where WISP-1
expression is triggered by Wnt-1.

                                 EXAMPLE 6
20   Wnt-1 expression in mammary epithelium promotes tumor
development in transgenic mice (Li et al., Oncogene, 19:1002-1009
(2000); Tsukamoto et al., Cell, 55:619-625 (1988)).   Because WISP-1
is a putative downstream effector of Wnt-1, the mRNA expression of
HAS2 and CD44 in spontaneous mammary tumors from MMTV-Wnt-1 trangenic
25   mice was measured.   When compared to mammary duct epithelium, HAS2
mRNA expression was increased between 2.5 and 5.5 fold in all mammary
tumors analyzed (n=5; Fig. 5d).   Similarly, CD44 mRNA expression was
induced between 2.2 and 4.2 fold in all tumors (n=5; Fig 5e).   These
results show that HAS2 and CD44 are overexpressed in MMTV-Wnt-1
30   trangenic mice mammary tumors expressing WISP-1.

                                 EXAMPLE 7
        In situ hybridization demonstrated elevated WISP-1 expression
in the peritumoral stroma of MMTV-Wnt-1 transgenic mouse mammary
35   tumors (Fig. 6a, b).   In contrast, HAS2 (Fig. 6c-d) and CD44 (Fig. 6
e-f) expression was found only in tumoral epithelial cells.   The
localization of CD44 in the tumor parenchyma was confirmed by
immunohistochemistry (Fig. 6g).   Link protein staining revealed an
accumulation of hyaluronan associated with the tumor stroma (Fig.
40   6h).   The highest staining intensity was found in the immediate
vicinity of the tumor lobule whereas weaker staining was localized to

the normal mammary duct epithelium. These findings are consistent
with the suggestion that WISP-1 may regulate interactions between
tumor and stromal cells that involve hyaluronic acid and CD44.

5   EXAMPLE 8
        The metastasis and growth potential of transformed lines was
evaluated as described previously (Welch et al., Cancer Res.,
60:1552-1556 (2000)). Nine-week-old Swiss nu/nu female mice were
used. Briefly, cells were harvested by trypsinization and washed
10   twice with PBS. Each mouse was injected into the lateral tail vein
with 100 µl of a suspension containing 5 X 10^4 or 2.5 X 10^5 cells.
At 2, 3 and 4 week postinjection, mice were examined using cine-
magnetic resonance imaging (MRI) for apparition of pulmonary lesions
and necropsies were performed. The lungs were perfused in Bouin's
15   fixative, excised and H&E stained sections were generated for
evaluation of pulmonary tumor colonization.
        Longitudinal sections of the left lung, and a single transverse
section of the cranial, medial, caudal, and accessory lobes of the
right lung were evaluated. Histologically, affected lungs had
20   spindloid neoplastic cells that infiltrated the pulmonary
interstitium. However, because the severity of the changes was
variable the following grading system was established.
I = Minimal involvement of the pulmonary interstitium – 10-20% of
the lung is affected. Nests and clusters of spindloid neoplastic
25   cells multifocally disrupt the pulmonary interstitium. Affected foci
are commonly along the pleural surface, extending into the
interstitium. No vessels or large airways are affected.
II = Moderate involvement of the pulmonary interstitium – 20 – 50% of
the lung is affected. Nests and clusters of spindloid neoplastic
30   cells multifocally disrupt the pulmonary interstitium. Some vessels
or large airways are filled with spindloid cells. Spindloid cells
frequently form a broad band or large mass subjacent to the pleura
and extending into the interstitium. Overlying mesothelium is plump
(reactive).
35   III = Severe involvement of the pulmonary interstitium – 50- 100% of
the lung is affected. Nests and clusters of spindloid neoplastic
cells multifocally disrupt the pulmonary interstitium. Blood vessels
and large airways are filled with spindloid cells. Spindloid cells
form a broad band or large mass subjacent to the pleura and extending
40   into the interstitium. Spindloid cells are often embedded in a pale
basophilic to amphophilic acellular material. Overlying mesothelium

77

is plump (reactive). Minimal unaffected area for gas exchange
remains.

The results of the lung colonization of nude mice inoculated
with NRK/WISP-1H, NRK/WISP-1L and NRK/control cells are summarized in

5   Figures 7 and 10. In mice inoculated with NRK/WISP-1H or NRK/WISP-
1L, cells formed lung masses in a time- and dose-dependent manner.
The most severe lesions were seen in mice injected with 2.5 X10^5
NRK/WISP-1H and necropsied at 4 weeks post-injection. At 2 and 3
weeks post-injection, the mice had less severe but progressive tumor

10   formation (grade I - II; see grading system above). Mice injected
with 2.5 X10^5 NRK/WISP-1L had only minimal lung tumor formation by 4
weeks post-injection. After 4 weeks post-injection, mice inoculated
with 0.5 X10^5 NRK/WISP-1L cells were either normal or had minimal
neoplastic infiltration (grade I), whereas mice injected with 0.5

15   X10^5 NRK/WISP-1H cells showed increased neoplastic infiltration
(grade I-II). Histological observation revealed that the lungs of
animals inoculated with NRK/control cells were normal (Fig. 7a-c).
In NRK/WISP-1 injected animals, neoplastic spindloid cells initially
formed small clusters within, protruding from, or subjacent to the

20   pleural surface of the lungs (grade I; Fig. 7d-f) often embedded in a
pale basophilic to amphophilic acellular material. In more severely
affected animals, the neoplastic cells formed a broad confluent band
subjacent to the pleura (grade II; Fig. 7g-i). In the most severely
affected animals, blood vessels and large airways were filled with

25   spindloid cells. (grade III; Fig. 7j-l). MRI analysis showed
increased density (hypersignal) outlining the right and left lungs
along the pleura in animals with histologic grade II and grade III
invasion. Severity of the lesion on MRI was consistent with the
histologic score (Figure 7a, d, g, j). These results indicate that

30   WISP-1 expression promotes cellular metastatic growth potential.

                              EXAMPLE 9
        NRK/WISP-1H cells (2.5 X 10^5 cells) were inoculated in the tail
vein of nude mice. Starting on the day of the cell inoculation, the

35   mice were injected intraperitoneally twice a week with 10 mg/kg of a
CD44 antibody, an isotype control antibody or with buffer only (PBS).
 The lungs were fixed and excised after four weeks for gross
anatomical analysis.
        After 4 weeks, the severity of the lesions found in CD44

40   antibody treated animals (n=5) varied from normal to grade I whereas
all (n=10) animals treated with a control antibody or saline had

                                 78

grade III lesions (Fig. 8a). The average area of metastatic foci in
the lungs of animals treated with CD44 antibody was reduced by 99%
(P< 0.00003) compared to animals treated with a control antibody
(Fig. 8b).

5

<center>EXAMPLE 10</center>

An assay was conducted to examine binding specificity of
certain WISP-1 antibodies. Full length mouse WISP-1 (GenBank
accession number NM_018865)and full length human WISP-1 (GenBank

10   accession number AF100779; Fig. 9) were cloned into an expression
vector encoding the human IgG_1 Fc region downstream of the WISP-1
sequence. The resulting recombinant fusion protein (WISP-1-Fc) was
synthesized in a baculovirus expression system using Sf9 insect cells
and purified to homogeneity from serum-free conditioned medium by

15   affinity chromatography on a Protein A-Sepharose 4 Fast Flow
(Amersham Pharmacia Biotech). Full length human WISP-1 was also
expressed with an amino terminal hexa-histidine tag (WISP-1-His) in
an *E. coli* strain. The cell lysate was subjected to chromatography
on a Ni^{2+}-NTA agarose column (Qiagen). WISP-1-His was eluted with a

20   0 to 500 mM imidazole gradient. Fractions containing the eluted
WISP-1-His were then pooled and dialyzed. Human WISP-1 from a
mammalian expression system was obtained by lysing NRK cells stably
transfected with human WISP-1 (Arnold Levine; Princeton University,
Princeton, NJ) with SDS-PAGE sample buffer. A control cell lysate

25   was generated with NRK cells stably transfected with an empty vector.

WISP-1 (50 ng) from various expression systems was
electrophoresed on a SDS polyacrylamide gel and electro-transferred
onto polyvinyldifluoride (PVDF) membranes and probed with different
WISP-1 monoclonal antibodies.

30   WISP-1 antibodies 3D11.D7 (also referred to herein as "3D11"),
11C2.C10 (also referred to herein as "11C2"), 9C11.C7 (also referred
to herein as "9C11") and 5D4.F6 (also referred to herein as "5D4")
bound specifically to WISP-1 generated from baculovirus, bacterial
and mammalian expression systems (Fig. 11a). These antibodies did

35   not bind to the murine WISP-1 from baculovirus and did not recognize
any protein from the control lysate. The WISP-1 antibodies 6F8, 3A7,
10H12, 3A11, 6E3, 3H10, 5G1, and 10B1 recognized both human and
murine WISP-1 only when generated with the baculovirus expression
system (Fig. 11b). These antibodies did not recognize human WISP-1

40   when produced in a bacterial or mammalian expression system. The

<center>79</center>

antibody from clone 9C10 did not bind to any protein after Western blot.

These results suggest that WISP-1 antibodies 3D11, 11C2, 9C11 and 5D4 specifically recognize human WISP-1 and can be used for WISP-1 detection by Western blot.

EXAMPLE 11

An assay was conducted to identify the epitopes recognized by the WISP-1 antibodies 11C2, 9C11, 5D4 and 3D11.

Full length human WISP-1 (GenBank accession number AF100779) was cloned into a pIRESpuro2 expression vector (Clontech Laboratories, Palo Alto, CA) encoding 6 histidines downstream of the WISP-1 sequence. Deletion mutants were also generated by removing one, two or three domains of human WISP-1. The resulting contructs were also cloned into the pIRESpuro2 expression vector. The nomenclature used to identify the different WISP-1 contructs refer to the domains they contain. (see Fig. 12B) Domain 1 is the insulin-like growth factor binding protein domain (IFGBP), domain 2 is the von Willebrand factor C (VWFc) domain, domain 3 is the thrombospondin (TSP) domain, and the domain 4 is the C-terminal (CT) domain. The variable region resides between domain 2 and 3. These regions and domains of WISP-1 are illustrated in Fig. 12A.

The sequences encoding these domains of WISP-1 are as follows:
Sequences of WISP-1 Constructs

Domain 1:
GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGCACCGTC
CTGGCCACGGCCCTCTCTCCAGCCCCTACGACCATGGACTTTACTCCAGCTCCACTGGAGGACACCTCC
TCACGCCCCCAATTCTGCAAGTGGCCATGTGAGTGCCCGCCATCCCCACCCCGCTGCCCGCTGGGGGTC
AGCCTCATCACAGATGGCTGTGAGTGCTGTAAGATGTGCGCTCAGCAGCTTGGGGACAACTGCACGGAG
GCTGCCATCTGTGACCCCCACCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCCGAGGTACGCAATA
GGAGTGTGTGCACAGGCGGCCGCACACCACCATCACCATCACCATCACTAAGTGAGGCCGCATAGATAA
CTGATCCAGTGTGCTGGAATTAATTC   (SEQ ID NO:3)

Domain 2:
GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGCACCGTC
CTGGCCACTGCAGTGGTCGGTGTGGGCTGCGTCCTGGATGGGGTGCGCTACAACAACGGCCAGTCCTTC
CAGCCTAACTGCAAGTACAACTGCACGTGCATCGACGGCGCGGTGGGCTGCACACCACTGTGCCTCCGA
GTGCGCCCCCCGCGTCTCTGGTGCCCCCACCCGCGGCGCGTGAGCATACCTGGCCACTGCTGTGAGCAG
TGGGTATGTGCGGCCGCACACCACCATCACCATCACCATCACTAAGTGAGGCCGCATAGATAAC (SEQ
ID NO:4)

Domain 3:
GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGCACCGTC
CTGGCCACTGCAGCATGGCACAGGAACTGCATAGCCTACACAAGCCCCTGGAGCCCTTGCTCCACCAGC
TGCGGCCTGGGGGTCTCCACTCGGATCTCCAATGTTAACGCCCAGTGCTGGCCTGAGCAAGAGAGCCGC
5   CTCTGCAACTTGCGGCCATGCGATGTGGACATCCATACACTCATTAAGGCGGCCGCACACCACCATCAC
CATCACCATCACTAAGTGAGGCCGCATAGATAACTGATCCAGTGT (SEQ ID NO:5)

Domain 4:
GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGCACCGTC
10   CTGGCCACTGCAGGGAAGAAGTGTCTGGCTGTGTACCAGCCAGAGGCATCCATGAACTTCACACTTGCG
GGCTGCATCAGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTTGCATGGACAATAGGTGCTGCATC
CCCTACAAGTCTAAGACTATCGACGTGTCCTTCCAGTGTCCTGATGGGCTTGGCTTCTCCCGCCAGGTC
CTATGGATTAATGCCTGCTTCTGTAACCTGAGCTGTAGGAATCCCAATGACATCTTTGCTGACTTGGAA
TCCTACCCTGACTTCTCAGAAATTGCCAACGCGGCCGCACACCACCATCACCATCACCATCACTAAGTG
15   AGGCCGCATAGATAACTGATCCAGTGTG   (SEQ ID NO:6)

Domain 1,2:
GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGCACCGTC
CTGGCCACGGCCCTCTCTCCAGCCCCTACGACCATGGACTTTACTCCAGCTCCACTGGAGGACACCTCC
20   TCACGCCCCCAATTCTGCAAGTGGCCATGTGAGTGCCCGCCATCCCCACCCCGCTGCCCGCTGGGGGTC
AGCCTCATCACAGATGGCTGTGAGTGCTGTAAGATGTGCGCTCAGCAGCTTGGGGACAACTGCACGGAG
GCTGCCATCTGTGACCCCCACCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCCGAGGTACGCAATA
GGAGTGTGTGCACAGGTGGTCGGTGTGGGCTGCGTCCTGGATGGGGTGCGCTACAACAACGGCCAGTCC
TTCCAGCCTAACTGCAAGTACAACTGCACGTGCATCGACGGCGCGGTGGGCTGCACACCACTGTGCCTC
25   CGAGTGCGCCCCCCGCGTCTCTGGTGCCCCCACCCGCGGCGCGTGAGCATACCTGGCCACTGCTGTGAG
CAGTGGGTATGTGCGGCCGCACACCACCATCACCATCACCATCACTAAGTGAGGCCGCATAGATAAC
(SEQ ID NO:7)

Domain 1,2,3:
30   GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGCACCGTC
CTGGCCACGGCCCTCTCTCCAGCCCCTACGACCATGGACTTTACTCCAGCTCCACTGGAGGACACCTCC
TCACGCCCCCAATTCTGCAAGTGGCCATGTGAGTGCCCGCCATCCCCACCCCGCTGCCCGCTGGGGGTC
AGCCTCATCACAGATGGCTGTGAGTGCTGTAAGATGTGCGCTCAGCAGCTTGGGGACAACTGCACGGAG
GCTGCCATCTGTGACCCCCACCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCCGAGGTACGCAATA
35   GGAGTGTGTGCACAGGTGGTCGGTGTGGGCTGCGTCCTGGATGGGGTGCGCTACAACAACGGCCAGTCC
TTCCAGCCTAACTGCAAGTACAACTGCACGTGCATCGACGGCGCGGTGGGCTGCACACCACTGTGCCTC
CGAGTGCGCCCCCCGCGTCTCTGGTGCCCCCACCCGCGGCGCGTGAGCATACCTGGCCACTGCTGTGAG
CAGTGGGTATGTGAGGACGACGCCAAGAGGCCACGCAAGACCGCACCCCGTGACACAGGAGCCTTCGAT
GCTGTGGGTGAGGTGGAGGCATGGCACAGGAACTGCATAGCCTACACAAGCCCCTGGAGCCCTTGCTCC
40   ACCAGCTGCGGCCTGGGGGTCTCCACTCGGATCTCCAATGTTAACGCCCAGTGCTGGCCTGAGCAAGAG
AGCCGCCTCTGCAACTTGCGGCCATGCGATGTGGACATCCATACACTCATTAAGGCgGCCGCACACCAC

81

CATCACCATCACCATCACTAAGTGAGGCCGCATAGATAACTGATCCAGTGTGCTGGA   (SEQ ID

NO:8)

Domain 1,2,4:

5   GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGCACCGTC

       CTGGCCACGGCCCTCTCTCCAGCCCCTACGACCATGGACTTTACTCCAGCTCCACTGGAGGACACCTCC

       TCACGCCCCCAATTCTGCAAGTGGCCATGTGAGTGCCCGCCATCCCCACCCCGCTGCCCGCTGGGGGTC

       AGCCTCATCACAGATGGCTGTGAGTGCTGTAAGATGTGCGCTCAGCAGCTTGGGGACAACTGCACGGAG

       GCTGCCATCTGTGACCCCCACCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCCGAGGTACGCAATA

10   GGAGTGTGTGCACAGGTGGTCGGTGTGGGCTGCGTCCTGGATGGGGTGCGCTACAACAACGGCCAGTCC

       TTCCAGCCTAACTGCAAGTACAACTGCACGTGCATCGACGGCGCGGTGGGCTGCACACCACTGTGCCTC

       CGAGTGCGCCCCCCGCGTCTCTGGTGCCCCCACCCGCGGCGCGTGAGCATACCTGGCCACTGCTGTGAG

       CAGTGGGTATGTCTGCAGGCAGGGAAGAAGTGTCTGGCTGTGTACCAGCCAGAGGCATCCATGAACTTC

       ACACTTGCGGGCTGCATCAGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTTGCATGGACAATAGG

15   TGCTGCATCCCCTACAAGTCTAAGACTATCGACGTGTCCTTCCAGTGTCCTGATGGGCTTGGCTTCTCC

       CGCCAGGTCCTATGGATTAATGCCTGCTTCTGTAACCTGAGCTGTAGGAATCCCAATGACATCTTTGCT

       GACTTGGAATCCTACCCTGACTTCTCAGAAATTGCCAACGCGGCCGCACACCACCATCACCATCACCAT

       CACTAAGTGAGGCCGCATAGATAACTGATCCAGTGTGCTGGAATTAATTCGCTGTCTGCGAGGGCCAGC

       TGTTGGGGTGAGTACTCCCTCTCAAAAGCGGGCATGACTTCTGCGCTA   (SEQ ID NO:9)

20

Domain 1,3,4:

       GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGCACCGTC

       CTGGCCACGGCCCTCTCTCCAGCCCCTACGACCATGGACTTTACTCCAGCTCCACTGGAGGACACCTCC

       TCACGCCCCCAATTCTGCAAGTGGCCATGTGAGTGCCCGCCATCCCCACCCCGCTGCCCGCTGGGGGTC

25   AGCCTCATCACAGATGGCTGTGAGTGCTGTAAGATGTGCGCTCAGCAGCTTGGGGACAACTGCACGGAG

       GCTGCCATCTGTGACCCCCACCGGGGCCTCTACTGTGACTACAGCGGGGACCGCCCGAGGTACGCAATA

       GGAGTGTGTGCGCATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAACTGCATAGCCTACACAAGCCCC

       TGGAGCCCTTGCTCCACCAGCTGCGGCCTGGGGGTCTCCACTCGGATCTCCAATGTTAACGCCCAGTGC

       TGGCCTGAGCAAGAGAGCCGCCTCTGCAACTTGCGGCCATGCGATGTGGACATCCATACACTCATTAAG

30   GCAGGGAAGAAGTGTCTGGCTGTGTACCAGCCAGAGGCATCCATGAACTTCACACTTGCGGGCTGCATC

       AGCACACGCTCCTATCAACCCAAGTACTGTGGAGTTTGCATGGACAATAGGTGCTGCATCCCCTACAAG

       TCTAAGACTATCGACGTGTCCTTCCAGTGTCCTGATGGGCTTGGCTTCTCCCGCCAGGTCCTATGGATT

       AATGCCTGCTTCTGTAACCTGAGCTGTAGGAATCCCAATGACATCTTTGCTGACTTGGAATCCTACCCT

       GACTTCTCAGAAATTGCCAACGCGGCCGCACACCACCATCACCATCACCATCACTAAGTGAGGCCGCAT

35   AGATAAC (SEQ ID NO:10)

Domain 2,3,4:

            GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGC

       ACCGTCCTGGCCACTGCAGTGGTCGGTGTGGGCTGCGTCCTGGATGGGGTGCGCTACAACAACGGCCAG

40   TCCTTCCAGCCTAACTGCAAGTACAACTGCACGTGCATCGACGGCGCGGTGGGCTGCACACCACTGTGC

       CTCCGAGTGCGCCCCCCGCGTCTCTGGTGCCCCCACCCGCGGCGCGTGAGCATACCTGGCCACTGCTGT

                                        82

GAGCAGTGGGTATGTGAGGACGACGCCAAGAGGCCACGCAAGACCGCACCCCGTGACACAGGAGCCTTC

GATGCTGTGGGTGAGGTGGAGGCATGGCACAGGAACTGCATAGCCTACACAAGCCCCTGGAGCCCTTGC

TCCACCAGCTGCGGCCTGGGGGTCTCCACTCGGATCTCCAATGTTAACGCCCAGTGCTGGCCTGAGCAA

GAGAGCCGCCTCTGCAACTTGCGGCCATGCGATGTGGACATCCATACACTCATTAAGGCAGGGAAGAAG

5 TGTCTGGCTGTGTACCAGCCAGAGGCATCCATGAACTTCACACTTGCGGGCTGCATCAGCACACGCTCC

TATCAACCCAAGTACTGTGGAGTTTGCATGGACAATAGGTGCTGCATCCCCTACAAGTCTAAGACTATC

GACGTGTCCTTCCAGTGTCCTGATGGGCTTGGCTTCTCCCGCCAGGTCCTATGGATTAATGCCTGCTTC

TGTAACCTGAGCTGTAGGAATCCCAATGACATCTTTGCTGACTTGGAATCCTACCCTGACTTCTCAGAA

ATTGCCAACGCGGCCGCACACCACCATCACCATCACCATCACTAAGTGAGGCCGCATAGATAACTGATC

10 CAGTGTGCTGGAATTAATTCGCTGTCTGCGA   (SEQ ID NO:11)

Cells (HEK 293T) were transfected with the different
constructs, and the culture media was collected after 48 hours. One
milliliter of culture media was incubated with 20 µl of
15 cobalt-agarose for 1 hour, centrifuged and washed. The adsorbed
proteins were eluted by heating the pellet at 100 °C for 5 minutes in
20 µl of SDS-PAGE sample buffer. The samples were electrophoresed,
electro-transferred onto PVDF and probed with the different WISP-1
antibodies.

20   Antibodies 11C2, 9C11 and 5D4 recognized only WISP-1 contructs
containing the 19 first amino acids of the variable region located
between domain 2 and 3 (Fig. 12C; 12E; 12G). The WISP-1 antibody
3D11 recognized only WISP-1 contructs containing the domain 1 (amino
acids 24 to 117; Fig. 12D; 12F).

25   These results indicate that the antibodies 11C2, 9C11 and 5D4
recognize specifically the variable region of WISP-1 whereas the
antibody 3D11 recognizes specifically the domain 1 of WISP-1.

EXAMPLE 12

30   An assay was conducted to identify the epitope recognized by
the WISP-1 antibody 9C10.F5 (also referred to herein as "9C10").

Culture media from HEK 293T cells transfected with the various
WISP-1 deletion contructs (as described above in Example 11) was
incubated with 1 µg of WISP-1 antibody 9C10 and 20 µl of protein
35 A-agarose for 1 hour at room temperature. The immunocomplex was
precipitated by centrifugation and eluted by heating the pellet at
100 °C for 5 minutes in 20 µl of SDS-PAGE sample buffer. The samples
were electrophoresed, electro-transferred onto PVDF and probed with
WISP-1 antibody 11C2.

40   The antibody 9C10 immunoprecipitated only constructs containing
the domain 1 of WISP-1 (Fig. 13). These results demonstrate that the

antibody 9C10 specifically recognizes the domain 1 of WISP-1 and can
be used for immunoprecipitation.

EXAMPLE 13

5   WISP-1 antibody 9C10 (100 µl of 2 µg/ml in carbonate buffer, pH
9.6) was coated to Maxisorb plates overnight at 4 °C. The plates
were blocked with 200 µl of PBS/3% BSA for 1 hour. A standard curve
was made of serial dilutions of WISP-1-Fc (100 µl in PBS/3% BSA) and
incubated for 1 hour. After the incubation, the plates were washed
10   with 100 µl PBS/0.05% Tween and WISP-1 antibodies (100 µl of 2 µg/ml)
in PBS/3% BSA (biotinylated 11C2 or 55B) were incubated for 1 hour.
For biotinylated 11C2, the plates were further incubated with 2 µg/ml
HRP-conjugated streptavidin. For 55B, the plates are washed and
incubated with HRP-conjugated donkey anti-rabbit IgG for 1 hour. At
15   the end of the incubation, the wells were washed 6 times with 200 µl
of PBS containing 0.05% Tween-20, and the signal was visualized using
100 µl of the horseradish peroxidase chromogenic substrate TMB
(Kirkegaard & Perry Laboratories). The reaction was stopped with 100
µl of 1 M phosphoric acid, and the OD at 450 nm was measured.
20   Non-specific binding was determined in parallel incubations by
omitting microtiter well coating. No signal was generated when
WISP-1-Fc or a WISP-1 antibody was omitted.

       Using the antibody 9C10 for capture and the antibodies 11C2 and
55B for detection, an ELISA was conducted capable of detecting
25   concentration of WISP-1 as low as 0.4 µg/ml (Fig. 14). This ELISA
may be useful for detecting WISP-1 protein in biological fluids such
as serum.

EXAMPLE 14

30   Maxisorb plates were coated overnight at 4 °C with 50 µl/well
of 10 µg/ml heparin (Sigma). The non specific binding sites were
blocked with 200µl of PBS/3% BSA for 1 hour. The plates were then
incubated for 1 hour with 50 µl of 6 µg/ml hWISP-1-Fc in PBS/3% BSA
in the presence of serial dilutions of WISP-1 antibodies. The plates
35   were washed with PBS/0.05% Tween and further incubated 1 hour with 50
µl of 2 µg/ml HRP conjugated anti-human IgG-Fc in PBS/3% BSA. The
plates were washed, and 100 µl of HRP substrate (TMB) was added. The
color development was stopped with 100 µl of 1 M phosphoric acid and
the OD at 450 nm was measured.

The WISP-1 antibodies 11C2, 5D4 and 9C11 inhibited WISP-1
binding to heparin with an IC_{50} of 1.9, 2.5 and 3.7 μg/ml,
respectively (Fig. 15). The antibody 3D11 moderately reduced WISP-1
binding to heparin with a maximal inhibition of 62% at the highest
5   concentration tested (40 μg/ml). The antibody 9C10 did not attenuate
WISP-1 heparin binding, showing an inhibition curve similar to the
irrelevant antibody control.

These results demonstrate that antibodies recognizing the
variable region can inhibit WISP-1 binding to heparin. Because the
10   two WISP-1 antibodies recognizing domain 1 have little or no effect
on WISP-1 binding to heparin, it is presently believed that the
domain 1 is less likely to participate in this interaction.

EXAMPLE 15

15   Haptotaxis was measured using a modified Boyden chamber system.
The underside of 8 μm porosity 24-well format PET membrane filters
(Becton Dickinson, Franklin Lakes, New Jersey) were coated overnight
at 4 °C with 50 μl of protein (50 μg/ml) in PBS. Normal rat kidney
cells (NRK; 5 x 10^4/0.5 ml HGDMEM/10% FBS) were added to the upper
20   chamber, the lower chamber was filled with the same media and the
plates were incubated at 37 °C. The next day, the upper chamber was
wiped with a cotton swab, and the cells that migrated to the lower
side of the insert were stained and counted under a microscope.
Triplicate sets of data were averaged for each condition. In certain
25   cases, the coated inserts were washed and treated for an additional 2
hours at room temperature.

In a transwell assay, WISP-1-Fc coated on the filters' lower
surface induced the haptotactic migration of NRK cells (Fig. 16A).
Coating of an irrelevant IgG chimeric protein (TNFR-Fc) or addition
30   of WISP-1-Fc to the lower chamber did not promote migration. In the
presence of coated WISP-1-Fc, five different WISP-1 antibodies (9C10,
11C2, 3D11, 9C11, 5D4) markedly inhibited cell migration. In the
absence of coated WISP-1-Fc, these antibodies did not show any effect
on cell migration. These results demonstrate that WISP-1 antibodies
35   can modulate cell migration in the presence of WISP-1. By blocking
cell migration, WISP-1 antibodies may play an important therapeutic
role in preventing cancer progression.

A summary of the characteristics and properties of the 3D11,
9C10, 11C2, 5D4, and 9C11 antibodies discussed in the Examples above
40   is provided in Fig. 16B.

EXAMPLE 16

Nine-week-old Swiss nu/nu female mice were injected into the
lateral tail vein with 100 µl of a suspension containing 2.5×10^5
5   cells. Starting on the day of the inoculation, the mice were treated
semiweekly by intraperitoneal injection (10 mg/kg) of WISP-1
antibodies (9C11, 11C2, 5D4, 9C10, 3D11) or isotype control antibody.
After 3 weeks, lungs were perfused with 4% neutral buffered
formalin, excised and H&E stained sections were generated.
10   Longitudinal sections of the left lung, and a transverse section of
the cranial, medial, caudal, and accessory lobes of the right lung
were evaluated. For each slide the number of metastatic foci was
counted and the average area of metastatic foci was measured using
the SPOT RT software (Diagnostic Instruments Incorporated,
15   Burlingame, California). The area (μm^2) was determined for at least
five individual metastatic foci in four sections of lung.
After 3 weeks, the severity of the lesions found in WISP-1
antibody treated animals was greatly attenuated compared to control
(Fig. 17 a, b). The number of nodules and the average area of the
20   metastatic foci found in mice treated with WISP-1 antibodies (n=5)
were reduced compared to animals treated with a control antibody
(Fig. 17 c,d). Furthermore, upon WISP-1 antibody treatment, the
total pulmonary area covered by the lesions was reduced by 82-97%
compared to animal treated with an isotype control antibody (Fig.
25   17e). These results demonstrate the *in vivo* efficacy of WISP-1
antibodies at reducing the tumor burden related to metastasis.
Although the mechanism of action of the WISP-1 antibodies is not
fully understood, it is believed their efficacy may be mediated by a
growth reducing ability and/or a capacity at inhibiting the motility,
30   invasion and seeding of cancer cells at a tissue site.

EXAMPLE 17

Full length mouse WISP-1 (GenBank accession number NM_018865)
was cloned into the pRK mammalian expression vector. The resulting
35   construct (pRK-WISP-1; 18ug) was co-transfected with 2ug pSVi-
puromycin plasmid in a 4T1 mouse mammary adenocarcinoma cell line
(obtained from Dr. Fred Miller, Barbara Ann Karmanos Cancer
Institute, Detroit, MI) using Fugene6 (Roche) according to
manufacturer's instructions. After 2 days, cells were selected in
40   2 µg/ml puromycin. After 2 weeks, clones were isolated and WISP-1

expression was evaluated by immunofluorescence. The same procedure
was used to generate control cell lines using an empty vector. The
resulting 4T1/control and 4T1/WISP-1 cell lines were maintained in
Iscove's Media containing 10% FBS and 3 μg/ml puromycin.

5   WISP-1 expression in 4T1/control, 4T1/WISP-1L, 4T1/WISP-1H,
NRK/control, NRK/WISP-1L and NRK/WISP-1H cells lines was measured by
semi-quantitative RT-PCR (Taqman) using primers and probes that do
not distinguish between human and mouse WISP-1 gene.

       WISP-1 was not expressed in 4T1/control cell lines. WISP-1
10   expression in 4T1/WISP-1H cell line was 2 fold higher than in
4T1/WISP-1L but 700 fold lower than in NRK/WISP-1H (Figure 18).

                              EXAMPLE 18
       To evaluate WISP-1 effect on 4T1 cell scattering, 100,000
15   4T1/control, 4T1/WISP-1L or 4T1/WISP-1H cells were seeded in 6 well
plate in Iscove's Media containing 10% fetal bovine serum. When
plated at a low density, 4T1/control cells proliferated and formed
well defined colonies (Fig. 19). Proliferating 4T1/WISP-1L cells
formed less defined groups as some cells departed from the growing
20   colonies (Fig. 19). No 4T1/WISP-1H colonies were seen, and cells
scattered in a random pattern (Fig. 19). Together these results
suggest that WISP-1 expression promotes cell migration.

                              EXAMPLE 19
25   WISP-1 effect on 4T1 cell invasion was also evaluated using a
Matrigel coated modified Boyden chamber system of 8 μm porosity 24-
well format PET membrane filters (Falcon). 4T1/control, 4T1/WISP-1L
or 4T1/WISP-1H cells (100,000 cells) were added to the upper chamber
in 0.5 ml Iscove's Media. The lower chamber was filled with 0.75 ml
30   of the same media containing 5% fetal bovine serum and the plates
were incubated overnight at 37°C. The next day the upper chamber was
wiped with a cotton swab and the cells that migrated to the lower
side of the insert were stained with the Diff-Quik Stain Kit (Dade
Behring Inc.) and counted under the microscope. Triplicate sets of
35   data were averaged for each condition. 4T1/WISP-1H and 4T1/WISP-1L
cells demonstrated a 12 and 6 fold increase invasion compared to
4T1/control, respectively (Fig. 20). These results suggest that
WISP-1 promotes tumorigenic mammary epithelial cell invasion and may
play a role in metastasis.

40

EXAMPLE 20

WISP-1 effects on mammary epithelial cells tumorigenesis were evaluated by injecting $1.5x\ 10^5$ cells (4T1/control 1, 4T1/control 2, 4T1/WISP-1L or 4T1/WISP-1H) into the fourth mammary fat pad of 6-8
5   week old female BALB/c mice (6 mice/group). Tumor volumes were measured three times per week. Thirty one days after injection, the mice were sacrificed, the tumors were excised and weighted.

Inoculation of 4T1/WISP-1L cells (Fig. 21a; empty sqares) and 4T1/WISP-1H cells (Fig. 21a; filled sqares) generated faster growing
10   tumors compared to 4T1/control 1 and 4T1/control 2 cells (Fig. 21a; empty and filled circles). After 31 days, the tumors formed by 4T1/WISP-1L and 4T1/WISP-1L inoculated were 4 fold larger (Fig. 21a) and 3 fold heavier (Fig. 21b) than the tumors formed by 4T1/control cells. These results suggest that WISP-1 may increase proliferation
15   of mammary epithelial tumor cells.

EXAMPLE 21

The expression of HAS2 and CD44 in tumors formed by the inoculated 4T1/control, 4T1/WISP-1L and 4T1/WISP-1H cells was
20   measured. When compared to 4T1/control cells tumor, CD44 expression was increased between 5 and 23 fold in 4T1/WISP-1 cells tumors (Fig. 22). On the other hand, HAS2 expression remained identical in all tumors analyzed. These results suggest that WISP-1 increases expression of CD44 in mice inoculated with 4T1 cells. The
25   overexpression of CD44 in these tumors may contribute to the promotion of metastasis.

EXAMPLE 22

WISP-1 effects on mammary epithelial cells metastasis were
30   evaluated by inoculating 4T1 cells in mice mammary fat pads (see Example 20) and examining the extent of the metastatic propagation by micro computer tomography and histology. After 31 days, the mice inoculated with 4T1/WISP-1L or 4T1/WISP-1H cells had extensive lung metastasis (Fig. 23b and 23d) compared to the 4T1/control injected
35   mice (Fig. 23a and 23c). No significant differences were seen between the metastatic potential of 4T1/WISP-1L and 4T1/WISP-1H cells. The mice inoculated with 4T1/control cells had an average of 2.11 pulmonary foci with an average mass of 0.68 grams whereas mice inoculated with 4T1/WISP-1 cells had an average of 20.25 pulmonary
40   foci with an average mass of 12.46 grams. Also, the average

histology score for the lung of 4T1/WISP-1 cells injected mice was
0.92 compared to 0.11 for the NRK/control cells injected mice.

Using immunohistochemistry, it was also observed that the
4T1/WISP-1 pulmonary metastatic foci expressed high levels of CD44
5   (Fig. 23e). In these tumors, CD44 was localized at the plasma
membrane of the 4T1/WISP-1 cells (Fig. 23f). Together these results
demonstrate that WISP-1 promotes the metastatic potential of 4T1
cells, increasing the number of pulmonary metastatic foci (10 fold)
and size (18 fold). Also, CD44 increased expression was maintained
10   after the 4T1/WISP-1 had metastasized to the lungs.

Clinical observations of mice inoculated with 4T1/control 1, or
4T1/WISP-1 cells demonstrated that WISP-1 expression promoted
metastasis at additional secondary sites. Two mice inoculated with
4T1/WISP-1H had a discolored white mass on the kidney whereas no
15   other mice had evidence of kidney tumors.

EXAMPLE 23

The human WISP-1 full length and deletion mutant constructs
20   described above were transfected in normal rat kidney cells (NRK-
49F). After 48 hours, the culture media was supplemented with 2
µg/ml puromycin. After 2 weeks, the pools of expressing cells were
analyzed and the resulting cell lines were maintained in High glucose
Dulbecco's Modified Eagle's Medium (HGDMEM) supplemented with 10%
25   fetal calf serum (FBS) and 2 µg/ml puromycin.

WISP-1 expression in NRK/control, NRK/WISP-1_1234, NRK/WISP-
1_134, NRK/WISP-1_234, NRK/WISP-1_123 and NRK/WISP-1_124 cells lines
was measured by semi-quantitative RT-PCR (Taqman). Results are
expressed as fold relative to WISP-1 expression in NRK/WISP-1_1234
30   (Figure 24A). WISP-1 expression in NRK/WISP-1_134 and NRK/WISP-1_234
is 0.035 and 0.09 fold respectively compared to NRK/WISP-1_1234.
NRK/WISP-1_123 expresses 16.1 fold and NRK/WISP-1_124 7.6 fold
compared to NRK/WISP-1_1234.

The contribution of particular domains to WISP-1 promoted
35   tumorigenesis was evaluated by injecting 5×10^6 cells (NRK/control,
NRK/WISP-1_1234, NRK/WISP-1_123, NRK/WISP-1_124, NRK/WISP-1_134,
NRK/WISP-1_234 cells) subcutaneously in 6-8 week old female nude mice
(10 mice/group). Tumor volumes were measured weekly. After 35 days
the mice were sacrificed, the tumors were excised and analyzed
40   histologically.

Inoculation of NRK/WISP-1_1234 (Figure 24B; filled triangles),
NRK/WISP-1_134 (Figure 24B; filled circles) and NRK/WISP-1_234 cells
(Figure 24B; filled squares) generated tumors. However the
inoculation of NRK/WISP-1_123 (Figure 24B; empty squares), NRK/WISP-
5   1_124 (Figure 24B; empty circles) and NRK/control (Figure 24B; empty
triangles) did not generate tumors. After 35 days, the tumors formed
by NRK/WISP-1_234 cells were comparable in size to the tumors formed
by NRK/WISP-1_1234 cells. However the tumors formed by NRK/WISP-
1_134 cells were 2.5 fold larger than the tumors formed by NRK/WISP-
10   1_1234 cells. These results suggest that the domains 1 and 2 are not
required for WISP-1 promoted NRK tumorigenesis but that the domains 3
and 4 are required for WISP-1 promoted NRK tumorigenesis. It is
believed that WISP-1 antagonists of the invention may preferably bind
to and/or block domains 3 and/or 4 of WISP-1.

15   In addition, results suggest the deletion of the domain 2 of
WISP-1 may increase its tumorigenic potential.
         Histological analysis of the excised tumors (Figure 25)
revealed that the neoplastic cells from NRK/WISP-1_234 tumors were
phenotypically similar to the neoplastic cells from NRK/WISP-1_1234
20   tumors. In these tumors, cells appeared fibroblastic, differentiated
and spindloid. However the neoplastic cells from NRK/WISP-1_134
tumors were phenotypically different and appeared less
differentiated, frequently multinucleated and had a brisk mitotic
rate as demonstrated by the presence of multiple mitotic figures
25   (arrows). In addition, neoplastic cells invaded several blood
vessels adjacent to NRK/WISP-1_134 tumors (Figure 26). These results
indicate that WISP-1_134 expression may confer tumorigenicity to NRK
cells by promoting their in vivo growth and invasive potential.
Moreover the expression of this construct induces a phenotypic
30   transformation characteristic of aggressive neoplastic cells.

                                EXAMPLE 24
         The contribution of the particular WISP-1 domains to the
promoted 4T1 cell invasion was evaluated using a Matrigel coated
35   modified Boyden chamber system of 8 μm porosity 24-well format PET
membrane filters (BD Biosciences). HEK 293 cells (20X10^6) stably
expressing the previously mentioned WISP-1 constructs (WISP-1_1234,
WISP-1_134, WISP-1_123, WISP-1_12, WISP-1_23, WISP-1_3, WISP-1_1 and
WISP-1_4) were seeded in the lower chamber with in 0.75 ml of 50:50
40   Media (1:1 mixture of DME and Ham's F-12 medium) containing 5% fetal

                                    90

bovine serum and the plates were kept overnight at 37°C. The next
day, 4T1 cells (100,000 cells) were added to the upper chamber in 0.5
ml of serum free 50:50 media and the plates were incubated overnight
at 37°C. The following day the upper chamber was wiped with a cotton
5   swab and the cells that migrated to the lower side of the insert were
stained with the Diff-Quik Stain Kit (Dade Behring Inc.) and counted
under the microscope. Triplicate sets of data were averaged for each
condition and results are expressed as fold invasion compared to a
control in which HEK 293 cells transfected with an empty vector were
10   plated in the lower chamber. 4T1 cells demonstrated a 4 fold
increase invasion when HEK 293 cells expressing constructs WISP-
1_1234, WISP-1_134 or WISP-123 were seeded in the lower chamber (Fig.
27). HEK 293 cells expressing the construct WISP-1_12 increased 4T1
cells invasion by only 2.5 fold. The increase in 4T1 cell invasion
15   was marginal when HEK 293 cells expressing WISP-1_23, WISP-1_3, WISP-
1_1 or WISP-1_4 were plated in the lower chamber. These results
suggest that the domain 1 is required for WISP-1 promoted 4T1 cell
invasion. In addition, the data shows that WISP-1's domain 1 alone
is likely not sufficient to promote 4T1 cell invasion.
20

EXAMPLE 25

     An assay was conducted to evaluate the antagonistic activity of
WISP-1's domain 1 on WISP-1 promoted 4T1 cell invasion. The domain 1
of WISP-1 was cloned into an expression vector immediately upstream
25   of the human IgG$_1$ Fc region sequence. The resulting recombinant
fusion protein (WISP-1-domain 1-Fc) was synthesized in a mammalian
expression system using Chinese hamster ovary (CHO) cells and
purified to homogeneity from conditioned medium by affinity
chromatography on a Protein A-Sepharose 4 Fast Flow (Amersham
30   Pharmacia Biotech). WISP-1's domain 1 was also expressed with an
amino terminal hexa-histidine tag (WISP-1-domain-1-His) in a CHO
expression system and purified to homogeneity from culture
supernatant by affinity chromatography on a Ni^{2+}-NTA agarose column
(Qiagen). Fractions containing the eluted WISP-1-domain-1-His were
35   then pooled and dialyzed.
     The antagonistic effect of purified soluble WISP-1-domain-1 on
WISP-1 promoted 4T1 cell invasion was evaluated using a Matrigel
coated modified Boyden chamber system of 8 μm porosity 24-well format
PET membrane filters (BD Biosciences). 4T1/control or 4T1/WISP-1
40   cells (100,000 cells) were added to the upper chamber in 0.5 ml

Iscove's Media. The lower chamber was filled with 0.75 ml of the
same media containing 5% fetal bovine serum. Various concentrations
of WISP-1-domain-1-Fc or WISP-1-domain-1-His were added to the upper
and lower chambers and the plates were incubated overnight at 37°C.

5   The next day the upper chamber was wiped with a cotton swab and the
cells that migrated to the lower side of the insert were stained with
the Diff-Quik Stain Kit (Dade Behring Inc.) and counted under the
microscope. Triplicate sets of data were averaged for each
condition. The results are expressed as relative fold invasion

10   compared to 4T1/ control cells. WISP-1-domain-1-His and WISP-1-
domain-1-Fc demonstrated a dose dependent antagonistic activity
toward WISP-1 promoted 4T1 invasion (Figure 28). Both WISP-1-domain-
1-His and WISP-1-domain-1-Fc showed an apparent IC_{50} of 0.01 μg/ml.
These results suggest that purified WISP-1-domain-1 antagonizes WISP-

15   1 promoted cell invasion.

                                  EXAMPLE 26

        An animal study was conducted to evaluate WISP-1 expression in
the HPAC xenograft model of human pancreatic adenocarcinomas.   5 x

20   10^6 human pancreatic adenocarcinomas cells (HPAC cell line, cat. no.
CRL-2119; ATCC, Manassas, VA, USA;) were injected subcutaneously in
6-8 week old female nude mice. After 21 days the mice were
sacrificed, the tumors were excised and WISP-1 expression was
analyzed by *in situ* hybridization using a human WISP-1 specific probe

25   and a mouse WISP-1 specific probe (Figure 29). The results
demonstrate a strong mouse WISP-1 expression in areas corresponding
to tumor stroma. On the other hand, no human WISP-1 expression was
found in the excised tumors. In addition, the tumors revealed a
strong α-smooth muscle actin and a weak vimentin immunohistochemical

30   staining over the tumoral stroma. These results indicate that HPAC
cells inoculation in nude mice induces the recruitment of a mouse
myofibroblastic stroma in which WISP-1 is expressed.

                                  EXAMPLE 27

35   An animal study was conducted to evaluate the in vivo efficacy of
WISP-1-domain-1 at retarding tumor growth. The human WISP-1_1, WISP-
1_12 constructs cloned into an expression vector (pIRES puro2;
Clontech Laboratories, Palo Alto, CA) were transfected in the HPAC
human pancreatic adenocarcinomas cell line. After 48 hours, the

40   culture media was supplemented with 2 μg/ml puromycin. After 2

weeks, the pools of expressing cells were analyzed and the resulting
cell lines were maintained in 50:50 media (1:1 mixture of DME and
Ham's F-12 medium) supplemented with 10% fetal calf serum (FBS) and 2
µg/ml puromycin.

5   The *in vivo* efficacy of WISP-1-domain-1 at retarding tumor growth
was evaluated by injecting 5 x 10^6 cells (HPAC/WISP-1_12, HPAC/WISP-
1_1 cells) subcutaneously in 6-8 week old female nude mice (10
mice/group). Tumor volumes were measured twice weekly until day 25.
The results demonstrate that the expression of WISP-1_1 or WISP-1_12
10   in HPAC cells retards their *in vivo* growth. The tumor volume of
HPAC/WISP-1_12 and HPAC/WISP-1_1 cells were 12% and 54% smaller
respectively compared to HPAC control cells tumors (Figure 30).
These results indicates that WISP-1-domain-1 and WISP-1-domain-12
expressed by HPAC cells retard their tumor growth possibly by
15   antagonizing mouse WISP-1 tumor promoting activities.

                              EXAMPLE 28
        In situ hybridization studies were conducted to evaluate WISP-1
expression in primary human pancreatic adenocarcinomas. Using a
20   tumor microarray (TMA), it was shown that 68% (125/184) of the
samples cores were positive for WISP-1 expression. In addition, in
these samples WISP-1 expression was restricted to the stromal
compartment (Figure 31). These results indicate a high incidence of
WISP-1 expression in the stromal compartment of human primary
25   pancreatic tumors.

                              EXAMPLE 29
        Immunohistochemical staining was conducted to evaluate WISP-1
expression in primary colon adenocarcinomas. A panel of 15 samples
30   of primary human adenocarcinomas were stained for WISP-1 using a
WISP-1 specific polyclonal goat antibody (R&D systems; cat. No.
AF1627). WISP-1 was detected in 100% (15/15) of the samples
analyzed. In all cases WISP-1 was located in the stromal compartment
surrounding the tumors (Figure 32). These results indicate that
35   WISP-1 is prevalent in the stromal compartment of human colon
adenocarcinomas.

WISP-1 constructs:
Domain 2,3:
40   GAATTCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTGACAGCAGCAGCCGCCAGCACCGTC
       CTGGCCACTGCAGTGGTCGGTGTGGGCTGCGTCCTGGATGGGGTGCGCTACAACAACGGCCAGTCCTTC

CAGCCTAACTGCAAGTACAACTGCACGTGCATCGACGGCGCGGTGGGCTGCACACCACTGTGCCTCCGA

GTGCGCCCCCGCGTCTCTGGTGCCCCCACCCGCGGCGCGTGAGCATACCTGGCCACTGCTGTGAGCAG

TGGGTATGTGAGGACGACGCCAAGAGGCCACGCAAGACCGCACCCCGTGACACAGGAGCCTTCGATGCT

GTGGGTGAGGTGGAGGCATGGCACAGGAACTGCATAGCCTACACAAGCCCCTGGAGCCCTTGCTCCACC

AGCTGCGGCCTGGGGGTCTCCACTCGGATCTCCAATGTTAACGCCCAGTGCTGGCCTGAGCAAGAGAGC

CGCCTCTGCAACTTGCGGCCATGCGATGTGGACATCCATACACTCATTAAGGCGGCCGCACACCACCAT

CACCATCACCATCACTAAGTGAGGCCGCATAGATAACTGATCCAGTGTGCTGGAATTAATTCGCTGTCT

GCGA   (SEQ ID NO:21)

Domain 1-IgG:
        CCTCGGTTCTATCGATTGAATTCCACCATGAGGTGGTTCCTGCCCTGGACGCTGGCAGCAGTG

ACAGCAGCAGCCGCCAGCACCGTCCTGGCCACGGCCCTCTCTCCAGCCCCTACGACCATGGACTTTACT

CCAGCTCCACTGGAGGACACCTCCTCACGCCCCCAATTCTGCAAGTGGCCATGTGAGTGCCCGCCATCC

CCACCCCGCTGCCCGCTGGGGGTCAGCCTCATCACAGATGGCTGTGAGTGCTGTAAGATGTGCGCTCAG

CAGCTTGGGGACAACTGCACGGAGGCTGCCATCTGTGACCCCCACCGGGGCCTCTACTGTGACTACAGC

GGGGACCGCCCGAGGTACGCAATAGGAGTGTGTGCACAGGTGGTCGGTGTGGGGGTCACCGACAAAACT

CACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAA

CCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAA

GACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGG

GAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAAT

GGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAA

GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGAAGAGATGACCAAGAAC

CAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT

GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTAC

AGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAG

GCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAATGAGTGCGACGGCCCTAG

AGTCGACCTGCAGAAGCTTGGCCGCCATGGCCC(SEQ ID NO:22)

Deposit of Material
        The following materials have been deposited with the
American Type Culture Collection, 10801 University Blvd., Manassas,
VA 20110-2209, USA (ATCC):

Material	ATCC Dep. No.	Deposit Date
3D11.D7	PTA-4624	Sept. 4, 2002
11C2.C10	PTA-4628	Sept. 4, 2002
9C10.F5	PTA-4626	Sept. 4, 2002
5D4.F6	PTA-4625	Sept. 4, 2002
9C11.C7	PTA-4627	Sept. 4, 2002

This deposit was made under the provisions of the
Budapest Treaty on the International Recognition of the Deposit of
Microorganisms for the Purpose of Patent Procedure and the
5   Regulations thereunder (Budapest Treaty). This assures maintenance
of a viable culture of the deposit for 30 years from the date of
deposit. The deposit will be made available by ATCC under the terms
of the Budapest Treaty, and subject to an agreement between
Genentech, Inc. and ATCC, which assures permanent and unrestricted
10   availability of the progeny of the culture of the deposit to the
public upon issuance of the pertinent U.S. patent or upon laying open
to the public of any U.S. or foreign patent application, whichever
comes first, and assures availability of the progeny to one
determined by the U.S. Commissioner of Patents and Trademarks to be
15   entitled thereto according to 35 USC '122 and the Commissioner's
rules pursuant thereto (including 37 CFR '1.14 with particular
reference to 886 OG 638).
        The assignee of the present application has agreed that if a
culture of the materials on deposit should die or be lost or
20   destroyed when cultivated under suitable conditions, the materials
will be promptly replaced on notification with another of the same.
Availability of the deposited material is not to be construed as a
license to practice the invention in contravention of the rights
granted under the authority of any government in accordance with its
25   patent laws.

        The foregoing written description is considered to be
sufficient to enable one skilled in the art to practice the
invention. The present invention is not to be limited in scope by
the example presented herein. Indeed, various modifications of the
30   invention in addition to those shown and described herein will become
apparent to those skilled in the art from the foregoing description
and fall within the scope of the appended claims.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1.   A method of inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, comprising exposing said mammalian cells to an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

      a)   a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1; and

      b)   a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

2.   The method according to claim 1, wherein said WISP-1-domain 1 polypeptide is fused to a Fc region of an immunoglobulin.

3.   The method according to claim 1, wherein said mammalian cells comprise cancer cells.

4.   The method according to claim 3, wherein said cancer cells comprise pancreatic cancer cells, colon or colorectal cancer cells, breast cancer cells, lung cancer cells, or brain cancer cells.

5.   The method according to claim 4, wherein said cancer cells comprise pancreatic adenocarcinoma cells or colonic adenocarcinoma cells.

6.   A method of treating cancer in a mammal, comprising administering to said mammal an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

      a)   a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1; and

      b)   a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

7.   The method according to claim 6, wherein said WISP-1-domain 1 polypeptide is fused to a Fc region of an immunoglobulin.

8.   The method according to claim 6, wherein said cancer is a pancreatic cancer, colon or colorectal cancer, breast cancer, lung cancer or brain cancer.

96

9.   The method according to claim 8, wherein said cancer is pancreatic adenocarcinoma or colonic adenocarcinoma.

5   10.   The method according to claim 6, wherein said polypeptide inhibits or reduces cancer cell growth or metastasis.

11.   The method according to claim 8, wherein said polypeptide inhibits or reduces lung cancer cell metastasis at a site in the mammal secondary or
10   different from the primary lung tumor site in the mammal.

12.   The method according to claim 6, wherein chemotherapy, radiation, a prodrug, a cytotoxic agent, a growth inhibitory agent, or a cytokine is also administered to said mammal.
15

13.   The method according to claim 6, wherein said polypeptide inhibits or neutralizes induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of mammalian cell.

20   14.   A method of inhibiting cancer cell motility, comprising exposing a cancer cell to an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:
        a)   a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117
25   of SEQ ID NO:1;   and
        b)   a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

15.   The method according to claim 14, wherein said WISP-1-domain 1
30   polypeptide is fused to a Fc region of an immunoglobulin.

16.   The method according to claim 14, wherein said cancer cell is a pancreatic cancer cell, colon or colorectal cancer cell, breast cancer cell, lung cancer cell, or brain cancer cell.
35

17.   A method of inhibiting cancer cell motility in a mammal comprising administering to said mammal an effective amount of a WISP-1-domain 1 polypeptide, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:
40   a)   a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117

97

of SEQ ID NO:1; and

    b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

18.   The method according to claim 17, wherein said WISP-1-domain 1 polypeptide is fused to a Fc region of an immunoglobulin.

19.   The method according to claim 17, wherein said cancer cell is a pancreatic cancer cell, colon or colorectal cancer cell, breast cancer cell, lung cancer cell, or brain cancer cell.

20.   The method according to claim 17, wherein said polypeptide inhibits or neutralizes induction or secretion of HAS2, HA, CD44 or RHAMM by native human WISP-1 polypeptide in at least one type of mammalian cell.

21.   Use of a WISP-1-domain 1 polypeptide in the manufacture of a medicament for inhibiting or neutralizing WISP-1 induction or secretion of HAS2, HA, CD44 or RHAMM in mammalian cells, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

    a) a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1; and

    b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

22.   Use of a WISP-1-domain 1 polypeptide in the manufacture of a medicament for inhibiting cancer cell motility, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

    a) a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1; and

    b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at least about 95% identity to amino acids 24 - 117 of SEQ ID NO:1.

23.   Use of a WISP-1-domain 1 polypeptide in the manufacture of a medicament for treating cancer, wherein said WISP-1-domain 1 polypeptide consists of a polypeptide selected from the group consisting of:

    a) a WISP-1-domain 1 polypeptide consisting of amino acids 24 - 117 of SEQ ID NO:1; and

    b) a WISP-1-domain 1 polypeptide consisting of a polypeptide with at

least about 95% identity to amino acids 24 – 117 of SEQ ID NO:1.

24.   The use according to claim 23, wherein said polypeptide inhibits or
neutralizes induction or secretion of HAS2, HA, CD44 or RHAMM by native
5   human WISP-1 polypeptide in at least one type of mammalian cell.

25.   A method according to any one of claims 1, 6, 14 or 17, or a use
according to any one of claims 21 to 23, substantially as herein described
with reference to any one of the examples or drawings.

0

FIG._1A   FIG._1B   FIG._1C

FIG._1D   FIG._1E

FIG._1F

FIG._2A

FIG._2B

FIG._2C

FIG._3A   **FIG._3B**   **FIG._3C**

FIG._3D   **FIG._3E**

Migration Distance (μm)

FIG._3F

Migration Area (μm²)

FIG._3G

FIG._4A

FIG._4B

FIG._4C

FIG._5C

FIG._5B

FIG._5A

FIG._5E

FIG._5D

Gene Expression
(Fold Induction)

HAS2 mRNA Expression
(Relative to Normal Mucosa)

CD44 mRNA Expression
(Relative to Normal Mucosa)

FIG._6A

FIG._6B

FIG._6C

FIG._6D

FIG._6E

FIG._6F

FIG._6G

FIG._6H

FIG._7A   FIG._7B   FIG._7C

FIG._7D   FIG._7E   FIG._7F

FIG._7I

FIG._7H

FIG._7G

FIG._7L

FIG._7K

FIG._7J

FIG._8A

FIG._8B

```
  1  CCCACGCGTC CGCTGGGCCC AGCTCCCCCG AGAGGTGGTC GGATCCTCTG GGCTGCTCGG TCGATGCCTG TGCCACTGAC GTCCAGGCAT GAGGTGGTTC
     GGGTGCGCAG GCGACCCGGG TCGAGGGGGC TCTCCACCAG CCTAGGAGAC CCGACGAGCC AGCTACGGAC ACGGTGACTG CAGGTCCGTA CTCCACCAAG
  1                                                                                               M   R   W   F

101  CTGCCCTGGA CGCTGGCAGC AGTGACAGCA GCAGCCGCCA GCACCGTCCT GGCCACGGCC CTCTCTCCAG CATGGACTTT ACTCCAGCTC
     GACGGGACCT GCGACCGTCG TCACTGTCGT CGTCGGCGGT CGTGGCAGGA CCGGTGCCGG GAGAGAGGTC GTACCTGAAA TGAGGTCGAG
  5    L   P   W   T   L   A   A   V   T   A   A   A   S   T   V   L   A   L   S   P   A   P   T   T   M   D   F   T   P   A   P

201  CACTGGAGGA CACCTCCTCA CGCCCCCAAT TCTGCAAGTG GCCATGTGAG TGCCCGCCTG GGGGTCAGCC TCATCACAGA
     GTGACCTCCT GTGGAGGAGT GCGGGGGTTA AGACGTTCAC CGGTACACTC ACGGGCGGAC CCCCAGTCGG AGTAGTGTCT
 39    L   E   D   T   S   S   R   P   Q   F   C   K   W   P   C   E   C   P   P   R   C   P   L   G   V   S   L   I   T   D

301  TGGCTGTGAG TGCTGCGCTCA GCAGCTTGGG GACAACTGCA CGGAGGCTGC CCCCACCGGG GCCTCTACTG TGACTACAGC
     ACCGACACTC ACGACGCGAGT CGTCGAACCC CTGTTGACGT GCCTCCGACG GGGGTGGCCC CGGAGATGAC ACTGATGTCG
 72    G   C   E   C   C   A   Q   Q   L   G   D   N   C   T   E   A   A   I   C   D   P   H   R   G   L   Y   C   D   Y   S

401  GGGGACCGCC CGAGGTACGC AATAGGAGTG TGTGCACAGG TGGTCGGTGT CTGGATGGGG TGCGCTACAA CAACGGCCAG TCCTTCCAGC
     CCCCTGGCGG GCTCCATGCG TTATCCTCAC ACACGTGTCC ACCAGCCACA GACCTACCCC ACGCGATGTT GTTGCCGGTC AGGAAGGTCG
105    G   D   R   P   R   Y   A   I   G   V   C   A   Q   V   G   V   L   D   G   V   R   Y   N   N   G   Q   S   F   Q   P

501  CTAACTGCAA GTACAACTGC ACGTGCATCG ACGGCGCGGT CGGCTGTGCC CCACTGTGCC TCCGAGTGCG CTCTGGTGCC CCCACCCGCG
     GATTGACGTT CATGTTGACG TGCACGTAGC TGCCGCGCCA GCCGACACGG GGTGACACGG AGGCTCACGC GAGACCACGG GGGTGGGCGC
139    N   C   K   Y   N   C   T   C   I   D   G   A   V   G   C   A   P   L   C   L   R   V   R   P   P   R   L   W   C   P   H   P   R

601  GCGCGTGAGC ATACCTGGCC ACTGCTGTGA TGTGAGGACG GCAGTGGGTA ACCGCCAAGAG GCCACGCACCC GTGACACAG AGCCTTCGAT
     CGCGCACTCG TATGGACCGG TGACGACACT ACACTCCTGC CGTCACCCAT TGGCGGTTCTC CGGTGCGTGGG CACTGTGTCC TCGGAAGCTA
172    R   V   S   I   P   G   H   C   C   E   Q   W   V   C   E   D   D   A   K   R   P   R   K   T   A   P   R   D   T   G   A   F   D

701  GCTGTGGGTG AGGTGGAGGC ATGGCACAGG AACTGCATAG CCTACACAAG CCTTGCTCCA CCAGCTGCGG CCTGGGGGTC TCCACTCGGA
     CGACACCCAC TCCACCTCCG TACCGTGTCC TTGACGTATC GGATGTGTTC GGAACGAGGT GGTCGACGCC GGACCCCCAG AGGTGAGCCT
205    A   V   G   E   V   E   A   W   H   R   N   C   I   A   Y   T   S   P   W   S   P   C   S   T   S   C   G   L   G   V   S   T   R   I

801  TCTCCAATGT TAACGCCCAG TGCTGGCCTG AGCAAGAGAG CCGCCTCTGC AACTTGCGGC CATGGCGATGT GGACATCCAT ACACTCATTA AGGCAGGGAA
     AGAGGTTACA ATTGCGGGTC ACGACCGGAC TCGTTCTCTC GGCGGAGACG TTGAACGCCG GTACGCTACA CCTGTAGGTA TGTGAGTAAT TCCGTCCCTT
239    S   N   V   N   A   Q   C   W   P   E   Q   E   S   R   L   C   N   L   R   P   C   D   V   D   I   H   T   L   I   K   A   G   K
```

FIG._9A

```
 901  GAAGTGTCTG GCTGTGTACC AGCCAGAGGC ATCCATGAAC TTCACACTTG CGGGCTGCAT CAGCACACGC TCCTATCAAC CCAAGTACTG TGGGAGTTGC
      CTTCACAGAC CGACACATGG TCGGTCTCCG TAGGTACTTG AAGTGTGAAC GCCCGACGTA GTCGTGTGCG AGGATAGTTG GGTTCATGAC ACCTCAAACG

 272   K  C  L  A  V  Y  Q  ,P  E  A  S  M  N  F  T  L  A  G  C  I  S  T  R  S  Y  Q  P  K  Y  C  G  V  C

1001  ATGGACAATA GGTGCTGCAT CCCTACAAAG TCTAAGACTA TCGACGTGTC CTGATGGGC TTGGCTCTC CCGCCAGGTC CTATGGATTA
      TACCTGTTAT CCACGACGTA GGGATGTTTC AGATTCTGAT AGCTGCACAG GACTACCCG AACCGAAGAG GGCGGTCCAG GATACCTAAT

 305   M  D  N  R  C  C  I  P  Y  K  S  K  T  I  D  V  S  F  Q  C  P  D  G  L  G  F  S  R  Q  Y  L  W  I  N

1101  ATGCCTGCTT CTGTAACCTG AGCTGTAGGA ATCCCAATGA CATCTTTGCT GACTTGGAAT CCTACCCTGA ATTGCCAACT AGGCAGGCAC
      TACGGACGAA GACATTGGAC TCGACATCCT TAGGGTTACT GTAGAAACGA CTGAACCTTA GGATGGGACT TAACGGTTGA TCCGTCCGTG

 339   A  C  F  C  N  L  S  C  R  N  P  N  D  I  F  A  D  L  E  S  Y  P  D  F  S  E  I  A  N  O

1201  AAATCTTGGG TCTTGGGGAC TAACCCAAATG CCTGTGAAGC AGTCAGCCCT TATGGCCAAT AACTTTTCAC CAATGAGCCT TAGTTACCCT GATCTGGACC
      TTTAGAACCC AGAACCCCTG ATTGGGTTAC GGACACTTCG TCAGTCGGGA ATACCGGTTA TTGAAAAGTG GTTACTCGGA ATCAATGGGA CTAGACCTGG

1301  CTTGGCCTCC ATTTCTGTCT CTAACCATTC AAATGACGCC CTAACCATTC GCTCAGGCCC ATGCTATGAG GATATCATTC AGCATCTACT
      GAACCGGAGG TAAAGACAGA GATTGGTAAG TTTACTGCGG GATTGGTAAG CGAGTCCGGG TACGATACTC CTATAGTAAG TCGTAGATGA

1401  CTAAAGAAAA ATGCCTGTCT CTAGCTGTTCT TGGACTACAC CCAAGCCTGA TCCAGCCTTT CCAAGTCACT CTGGATCTTG CCTAAATCCC
      GATTTCTTTT TACGGACAGA GATCGACAAG ACCTGATGTG GGTTCGGACT AGGTCGGAAA GGTTCAGTGA GACCTAGAAC GGATTTAGGG

1501  AAGAAATGGA ATCAGGTAGA CTTTTAATAT CACTAATTTC TTCTTTAGAT GCCAAACCAC AAGACTCTTT GGGTCCATTC AGATGAAATTG
      TTCTTTACCT TAGTCCATCT GAAAATTATA GTGATTAAAG AAGAAATCTA CGGTTTGGTG TTCTGAGAAA CCCAGGTAAG TCTACTTATC

1601  GAACAATAGA ATAATCTATT ATTTGGAGCC TGCCAAGAGG TACTGTAATG GGTAATTCTG ACGTCAGCGC ACCAAAAACTA TCCTGATTCC AAATATGTAT
      CTTGTTATCT TATTAGATAA TAAACCTCGG ACGGTTCTCC ATGACATTAC CCATTAAGAC TGCAGTCGCG TGGTTTTGAT AGGACTAAGG TTTATACATA

1701  GCACCTCAAG GTCATCAAAC ATTTGCCAAG TGAGTTGAAT AGTTGCTTAA TTTTGATTTT TAATGGAAAG TTGTATCCAT TAACCTGGGC ATTGTTGAGG
      CGTGGAGTTC CAGTAGTTTG TAAACGGTTC ACTCAACTTA TCAACGAATT AAAACTAAAA AATTACCTTTC AACATAGGTA ATTGGACCCG TAACAACTCC

1801  TTAAGTTTCT CTTCACCCCT ACACTGTGAA GGGTACAGAT TAGGTTTGTC CCAGTCAGAA ATAAAAATTTG ATAAACATTC CTGTTGATGG GAAAAGCCCC
      AATTCAAAGA GAAGTGGGGA TGTGACACTT CCCATGTCTA ATCCAAACAG GGTCAGTCTT TATTTTAAAC TATTTGTAAG GACAACTACC CTTTTCGGGG

1901  CAGTTAATAC TCCAGAGACA GGGAAAGGTC AGCCCATTTC AGAAGGACCA ATTGACTCTC ACACTGAATC AGCTGCTGAC TGGCCAGGGCT TTGGGCAGTT
      GTCAATTATG AGGTCTCTGT CCCTTTCCAG TCGGGTAAAG TCGGGTAAAG AGAAGGACCA ATTGACTCTC ACACTGAATC AGCTGCTGAC TGGCCAGGGCT
```

FIG._9B

```
2001  GGCCAGGCTC TTCCTTGAAT CTTCTCCCTT GTCCTGCTTG GGTTCATAGG AATTGGTAAG GCCTCTGGAC TGGCCTGTCT GGCCCCTGAG AGTGGTGCCC
      CCGGTCCGAG AAGGAACTTA GAAGAGGGAA CAGGACGAAC CCAAGTATCC TTAACCATTC CGGAGACCTG ACCGGACAGA CCGGGGACTC TCACCACGGG

2101  TGGAACACTC CTCTACTCTT ACAGAGCCTT GAGAGACCCA GCTGCAGACC ATGCCAGACC CACTGAAATG ACCAAGACAG GTTCAGGTAG GGGTGTGGGT
      ACCTTGTGAG GAGATGAGAA TGTCTCGGAA CTCTCTGGGT CGACGTCTGG TACGGTCTGG TGGTTCTGTC CAAGTCCATC CCCACACCCA

2201  CAAACCAAGA AGTGGGTGCC CTTGGTAGCA GCCTGGGGTG ACCTCTAGAG CTGGAGGCTG TGTTCAGGAC ACATCTATTG
      GTTTGGTTCT TCACCCACGG GAACCATCGT CGGACCCCAC TGGAGATCTC GACCTCCGAC ACAAGTCCTG TGTAGATAAC

2301  CAGAGACTCA TTTCACAGCC TTTCGTTCTG CTGACCAAAT GGCCAGTTTT CTGGTAGGAA GATGGAGGTT TTAGAAACAG AAATAGACTT
      GTCTCTGAGT AAAGTGTCGG AAAGCAAGAC GACTGGTTTA CCGGTCAAAA GACCATCCTT CTACCTCCAA ATGGTCAACA TTTATCTGAA

2401  AATAAAGGTT TAAAGCTGAA GAGGTTGAAG CTAAAAGGAA AAGGTTGTTG TTAATGAATA TCAGGCTATT ATTTATTGTA TTAGGAAAAT ATAATATTTA
      TTATTTCCAA ATTTCGACTT CTCCAACTTC GATTTTCCTT TTCCAACTTC AATTACTTAT AGTCCGATAA TAAATAACAT AATCCTTTTA TATTATAAAT

2501  CTGTTAGAAT TCTTTTATTT AGGGCCTTTT CTGTGCCAGA CATTGCTCTC AGTGCTTTGC ATGTATTAGC TTCACGGACAA TGTTGAGAAG
      GACAATCTTA AGAAAATAAA TCCCGGAAAA GACACGGTCT GTAACGAGAG TACATAATCG AGTGACTTAG AAGTGCTGTT ACAACTCTTC

2601  TTCCCATTAT TATTTCTGTT CTTACAAATG TGAAACGGAA GCTCATAGAG GTGAGAAAAC TCACCCAGTT GGTGACTGGG AAAGTTAGGA
      AAGGGTAATA ATAAAGACAA GAATGTTTAC ACTTTGCCTT CGAGTATCTC CACTCTTTTG AGTTGGTCTC CCACTGACCC TTTCAATCCT

2701  TTCAGATCGA AATTGGACTG TCTTTATAAC CCATATTTTC CCCCTGTTTT TAGAGCTTCC AAATGTGTCA GAATAGGAAA ACATTGCAAT AAATGGCTTG
      AAGTCTAGCT TTAACCTGAC AGAAATATTG GGTATAAAAG GGGGACAAAA ATCTCGAAGG CTTATCCTTT TGTAACGTTA TTTACCGAAC

2801  ATTTTTTAAA AAAAAAAAAA AAAAAAAAAA
      TAAAAAATTT TTTTTTTTTT TTTTTTTTTT
```

FIG._9C

Effect of WISP-1 Expression on NRK Metastatic Potential				
No. Cells Injected	Weeks after Innoculation	Incidence of Lung Metastasis		
		NRK/Control	NRK/WISP-1L	NRK/WISP-1H
2.5×10^5	2	0/1	0/1	2/2 (Grade I)
	3	0/4	3/3 (Grade I)	4/4 (Grade I-II)
	4	0/4	4/4 (Grade I)	3/3 (Grade III)
0.5×10^5	2	0/2	0/2	1/2 (Grade I)
	3	0/4	2/4 (Grade I)	3/4 (Grade I)
	4	0/4	4/4 (Grade I)	3/4 (Grade I-II)

FIG._10

FIG._11A

FIG._11B

FIG._12A

Deletion Mutants of Human WISP-1

FIG._12B

Epitope of WISP-1 Antibodies Clones 11C2, 5D4 and 9C11

32 a.a.

19 a.a.

VWC

. . . E Q W V C E D D A K R P R K T A P R D T G A F D A V G E V E A W H R N C I A Y T S P . . .

Epitope

→ The Epitope of the WISP-1 Antibodies Clones 11C2, 5D4 and 9C11 is Located within the First 19 Amino Acids of WISP-1 Variable Region.

FIG._12C

Epitope Mapping of WISP-1 Antibody 3D11

FIG._12D

→ The Epitope of the WISP-1 Antibody 3D11 is Located within WISP-1 Domain 1.

FIG._12E

FIG._12F

FIG._12G

FIG._13

FIG._14

FIG._15

FIG._16A

WISP-1 Antibodies Characterization								
Clones	Isotype	Epitope		IP	WB	Blocking Activity		
		Struct.	Cross Compet.			Heparin Binding	Cell Migrat.	Lung Met.
3D11	2b	Domain 1	A	−	+	+/−	+	+
9C10	2b	Domain 1	B	+	−	−	+	+
11C2	2b	Variable Region	C	+	+	+	+	+
5D4	2a	Variable Region	C	+	+	+	+	+
9C11	2a	Variable Region	C	+	+	+	+	+

FIG._16B

FIG._17A

FIG._17B

FIG._17C

FIG._17D

FIG._17E

FIG._18

4T1/Control   4T1/WISP-1L   4T1/WISP-1H

FIG._19

FIG._20

FIG._21A

FIG._21B

FIG._22

FIG._23B

FIG._23D

FIG._23F

FIG._23A

FIG._23C

FIG._23E

Figure 24

Figure 25

Vascular Invasion in NRK/WISP-1_134 Xenograft

Figure 26

Figure 27

Figure 28

Figure 29

Figure 30

H&E Staining

WISP-1 in situ Hybridization

Figure 31

Figure 32

P1918R1P1.txt
Sequence Listing

<110> GENENTECH, INC.
      DESNOYERS, LUC
      FILVAROFF, ELLEN

<120> Methods and Compositions for Modulating and Detecting
      WISP Activitiy

<130> P1918R1P1

<150> US 11/105,876

<151> 2005-04-14

<160> 22

<210> 1
<211> 367
<212> PRT
<213> Homo sapiens

<400> 1
 Met Arg Trp Phe Leu Pro Trp Thr Leu Ala Ala Val Thr Ala Ala
  1   5   10   15

 Ala Ala Ser Thr Val Leu Ala Thr Ala Leu Ser Pro Ala Pro Thr
             20   25   30

 Thr Met Asp Phe Thr Pro Ala Pro Leu Glu Asp Thr Ser Ser Arg
             35   40   45

 Pro Gln Phe Cys Lys Trp Pro Cys Glu Cys Pro Pro Ser Pro Pro
             50   55   60

 Arg Cys Pro Leu Gly Val Ser Leu Ile Thr Asp Gly Cys Glu Cys
             65   70   75

 Cys Lys Met Cys Ala Gln Gln Leu Gly Asp Asn Cys Thr Glu Ala
             80   85   90

 Ala Ile Cys Asp Pro His Arg Gly Leu Tyr Cys Asp Tyr Ser Gly
             95   100   105

 Asp Arg Pro Arg Tyr Ala Ile Gly Val Cys Ala Gln Val Val Gly
            110   115   120

 Val Gly Cys Val Leu Asp Gly Val Arg Tyr Asn Asn Gly Gln Ser
            125   130   135

 Phe Gln Pro Asn Cys Lys Tyr Asn Cys Thr Cys Ile Asp Gly Ala
            140   145   150

 Val Gly Cys Thr Pro Leu Cys Leu Arg Val Arg Pro Pro Arg Leu
            155   160   165

 Trp Cys Pro His Pro Arg Arg Val Ser Ile Pro Gly His Cys Cys
            170   175   180

 Glu Gln Trp Val Cys Glu Asp Asp Ala Lys Arg Pro Arg Lys Thr
            185   190   195

 Ala Pro Arg Asp Thr Gly Ala Phe Asp Ala Val Gly Glu Val Glu
            200   205   210

 Ala Trp His Arg Asn Cys Ile Ala Tyr Thr Ser Pro Trp Ser Pro
            215   220   225

P1918R1P1.txt

```
Cys Ser Thr Ser Cys Gly Leu Gly Val Ser Thr Arg Ile Ser Asn
                230                 235                 240

Val Asn Ala Gln Cys Trp Pro Glu Gln Glu Ser Arg Leu Cys Asn
                245                 250                 255

Leu Arg Pro Cys Asp Val Asp Ile His Thr Leu Ile Lys Ala Gly
                260                 265                 270

Lys Lys Cys Leu Ala Val Tyr Gln Pro Glu Ala Ser Met Asn Phe
                275                 280                 285

Thr Leu Ala Gly Cys Ile Ser Thr Arg Ser Tyr Gln Pro Lys Tyr
                290                 295                 300

Cys Gly Val Cys Met Asp Asn Arg Cys Cys Ile Pro Tyr Lys Ser
                305                 310                 315

Lys Thr Ile Asp Val Ser Phe Gln Cys Pro Asp Gly Leu Gly Phe
                320                 325                 330

Ser Arg Gln Val Leu Trp Ile Asn Ala Cys Phe Cys Asn Leu Ser
                335                 340                 345

Cys Arg Asn Pro Asn Asp Ile Phe Ala Asp Leu Glu Ser Tyr Pro
                350                 355                 360

Asp Phe Ser Glu Ile Ala Asn
                365
```

<210> 2
<211> 2830
<212> DNA
<213> Homo sapiens

<400> 2

```
cccacgcgtc cgctgggccc agctcccccg agaggtggtc ggatcctctg 50

ggctgctcgg tcgatgcctg tgccactgac gtccaggcat gaggtggttc 100

ctgccctgga cgctggcagc agtgacagca gcagccgcca gcaccgtcct 150

ggccacggcc ctctctccag ccctacgac catggacttt actccagctc 200

cactggagga cacctcctca cgcccccaat tctgcaagtg gccatgtgag 250

tgcccgccat ccccacccg ctgcccgctg ggggtcagcc tcatcacaga 300

tggctgtgag tgctgtaaga tgtgcgctca gcagcttggg gacaactgca 350

cggaggctgc catctgtgac ccccaccggg gcctctactg tgactacagc 400

ggggaccgcc cgaggtacgc aataggagtg tgtgcacagg tggtcggtgt 450

gggctgcgtc ctggatgggg tgcgctacaa caacggccag tccttccagc 500

ctaactgcaa gtacaactgc acgtgcatcg acggcgcggt gggctgcaca 550

ccactgtgcc tccgagtgcg ccccccgcgt ctctggtgcc cccacccgcg 600

gcgcgtgagc atacctggcc actgctgtga gcagtgggta tgtgaggacg 650

acgccaagag gccacgcaag accgcacccc gtgacacagg agccttcgat 700

gctgtgggtg aggtggaggc atggcacagg aactgcatag cctacacaag 750

cccctggagc ccttgctcca ccagctgcgg cctggggggtc tccactcgga 800
```

P1918R1P1.txt

tctccaatgt taacgcccag tgctggcctg agcaagagag ccgcctctgc 850

aacttgcggc catgcgatgt ggacatccat acactcatta aggcagggaa 900

gaagtgtctg gctgtgtacc agccagaggc atccatgaac ttcacacttg 950

cgggctgcat cagcacacgc tcctatcaac ccaagtactg tggagtttgc 1000

atggacaata ggtgctgcat cccctacaag tctaagacta tcgacgtgtc 1050

cttccagtgt cctgatgggc ttggcttctc ccgccaggtc ctatggatta 1100

atgcctgctt ctgtaacctg agctgtagga atcccaatga catctttgct 1150

gacttggaat cctaccctga cttctcagaa attgccaact aggcaggcac 1200

aaatcttggg tcttggggac taacccaatg cctgtgaagc agtcagccct 1250

tatggccaat aacttttcac caatgagcct tagttaccct gatctggacc 1300

cttggcctcc atttctgtct ctaaccattc aaatgacgcc tgatggtgct 1350

gctcaggccc atgctatgag ttttctcctt gatatcattc agcatctact 1400

ctaaagaaaa atgcctgtct ctagctgttc tggactacac ccaagcctga 1450

tccagccttt ccaagtcact agaagtcctg ctggatcttg cctaaatccc 1500

aagaaatgga atcaggtaga cttttaatat cactaatttc ttctttagat 1550

gccaaaccac aagactcttt gggtccattc agatgaatag atggaatttg 1600

gaacaataga ataatctatt atttggagcc tgccaagagg tactgtaatg 1650

ggtaattctg acgtcagcgc accaaaacta tcctgattcc aaatatgtat 1700

gcacctcaag gtcatcaaac atttgccaag tgagttgaat agttgcttaa 1750

ttttgatttt taatggaaag ttgtatccat taacctgggc attgttgagg 1800

ttaagtttct cttcacccct acactgtgaa gggtacagat taggtttgtc 1850

ccagtcagaa ataaaatttg ataaacattc ctgttgatgg gaaaagcccc 1900

cagttaatac tccagagaca gggaaaggtc agcccatttc agaaggacca 1950

attgactctc acactgaatc agctgctgac tggcagggct ttgggcagtt 2000

ggccaggctc ttccttgaat cttctccctt gtcctgcttg ggttcatagg 2050

aattggtaag gcctctggac tggcctgtct ggcccctgag agtggtgccc 2100

tggaacactc ctctactctt acagagcctt gagagaccca gctgcagacc 2150

atgccagacc cactgaaatg accaagacag gttcaggtag gggtgtgggt 2200

caaaccaaga agtgggtgcc cttggtagca gcctggggtg acctctagag 2250

ctggaggctg tgggactcca ggggcccccg tgttcaggac acatctattg 2300

cagagactca tttcacagcc tttcgttctg ctgaccaaat ggccagtttt 2350

ctggtaggaa gatggaggtt taccagttgt ttagaaacag aaatagactt 2400

aataaaggtt taaagctgaa gaggttgaag ctaaaaggaa aaggttgttg 2450

ttaatgaata tcaggctatt atttattgta ttaggaaaat ataatatttta 2500

Page 3

P1918R1P1.txt
```
ctgttagaat tctttattt agggccttt ctgtgccaga cattgctctc 2550

agtgctttgc atgtattagc tcactgaatc ttcacgacaa tgttgagaag 2600

ttcccattat tatttctgtt cttacaaatg tgaaacggaa gctcatagag 2650

gtgagaaaac tcaaccagag tcacccagtt ggtgactggg aaagttagga 2700

ttcagatcga aattggactg tctttataac ccatattttc cccctgtttt 2750

tagagcttcc aaatgtgtca gaataggaaa acattgcaat aaatggcttg 2800

attttttaaa aaaaaaaaa aaaaaaaaaa 2830
```

<210> 3
<211> 440
<212> DNA
<213> Homo sapiens

<400> 3
```
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccacggc cctctctcca gcccctacga 100

ccatggactt tactccagct ccactggagg acacctcctc acgcccccaa 150

ttctgcaagt ggccatgtga gtgcccgcca tccccacccc gctgcccgct 200

gggggtcagc ctcatcacag atggctgtga gtgctgtaag atgtgcgctc 250

agcagcttgg ggacaactgc acggaggctg ccatctgtga cccccaccgg 300

ggcctctact gtgactacag cggggaccgc ccgaggtacg caataggagt 350

gtgtgcacag gcggccgcac accaccatca ccatcaccat cactaagtga 400

ggccgcatag ataactgatc cagtgtgctg gaattaattc 440
```

<210> 4
<211> 340
<212> DNA
<213> Homo sapiens

<400> 4
```
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccactgc agtggtcggt gtgggctgcg 100

tcctggatgg ggtgcgctac aacaacggcc agtccttcca gcctaactgc 150

aagtacaact gcacgtgcat cgacggcgcg gtgggctgca caccactgtg 200

cctccgagtg cgcccccgc gtctctggtg cccccacccg cggcgcgtga 250

gcatacctgg ccactgctgt gagcagtggg tatgtgcggc cgcacaccac 300

catcaccatc accatcacta agtgaggccg catagataac 340
```

<210> 5
<211> 321
<212> DNA
<213> Homo sapiens

<400> 5
```
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccactgc agcatggcac aggaactgca 100
```

Page 4

P1918R1P1.txt
```
tagcctacac aagcccctgg agcccttgct ccaccagctg cggcctgggg 150

gtctccactc ggatctccaa tgttaacgcc cagtgctggc ctgagcaaga 200

gagccgcctc tgcaacttgc ggccatgcga tgtggacatc catacactca 250

ttaaggcggc cgcacaccac catcaccatc accatcacta agtgaggccg 300

catagataac tgatccagtg   t 321
```

<210> 6
<211> 442
<212> DNA
<213> Homo sapiens

<400> 6
```
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccactgc agggaagaag tgtctggctg 100

tgtaccagcc agaggcatcc atgaacttca cacttgcggg ctgcatcagc 150

acacgctcct atcaacccaa gtactgtgga gtttgcatgg acaataggtg 200

ctgcatcccc tacaagtcta agactatcga cgtgtccttc cagtgtcctg 250

atgggcttgg cttctcccgc caggtcctat ggattaatgc ctgcttctgt 300

aacctgagct gtaggaatcc caatgacatc tttgctgact ggaatccta 350

ccctgacttc tcagaaattg ccaacgcggc cgcacaccac catcaccatc 400

accatcacta agtgaggccg catagataac tgatccagtg   tg 442
```

<210> 7
<211> 619
<212> DNA
<213> Homo sapiens

<400> 7
```
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccacggc cctctctcca gccccctacga 100

ccatggactt tactccagct ccactggagg acacctcctc acgcccccaa 150

ttctgcaagt ggccatgtga gtgcccgcca tccccacccc gctgcccgct 200

gggggtcagc ctcatcacag atggctgtga gtgctgtaag atgtgcgctc 250

agcagcttgg ggacaactgc acggaggctg ccatctgtga cccccaccgg 300

ggcctctact gtgactacag cggggaccgc ccgaggtacg caataggagt 350

gtgtgcacag gtggtcggtg tgggctgcgt cctggatggg gtgcgctaca 400

acaacggcca gtccttccag cctaactgca agtacaactg cacgtgcatc 450

gacggcgcgg tgggctgcac accactgtgc ctccgagtgc gcccccgcg 500

tctctggtgc ccccacccgc ggcgcgtgag catacctggc cactgctgtg 550

agcagtgggt atgtgcggcc gcacaccacc atcaccatca ccatcactaa 600

gtgaggccgc atagataac 619
```

<210> 8
<211> 885

P1918R1P1.txt

<212> DNA
<213> Homo sapiens

<400> 8
```
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccacggc cctctctcca gccccctacga 100

ccatggactt tactccagct ccactggagg acacctcctc acgcccccaa 150

ttctgcaagt ggccatgtga gtgcccgcca tccccacccc gctgcccgct 200

gggggtcagc ctcatcacag atggctgtga gtgctgtaag atgtgcgctc 250

agcagcttgg ggacaactgc acggaggctg ccatctgtga cccccaccgg 300

ggcctctact gtgactacag cggggaccgc ccgaggtacg cataggagt 350

gtgtgcacag gtggtcggtg tgggctgcgt cctggatggg gtgcgctaca 400

acaacggcca gtccttccag cctaactgca agtacaactg cacgtgcatc 450

gacggcgcgg tgggctgcac accactgtgc ctccgagtgc gccccccgcg 500

tctctggtgc ccccacccgc ggcgcgtgag catacctggc cactgctgtg 550

agcagtgggt atgtgaggac gacgccaaga ggccacgcaa gaccgcaccc 600

cgtgacacag gagccttcga tgctgtgggt gaggtggagg catggcacag 650

gaactgcata gcctacacaa gcccctggag cccttgctcc accagctgcg 700

gcctgggggt ctccactcgg atctccaatg ttaacgccca gtgctggcct 750

gagcaagaga gccgcctctg caacttgcgg ccatgcgatg tggacatcca 800

tacactcatt aaggcggccg cacaccacca tcaccatcac catcactaag 850

tgaggccgca tagataactg atccagtgtg ctgga 885
```

<210> 9
<211> 1014
<212> DNA
<213> Homo sapiens

<400> 9
```
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccacggc cctctctcca gccccctacga 100

ccatggactt tactccagct ccactggagg acacctcctc acgcccccaa 150

ttctgcaagt ggccatgtga gtgcccgcca tccccacccc gctgcccgct 200

gggggtcagc ctcatcacag atggctgtga gtgctgtaag atgtgcgctc 250

agcagcttgg ggacaactgc acggaggctg ccatctgtga cccccaccgg 300

ggcctctact gtgactacag cggggaccgc ccgaggtacg cataggagt 350

gtgtgcacag gtggtcggtg tgggctgcgt cctggatggg gtgcgctaca 400

acaacggcca gtccttccag cctaactgca agtacaactg cacgtgcatc 450

gacggcgcgg tgggctgcac accactgtgc ctccgagtgc gccccccgcg 500

tctctggtgc ccccacccgc ggcgcgtgag catacctggc cactgctgtg 550
```

P1918R1P1.txt

```
agcagtgggt atgtctgcag gcagggaaga agtgtctggc tgtgtaccag 600

ccagaggcat ccatgaactt cacacttgcg ggctgcatca gcacacgctc 650

ctatcaaccc aagtactgtg gagtttgcat ggacaatagg tgctgcatcc 700

cctacaagtc taagactatc gacgtgtcct tccagtgtcc tgatgggctt 750

ggcttctccc gccaggtcct atggattaat gcctgcttct gtaacctgag 800

ctgtaggaat cccaatgaca tctttgctga cttggaatcc taccctgact 850

tctcagaaat tgccaacgcg ccgcacacc accatcacca tcaccatcac 900

taagtgaggc cgcatagata actgatccag tgtgctggaa ttaattcgct 950

gtctgcgagg gccagctgtt ggggtgagta ctccctctca aaagcgggca 1000

tgacttctgc  gcta 1014
```

<210> 10
<211> 904
<212> DNA
<213> Homo sapiens

<400> 10

```
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccacggc cctctctcca gcccctacga 100

ccatggactt tactccagct ccactggagg acacctcctc acgcccccaa 150

ttctgcaagt ggccatgtga gtgcccgcca tccccacccc gctgcccgct 200

gggggtcagc ctcatcacag atggctgtga gtgctgtaag atgtgcgctc 250

agcagcttgg ggacaactgc acggaggctg ccatctgtga cccccaccgg 300

ggcctctact gtgactacag cggggaccgc ccgaggtacg caataggagt 350

gtgtgcgcat gctgtgggtg aggtggaggc atggcacagg aactgcatag 400

cctacacaag cccctggagc ccttgctcca ccagctgcgg cctgggggtc 450

tccactcgga tctccaatgt taacgcccag tgctggcctg agcaagagag 500

ccgcctctgc aacttgcggc catgcgatgt ggacatccat acactcatta 550

aggcagggaa gaagtgtctg gctgtgtacc agccagaggc atccatgaac 600

ttcacacttg cgggctgcat cagcacacgc tcctatcaac ccaagtactg 650

tggagtttgc atggacaata ggtgctgcat cccctacaag tctaagacta 700

tcgacgtgtc cttccagtgt cctgatgggc ttggcttctc cgccaggtc 750

ctatggatta atgcctgctt ctgtaacctg agctgtagga atcccaatga 800

catctttgct gacttggaat cctaccctga cttctcagaa attgccaacg 850

cggccgcaca ccaccatcac catcaccatc actaagtgag gccgcataga 900

taac 904
```

<210> 11
<211> 922
<212> DNA
<213> Homo sapiens

P1918R1P1.txt

<400> 11
```
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccactgc agtggtcggt gtgggctgcg 100

tcctggatgg ggtgcgctac aacaacggcc agtccttcca gcctaactgc 150

aagtacaact gcacgtgcat cgacggcgcg gtgggctgca caccactgtg 200

cctccgagtg cgccccccgc gtctctggtg cccccacccg cggcgcgtga 250

gcatacctgg ccactgctgt gagcagtggg tatgtgagga cgacgccaag 300

aggccacgca agaccgcacc ccgtgacaca ggagccttcg atgctgtggg 350

tgaggtggag gcatggcaca ggaactgcat agcctacaca agcccctgga 400

gcccttgctc caccagctgc ggcctggggg tctccactcg gatctccaat 450

gttaacgccc agtgctggcc tgagcaagag agccgcctct gcaacttgcg 500

gccatgcgat gtggacatcc atacactcat taaggcaggg aagaagtgtc 550

tggctgtgta ccagccagag gcatccatga acttcacact tgcgggctgc 600

atcagcacac gctcctatca acccaagtac tgtggagttt gcatggacaa 650

taggtgctgc atcccctaca agtctaagac tatcgacgtg tccttccagt 700

gtcctgatgg gcttggcttc tcccgccagg tcctatggat taatgcctgc 750

ttctgtaacc tgagctgtag gaatcccaat gacatctttg ctgacttgga 800

atcctaccct gacttctcag aaaattgccaa cgcggccgca caccaccatc 850

accatcacca tcactaagtg aggccgcata gataactgat ccagtgtgct 900

ggaattaatt cgctgtctgc ga 922
```

<210> 12
<211> 19
<212> DNA
<213> Mus musculus

<400> 12
```
ggctgccatc tgtgaccca 19
```

<210> 13
<211> 21
<212> DNA
<213> Mus musculus

<400> 13
```
cataggacct gccgggagaa a 21
```

<210> 14
<211> 19
<212> DNA
<213> Mus musculus

<400> 14
```
gccgtggcag tcctgaggg 19
```

<210> 15
<211> 21
<212> DNA
<213> Mus musculus

P1918R1P1.txt

<400> 15
cagcaccggg cattgacgtt a 21

<210> 16
<211> 21
<212> DNA
<213> Mus musculus

<400> 16
tggagaaaaa tggccgctac a 21

<210> 17
<211> 20
<212> DNA
<213> Mus musculus

<400> 17
tggggtgctc ttctcgatgg 20

<210> 18
<211> 21
<212> DNA
<213> Mus musculus

<400> 18
ggacaaatcg gccacgtaca t 21

<210> 19
<211> 19
<212> DNA
<213> Mus musculus

<400> 19
cttgctccat cgggtctgc 19

<210> 20
<211> 42
<212> PRT
<213> Homo sapiens

<400> 20
Glu Gln Trp Val Cys Glu Asp Asp Ala Lys Arg Pro Arg Lys Thr
 1   5   10   15

Ala Pro Arg Asp Thr Gly Ala Phe Asp Ala Val Gly Glu Val Glu
             20   25   30

Ala Trp His Arg Asn Cys Ile Ala Tyr Thr Ser Pro
         35   40

<210> 21
<211> 625
<212> DNA
<213> Homo sapiens

<400> 21
gaattcacca tgaggtggtt cctgccctgg acgctggcag cagtgacagc 50

agcagccgcc agcaccgtcc tggccactgc agtggtcggt gtgggctgcg 100

tcctggatgg ggtgcgctac aacaacggcc agtccttcca gcctaactgc 150

aagtacaact gcacgtgcat cgacggcgcg gtgggctgca caccactgtg 200

cctccgagtg cgcccccccgc gtctctggtg cccccacccg cggcgcgtga 250

gcatacctgg ccactgctgt gagcagtggg tatgtgagga cgacgccaag 300

Page 9

P1918R1P1.txt

aggccacgca agaccgcacc ccgtgacaca ggagccttcg atgctgtggg 350

tgaggtggag gcatggcaca ggaactgcat agcctacaca agcccctgga 400

gcccttgctc caccagctgc ggcctggggg tctccactcg gatctccaat 450

gttaacgccc agtgctggcc tgagcaagag agccgcctct gcaacttgcg 500

gccatgcgat gtggacatcc atacactcat taaggcggcc gcacaccacc 550

atcaccatca ccatcactaa gtgaggccgc atagataact gatccagtgt 600

gctggaatta attcgctgtc　tgcga 625

<210> 22
<211> 1131
<212> DNA
<213> Homo sapiens

<400> 22
cctcggttct atcgattgaa ttccaccatg aggtggttcc tgccctggac 50

gctggcagca gtgacagcag cagccgccag caccgtcctg gccacggccc 100

tctctccagc ccctacgacc atggacttta ctccagctcc actggaggac 150

acctcctcac gcccccaatt ctgcaagtgg ccatgtgagt gcccgccatc 200

cccaccccgc tgcccgctgg gggtcagcct catcacagat ggctgtgagt 250

gctgtaagat gtgcgctcag cagcttgggg acaactgcac ggaggctgcc 300

atctgtgacc cccaccgggg cctctactgt gactacagcg gggaccgccc 350

gaggtacgca ataggagtgt gtgcacaggt ggtcggtgtg ggggtcaccg 400

acaaaactca cacatgccca ccgtgcccag cacctgaact cctggggggga 450

ccgtcagtct tcctcttccc cccaaaaccc aaggacaccc tcatgatctc 500

ccggacccct gaggtcacat gcgtggtggt ggacgtgagc cacgaagacc 550

ctgaggtcaa gttcaactgg tacgtggacg gcgtggaggt gcataatgcc 600

aagacaaagc cgcgggagga gcagtacaac agcacgtacc gtgtggtcag 650

cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt 700

gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc 750

aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc 800

ccgggaagag atgaccaaga accaggtcag cctgacctgc ctggtcaaag 850

gcttctatcc cagcgacatc gccgtggagt gggagagcaa tgggcagccg 900

gagaacaact acaagaccac gcctcccgtg ctggactccg acggctcctt 950

cttcctctac agcaagctca ccgtggacaa gagcaggtgg cagcagggga 1000

acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg 1050

cagaagagcc tctccctgtc tccgggtaaa tgagtgcgac ggccctagag 1100

tcgacctgca gaagcttggc cgccatggcc　c 1131